0001493152-18-016490.txt : 20181119 0001493152-18-016490.hdr.sgml : 20181119 20181119163954 ACCESSION NUMBER: 0001493152-18-016490 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181119 DATE AS OF CHANGE: 20181119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adhera Therapeutics, Inc. CENTRAL INDEX KEY: 0000737207 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 112658569 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-13789 FILM NUMBER: 181192958 BUSINESS ADDRESS: STREET 1: 4721 EMPEROR BOULEVARD STREET 2: SUITE 350 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-578-5901 MAIL ADDRESS: STREET 1: 4721 EMPEROR BOULEVARD STREET 2: SUITE 350 CITY: DURHAM STATE: NC ZIP: 27703 FORMER COMPANY: FORMER CONFORMED NAME: Marina Biotech, Inc. DATE OF NAME CHANGE: 20100722 FORMER COMPANY: FORMER CONFORMED NAME: MDRNA, Inc. DATE OF NAME CHANGE: 20080610 FORMER COMPANY: FORMER CONFORMED NAME: NASTECH PHARMACEUTICAL CO INC DATE OF NAME CHANGE: 19920703 10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: September 30, 2018

 

or

 

[  ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to _____________.

 

Commission File Number: 000-13789

 

ADHERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   11-2658569
(State or other jurisdiction of   (IRS Employer
incorporation or organization)   Identification No.)

 

4721 Emperor Boulevard, Suite 350

Durham, NC

   27703
(Address of principal executive offices)   (Zip Code)

 

(919) 578-5901

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [  ] Accelerated filer [  ]
       
Non-accelerated filer [  ] (Do not check if a smaller reporting company) Smaller reporting company [X]
       
    Emerging Growth Company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act: [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X].

 

As of November 19, there were 10,761,684 shares of the registrant’s common stock outstanding.

 

 

 

 

 

 

ADHERA THERAPEUTICS, INC.

FORM 10-Q

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2018

 

TABLE OF CONTENTS

 

    Page
PART I - FINANCIAL INFORMATION  
     
ITEM 1 Financial Statements (unaudited)  3
     
  Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017 3
     
  Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2018 and 2017 4
     
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and 2017 5
     
  Condensed Consolidated Statement of Stockholders’ Equity for the Nine Months Ended September 30, 2018 6
   
  Notes to Condensed Consolidated Financial Statements 7
     
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 26
     
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk 34
     
ITEM 4. Controls and Procedures 34
     
PART II - OTHER INFORMATION  
     
ITEM 1. Legal Proceedings 35
     
ITEM 1A. Risk Factors 35
     
ITEM 6. Exhibits 36
     
SIGNATURES 37

 

Items 2, 3, 4 and 5 have not been included as they are not applicable.

 

2

 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

   September 30, 2018   December 31, 2017 
         
ASSETS          
           
Current assets          
Cash  $6,506,127   $106,378 
Accounts receivable   135,150    - 
Inventory   364,851    - 
Prepaid expenses and other assets   448,244    18,565 
Total current assets   7,454,372    124,943 
           
Furniture and fixtures, net of depreciation   28,795    - 
Intangible assets, net of amortization   815,514    2,555,974 
Goodwill   -    3,502,829 
    844,309    6,058,803 
           
Total assets  $8,298,681   $6,183,746 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current liabilities          
Accounts payable  $851,063   $1,033,353 
Due to related party, including warrant liability   155,442    1,336,518 
Accrued expenses   978,733    1,139,369 
Accrued fee payable   -    320,000 
Deferred revenue   200,000    - 
Notes payable   -    444,223 
Notes payable - related parties   -    1,462,040 
Total current liabilities  $2,185,238   $5,735,503 
           
Commitments and contingencies (Note 9)          
           
Stockholders’ equity          
Preferred stock, $0.01 par value; 100,000 shares authorized          
           
Series C convertible preferred stock, $0.01 par value; $5,100 liquidation preference; 1,200 shares authorized; 100 and 750 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively   -    - 
           
Series D convertible preferred stock, $0.01 par value; $300 liquidation preference; 220 shares authorized; 40 and 60 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively   -    - 
           
Series E convertible preferred stock, $0.01 par value; $5,000 liquidation preference; 3,500 shares authorized; 3,490 and 0 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively   35    - 
           
Series F convertible preferred stock, $0.01 par value; $5,000 liquidation preference; 2,200 shares authorized; 308 and 0 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively   3    - 
           
Common stock, $0.006 par value; 180,000,000 shares authorized, 11,241,684 and 10,521,728 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively   64,700    63,127 
Additional paid-in capital   28,516,045    8,413,823 
Accumulated deficit   (22,467,340)   (8,028,707)
           
Total stockholders’ equity   6,113,443    448,243 
           
Total liabilities and stockholders’ equity  $8,298,681   $6,183,746 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2018   2017   2018   2017 
                 

Net sales

  $76,186   $-   $76,186   $- 
Cost of sales   7,760    -   $7,760    - 
Gross profit   68,426    -    68,426    - 
                     
Operating expenses                    
                     
Sales, marketing and commercial operations  $870,926   $-   $3,456,871   $- 
Research and development   -    232,896    173,256    746,221 
General and administrative   2,140,992    680,063    4,119,988    1,878,301 
Amortization   41,937    123,038    288,460    327,642 
Goodwill and intangible assets impairment   4,794,030    -    4,794,030    - 
Total operating expenses   7,847,885    1,035,997    12,832,605    2,952,164 
                     
Loss from operations   (7,779,459)   (1,035,997)   (12,764,179)   (2,952,164)
                     
Other expense                    
                     
Interest expense   -    (24,301)   (149,900)   (51,575)
Change in fair value liability of warrants   -    7,442    -    (106,345)
Loss on settlement   -    -    (874,697)   - 
Change in fair value of derivative liability   -    80,672    -    (115,271)
    -    63,813    (1,024,597)   (273,191)
                     
Loss before provision for income taxes   (7,779,459)   (972,184)   (13,788,776)   (3,225,355)
                     
Provision for income taxes   -    -    -    800 
                     
Net loss  $(7,779,459)  $(972,184)  $(13,788,776)  $(3,226,155)
                     
Net loss per share - basic and diluted  $(0.69)  $(0.10)  $(1.27)  $(0.33)
                     
Weighted average shares outstanding   11,241,684    9,869,672    10,864,036    9,645,954 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

    For the Nine Months Ended September 30,  
    2018     2017  
             
Cash Flows Used in Operating Activities:                
                 
Net loss   $ (13,788,776 )   $ (3,226,155 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Share based compensation     1,307,046       218,295  
Common shares issued to third party for services     -       54,000  
Loss on settlement with issuance of common shares     250,000       -  
Loss on note settlement with issuance of preferred shares     375,000       -  
Common shares issued to license agreement     75,000       -  
Goodwill and intangible assets impairment     4,794,030          
Amortization of intangibles     288,460       327,642  
Amortization of debt discount     113,171       -  
Non-cash interest expense     36,729       -  
Loss on settlement     874,697          
Change in fair value liabilities for price adjustable warrants     -       106,345  
Change in fair value of derivative liability     -       115,271  
Changes in operating assets and liabilities:                
Accounts receivable     (135,150 )     -  
Inventory     (204,051 )     -  
Prepaid expenses and other assets     (429,679 )     125,098  
Accounts payable     (122,229 )     419,494  
Accrued expenses     (641,157 )     637,642  
Accrued fee payable     (320,000 )     -  
Deferred revenue     200,000       -  
Due to related party     313,393       299,166  
                 
Net Cash Used in Operating Activities     (7,013,516 )     (923,202 )
                 
Cash Flows Used in Investing Activities:                
Purchase of furniture and fixtures     (28,795 )     -  
Purchase of intangible assets     -       (375,000 )
                 
Net Cash Used in Investing Activities     (28,795 )     (375,000 )
                 
Cash Flows Provided By Financing Activities:                
Proceeds from sale of preferred stock, net of offering expenses     13,585,894       -  
Proceeds from sale of common stock to related party     -       250,000  
Proceeds from notes payable due to related party     -       90,888  
Proceeds from convertible notes     -       400,000  
Proceeds from convertible notes due to related parties, net     -       290,000  
Proceeds from exercise of warrants for common stock     -       170,643  
Payments for notes payable     (143,834 )     -  
                 
Net Cash Provided by Financing Activities     13,442,060       1,201,531  
                 
Net increase (decrease) in cash     6,399,749       (96,671 )
                 
Cash - Beginning of Period     106,378       105,347  
Cash - End of Period   $ 6,506,127     $ 8,676  
                 
Supplementary Cash Flow Information:                
Income taxes paid   $ -     $ 800  
                 
Non-cash Investing and Financing Activities:                
Issuance of warrants for liabilities, related party   $ 1,494,469     $ -  
Common stock issued for settlement of accrued expenses   $ -     $ 976,714  
Return of common stock for other assets   $ -     $ 31,404  
Adjustment to goodwill   $ -     $ 55,247  
Accrued interest   $ -     $ 32,080  
Assumption of liabilities for acquisition of assets   $ -     $ 320,000  
Preferred share settlement of debt and accrued liabilities   $ 3,437,735     $ -  
Issuance of warrants   $ 32,420,580     $ -  
Accrued dividends   $ 649,857     $ -  
Cancellation of Series E Preferred Stock   $ 46,311     $ -  
Goodwill reclassified to inventory   $ 160,800     $ -  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(Unaudited)

 

   Series E Preferred Stock   Series F Preferred Stock   Common Stock  

Additional

  

Additional

Paid-in

         
   Number   Par Value   Number   Par Value   Number   Par Value  

Paid-in

Capital

   Capital -Warrants   Accumulated
Deficit		   Total 
                                         
Balance, December 31, 2017   -   $-    -    $-    10,521,278   $63,127   $8,413,823   $-   $(8,028,707)  $448,243 
                                                   
Issuance of Series E Preferred Stock, net of fees   2,812    28    -     -    -    -    12,247,297    -    -    12,247,325 
                                                   
Warrants issued with Series E Preferred Stock   -    -    -     -    -    -    (31,106,896)   31,106,896    -    - 
                                                   
Issuance of Series F Preferred Stock, net of fees   -    -    308    3    -    -    1,338,566    -    -    1,338,569 
                                                   
Warrants issued with Series F Preferred Stock   -    -    -     -    -    -    (1,313,684)   1,313,684    -    - 
                                                   
Issuance of Series E Preferred for debt and accounts payable   687    7    -     -    -    -    3,437,728    -    -    3,437,735 
                                                   
Conversion of Series C Preferred stock for common stock   -    -    -     -    433,334    -    -    -    -    - 
                                                   
Conversion of Series D Preferred stock for common stock   -    -    -     -    25,000    -    -    -    -    - 
                                                   
Warrants issued for settlement of liability   -    -    -     -    -    -    -    1,494,469    -    1,494,469 
                                                   
Shares issued for settlement of litigation   -    -    -     -    210,084    1,261    248,739    -    -    250,000 
                                                   
Shares issued for License Agreement   -    -    -     -    51,988    312    74,688    -    -    75,000 
                                                   
Accrued dividend   -    -    -     -    -    -    -    -    (649,857)   (649,857)
                                                   
Share based compensation   -    -    -     -    -    -    1,307,046    -    -    1,307,046 
                                                   
Cancellation of Series E Preferred Stock   (9)   -    -     -    -    -    (46,311)   -    -    (46,311)
                                                   
Net loss   -    -    -     -    -    -    -    -    (13,788,776)   (13,788,776)
                                                   
Balance, September 30, 2018   3,490   $35    308   $3    11,241,684   $64,700   $(5,399,004)  $33,915,049   $(22,467,340)  $6,113,443 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

6

 

 

ADHERA THERAPEUTICS, INC.

Notes to Condensed Consolidated Financial Statements

FOR THE THREE AND nine MONTHS ENDED september 30, 2018

(Unaudited)

 

Note 1 - Nature of Operations, Basis of Presentation and Significant Accounting Policies

 

Business Overview

 

Adhera Therapeutics, Inc. (formerly known as Marina Biotech, Inc.) and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IthenaPharma, Inc. (“Ithena”) (collectively “Adhera,”, the “Company”, “we,” “our,” or “us”) is an emerging specialty pharmaceutical company leveraging innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic and acute diseases. Adhera is focused on fixed dose combination (“FDC”) therapies in hypertension, with plans to expand the portfolio of drugs we commercialize to include other therapeutic areas.

 

We began marketing Prestalia®, a single-pill FDC of perindopril arginine (an angiotensin-converting-enzyme) inhibitor and amlodipine besylate (a calcium channel blocker), which was approved by the U.S. Food and Drug Administration (“FDA”) in June of 2018. Prestalia was developed in coordination with Servier, a French pharmaceutical conglomerate, that sells the formulation outside the United States under the brand name - Viacoram. Prestalia is distributed through the DyrectAxess platform which we acquired in 2017. DyrectAxess is a patented  technology platform, also known as Total Care®, that offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to achieve optimal care.

 

By combining Prestalia, DyrectAxess, and a specialty pharma network, we have created proprietary platform for drug adherence and the effective treatment of hypertension, improving the distribution of FDC hypertensive drugs, such as our FDA-approved product Prestalia, devices for therapeutic drug monitoring (e.g., blood pressure and other cardiac monitors), as well as patient counseling and prescription reminder services.

 

On November 15, 2016, Adhera entered into, and consummated the transactions contemplated by, an Agreement and Plan of Merger between and among IthenaPharma, Inc., a Delaware corporation (“IThena”), IThena Acquisition Corporation, a Delaware corporation and wholly-owned subsidiary of Adhera (“Merger Sub”), and a representative of the stockholders of IThena (the “Merger Agreement”), pursuant to which IThena merged into Merger Sub (the “Merger”).

 

As reported in our Annual Report on Form 10-K, in April 2018, we raised in excess of $10 million, net of fees and expenses, from a private placement of our newly created Series E Convertible Preferred Stock (See Recent Developments: Series E Convertible Preferred Stock Private Placement Offering below). Further, in May 2018, we raised an additional $2 million, net of fees and expenses, from the private placement. In July 2018, we raised $1.3 million net of fees and expenses, from a private placement of our newly created Series F Convertible Preferred Stock. The use of funds from the raise will be on the commercialization of Prestalia, funding working capital, capital expenditure needs, payment of certain liabilities and other general corporate requirements. We plan to license or divest our other pharmaceutical assets and halt any other FDC development programs, since they no longer align with our focus on the treatment of hypertension.

 

7

 

 

Change of Company Name and OTC Markets Symbol

 

On October 4, 2018, we filed a Certificate of Amendment to the Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware to change the name of our company from “Marina Biotech, Inc.” to “Adhera Therapeutics, Inc.” The change of name was effective October 9, 2018.

 

Following the name change from Marina Biotech, Inc. to Adhera Therapeutics, Inc., the common stock, par value $0.006 per share, of the Company began trading on the OTCQB tier of the OTC Markets under the symbol “ATRX”.

 

Reverse Stock Split

 

In August 2017, we filed a Certificate of Amendment of our Amended and Restated Certificate of Incorporation to effect a one-for-ten reverse split of our issued and outstanding shares of common stock. Our common stock commenced trading on the OTCQB tier of the OTC Markets on a split-adjusted basis on Thursday, August 3, 2017. Unless indicated otherwise, all share and per share information included in these financial statements and Notes to the Consolidated Financial Statements give effect to the reverse split.

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete audited financial statements. The accompanying unaudited financial information should be read in conjunction with the audited consolidated financial statements, including the notes thereto, as of and for the year ended December 31, 2017, included in our 2017 Annual Report on Form 10-K filed with the SEC. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the nine months ended September 30, 2018 are not necessarily indicative of the results for the year ending December 31, 2018 or for any future period.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of IThena and Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions.

 

Going Concern and Management’s Liquidity Plans 

 

The accompanying condensed consolidated financial statements have been prepared on the basis that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At September 30, 2018, we had a significant accumulated deficit of approximately $22 million and working capital of approximately $5 million. Our operating activities consume the majority of our cash resources. We anticipate that we will continue to incur operating losses as we execute our commercialization plans for Prestalia, as well as strategic and business development initiatives. In addition, we have had and will continue to have negative cash flows from operations, at least into the near future. We have previously funded, and plan to continue funding, our losses primarily through the sale of common and preferred stock, combined with or without warrants, the sale of notes, cash generated from the outlicensing or sale of our licensed assets and, to a lesser extent, equipment financing facilities and secured loans. However, we cannot be certain that we will be able to obtain such funds required for our operations at terms acceptable to us or at all.

 

In April and May 2018, we raised approximately $12.2 million net proceeds from a private placement of shares of our Series E Convertible Preferred Stock, and warrants to purchase shares of our common stock. Further, in July 2018, we raised an additional $1.4 million net proceeds from the private placement of our Series F Convertible Preferred Stock. For our assessment as of September 30, 2018, we have considered the amount raised and we believe that the $13.6 million will provide us the ability to continue as a going concern for one year from the issuance date of this Form 10-Q. We may continue to attempt to obtain future financing or engage in strategic transactions which may require us to curtail our operations. We cannot predict, with certainty, the outcome of our actions to generate liquidity, including the availability of additional equity or debt financing, or whether such actions would generate the expected liquidity as currently planned.

 

8

 

 

Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include valuation allowance for deferred income tax assets, legal contingencies and fair value of financial instruments. Actual results could differ materially from such estimates under different assumptions or circumstances.

 

Fair Value of Financial Instruments

 

We consider the fair value of cash, accounts payable, due to related parties, notes payable, notes payable to related parties, accounts receivable and accrued liabilities not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
   
Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
   
Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

 

Our cash is subject to fair value measurement and is determined by Level 1 inputs. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. There were no liabilities measured at fair value as of September 30, 2018 or December 31, 2017.

 

Goodwill and Intangible Assets

 

The Company periodically reviews the carrying value of intangible assets, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit.

 

As of September 30, 2018, the Company determined that goodwill was impaired and, as a result, a loss on impairment of $3,502,830 was recognized for the three and nine-month periods ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company’s strategic objectives . There was no such loss on impairment for the year ended December 31, 2017.

 

Impairment of Long-Lived Assets

 

We review all of our long-lived assets for impairment indicators throughout the year and perform detailed testing whenever impairment indicators are present. In addition, we perform detailed impairment testing for indefinite-lived intangible assets, at least annually, at December 31. When necessary, we record charges for impairments. Specifically:

 

● For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, we compare the undiscounted amount of the projected cash flows associated with the asset, or asset group, to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate; and

 

● For indefinite-lived intangible assets, such as acquired in-process R&D assets, each year and whenever impairment indicators are present, we determine the fair value of the asset and record an impairment loss for the excess of book value over fair value, if any.

 

As of September 30, 2018, the Company determined that the intangible asset from the merger was impaired and, as a result, a loss on impairment of $1,291,200 was recognized for the three and nine-month periods ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company’s strategic objectives . There was no such loss on impairment for the year ended December 31, 2017.

 

9

 

 

Revenue Recognition

 

The Company has adopted the new revenue recognition guidelines in accordance with ASC 606, Revenue from Contracts with Customers (ASC 606), effective with the quarter ended March 31, 2018.

 

The Company sells its medicines primarily to wholesale distributors and specialty pharmacy providers. These customers subsequently resell the Company’s medicines to health care patients. In addition, the Company enters into arrangements with health care providers and payers that provide for government-mandated or privately-negotiated discounts and allowances related to the Company’s medicines. Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company’s contracts have a single performance obligation to transfer medicines. Accordingly, revenues from medicine sales are recognized when the customer obtains control of the Company’s medicines, which occurs at a point in time, typically upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring medicines and is generally based upon a list or fixed price less allowances for medicine returns, rebates and discounts. The Company sells its medicines to wholesale pharmaceutical distributors and pharmacies under agreements with payment terms typically less than 90 days.

 

Medicine Sales Discounts and Allowances

 

The nature of the Company’s contracts gives rise to variable consideration because of allowances for medicine returns, rebates and discounts. Allowances for medicine returns, rebates and discounts are recorded at the time of sale to wholesale pharmaceutical distributors and pharmacies. The Company applies significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, the Company will be required to make adjustments to these allowances in the future. The Company’s adjustments to gross sales are discussed further below.

 

Distribution Service Fees

 

The Company includes distribution service fees paid to its wholesalers for distribution and inventory management services as a reduction to revenue. The Company calculates accrued distribution service fee estimates using the most likely amount method. The Company accrues estimated distribution fees based on contractually determined amounts, typically as a percentage of revenue. Accrued distribution service fees are included in “accrued expenses”  on the condensed consolidated balance sheet.

 

Patient Access Programs

 

The Company offers discounts to patients under which the patient receives a discount on his or her prescription. In circumstances when a patient’s prescription is rejected by a third party payer, the Company will pay for the full cost of the prescription.  The Company reimburses pharmacies for this discount directly or through third-party vendors. The Company reduces gross sales by the amount of actual co-pay and other patient assistance in the period based on the invoices received. The Company also records an accrual to reduce gross sales for estimated co-pay and other patient assistance on units sold to distributors or pharmacies that have not yet been prescribed/dispensed to a patient. The Company calculates accrued co-pay and other patient assistance fee estimates using the expected value method. The estimate is based on contract prices, estimated percentages of medicine that will be prescribed to qualified patients, average assistance paid based on reporting from the third-party vendors and estimated levels of inventory in the distribution channel. Accrued co-pay and other patient assistance fees are included in “accrued expenses”  on the condensed consolidated balance sheet. Patient assistance programs include both co-pay assistance and fully bought down prescriptions.

 

10

 

 

Sales Returns

 

Consistent with industry practice, the Company maintains a return policy that allows customers to return medicines within a specified period prior to and subsequent to the medicine expiration date. Generally, medicines may be returned for a period beginning six months prior to its expiration date and up to one year after its expiration date. The right of return expires on the earlier of one year after the medicine expiration date or the time that the medicine is dispensed to the patient. The majority of medicine returns result from medicine dating, which falls within the range set by the Company’s policy, and are settled through the issuance of a credit to the customer. The Company calculates sales returns using the expected value method. The estimate of the provision for returns is based upon industry experience. This period is known to the Company based on the shelf life of medicines at the time of shipment.  The Company records sales returns in “accrued expenses” and as a reduction of revenue.  

 

Shipping Fees

 

The Company includes fees incurred by pharmacies for shipping medicines to patients as a reduction to revenue. The Company calculates accrued shipping fee estimates using the expected value method. The Company records accrued shipping fees in “accrued expenses” on the condensed consolidated balance sheet.

 

Licensing Agreements

 

In terms of licensing agreements entered into by the Company, they typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.

 

11

 

 

During the nine months ended September 30, 2018 , Adhera entered into a Licensing Agreement, whereby Adhera granted exclusive rights to the company’s DiLA2 delivery system in exchange for an upfront payment of approximately $200,000 and further potential future consideration dependent upon event and sales-based milestones. Under the terms of the agreement, Adhera has agreed to assign ownership of the intellectual property associated with the DiLA2 delivery system to the purchaser. The Company has yet to complete certain performance obligations under the agreement and accordingly has deferred the recognition of revenue from the sale of the asset until such obligations are fulfilled.

 

Recently Issued Accounting Pronouncements

 

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). Under the provisions of ASU 2014-09, entities should recognize revenue in an amount that reflects the consideration to which they expect to be entitled to in exchange for goods and services provided. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017. The Company adopted the provisions of this standard effective January 1, 2018.

 

In February 2016, the FASB issued ASU 2016 02, Leases (Topic 842) (“ASU 2016 02”). The provisions of ASU 2016 02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right of use asset and a lease liability for all leases with a term of greater than 12 months, regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases. ASU 2016 02 supersedes the previous lease standard, Topic 840, Leases. This guidance is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.

 

12

 

 

Net Income (Loss) per Common Share

 

Basic net income (loss) per common share (after giving effect of the one for ten reverse stock split) is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period, excluding any unvested restricted stock awards. Diluted net income (loss) per share includes the effect of common stock equivalents (stock options, unvested restricted stock, and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. Net income (loss) is adjusted for the dilutive effect of the change in fair value liability for price adjustable warrants, if applicable. The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive:

 

   Nine Months Ended September 30, 
   2018   2017 
         
Stock options outstanding   5,380,957    233,400 
Warrants   35,646,829    2,492,945 
Shares to be issued upon conversion of notes payable   -    315,746 
Restricted common stock   -    70,000 
Series E Preferred Stock   

34,900,000

    - 
Series F Preferred Stock   3,080,000    - 
Total   79,007,786    3,112,091 

 

Reclassification of Prior Period Presentation

 

Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.

 

NOTE 2 - OTHER ASSETS 

 

The Company has deposit of approximately $200,000 with a customer which is included in prepaid expenses and other assets on the accompanying balance sheet. The deposit is for use by the customer to fund co-pay assistance for a specified period of time, with any unused amounts to then be refunded to the Company.

 

Note 3 - Intangible Assets

 

Acquisition of Prestalia & DyrctAxess

 

In June 2017, we entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Symplmed Pharmaceuticals LLC (“Symplmed”) pursuant to which we purchased from Symplmed, for aggregate consideration of approximately $620,000 (consisting of $300,000 in cash plus the assumption of certain liabilities of Symplmed in the amount of approximately $320,000), Symplmed’s assets relating to a single-pill FDC of perindopril arginine and amlodipine besylate known as Prestalia® (“Prestalia”), that has been approved by the FDA for the treatment of hypertension. In addition, as part of the transactions contemplated by the Purchase Agreement: (i) Symplmed agreed to transfer to us, not later than 150 days following the closing date, the New Drug Applications for the approval of Prestalia as a new drug by the FDA; and (ii) Symplmed assigned to us all of its rights and obligations under that certain Amended and Restated License and Commercialization Agreement by and between Symplmed and Les Laboratoires Servier (“Servier”) dated January 2012, pursuant to which Symplmed has an exclusive license from Servier to manufacture, have manufactured, develop, promote, market, distribute and sell Prestalia in the U.S. (and its territories and possessions) in consideration of regulatory and sales-based milestone payments and royalty payments based on net sales. Management has determined that this acquisition was deemed an asset purchase under FASB ASC 805.

 

The purchase price of $620,000 was allocated based on a preliminary estimate of the fair value of the assets acquired and was included in intangible assets as of December 31, 2017. During the three months ended September 30, 2018, the allocation of the purchase price was finalized which resulted in $160,800 of the price being allocated to raw materials received from Symplmed, and the remaining $459,200 being allocated to intangible assets.

 

13

 

 

Further, we hired our current Chief Commercial Officer, who was the President and Chief Executive Officer of Symplmed, which appointment became effective in June 2017. We also agreed in such offer letter to issue 60,000 restricted shares of our common stock under our 2014 Long-Term Incentive Plan to our Chief Commercial Officer, with all of such shares vesting on the six (6) month anniversary of the date of grant. These shares were fully vested on December 31, 2017.

 

In furtherance of the acquisition and commercialization of Prestalia, in July 2017 we acquired from Symplmed and its wholly-owned subsidiary, Symplmed Technologies, LLC, certain of the intellectual property assets related to the patented technology platform known as DyrctAxess, also known as Total Care, that offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to help achieve optimal care for $75,000 in cash.

 

Intangible Asset Summary

 

The following table summarizes the estimated fair values as of September 30, 2018 of the identifiable intangible assets acquired, their useful life, and method of amortization:

 

   Estimated
Fair Value		  

Remaining

Estimated
Useful Life
(Years)

   Annual
Amortization
Expense		 
Intangible asset from the Merger  $590,267    4.17   $97,450 
Intangible asset - Prestalia   459,200    5.25    94,177 
Intangible asset - DyrctAxess   75,000    12.84    5,357 
Total  $1,124,467        $196,984 

 

As of September 30, 2018, the Company determined that the intangible asset from the Merger was impaired and, as a result, a loss on impairment of approximately $1,291,200 was recognized for the three and nine months ended September 30, 2018 (see Note 1).

 

The net intangible asset was $815,514, net of accumulated amortization of $308,953, as of September 30, 2018. Amortization expense was $288,460 and $327,642 for the nine months ended September 30, 2018 and 2017, respectively, and $41,937 and $123,038 for the three months ended September 30, 2018 and 2017, respectively.

 

Note 4 - Related Party Transactions

 

Due to Related Party

 

The Company and other related entities have  had a commonality of ownership and/or management control, and as a result, the reported operating results and /or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous.

 

The Company had a Master Services Agreement (“MSA”) with Autotelic Inc ., a related party that is partly-owned by one of the Company’s Board members, namely Vuong Trieu, Ph.D., effective November 15, 2016. Autotelic Inc. currently owns less than 5% of the Company. The MSA states that Autotelic Inc. will provide business functions and services to the Company and allows Autotelic Inc. to charge the Company for these expenses paid on its behalf. The MSA includes personnel costs allocated based on amount of time incurred and other services such as consultant fees, clinical studies, conferences and other operating expenses incurred on behalf of the Company. The MSA requires a 90-day written termination notice in the event either party requires to terminate such services. We and Autotelic Inc. have agreed to terminate the MSA effective October 31, 2018. Dr. Trieu resigned as a director of our company effective October 1, 2018.

 

During the period commencing November 15, 2016 (the “Effective Date”) and ending on the date that the Company had completed an equity offering of either common or preferred stock in which the gross proceeds therefrom is no less than $10 million (the “Equity Financing Date”), the Company shall pay Autotelic the following compensation: cash in an amount equal to the actual labor cost (paid on a monthly basis), plus 100% markup in warrants for shares of the Company’s common stock with a strike price equal to the fair market value of the Company’s common stock at the time said warrants are issued. The Company shall also pay Autotelic for the services provided by third party contractors plus 20% mark up. The warrant price per share will be calculated based on the Black-Scholes model.

 

14

 

 

After the Equity Financing Date, the Company shall pay Autotelic Inc. a cash amount equal to the actual labor cost plus 100% mark up of provided services and 20% mark up of provided services by third party contractors or material used in connection with the performance of the contracts, including but not limited to clinical trial, non-clinical trial, Contract Manufacturing Organizations (“CMO”), FDA regulatory process, Contract Research Organizations (“CRO”) and Chemistry and Manufacturing Controls (“CMC”).

 

In accordance with the MSA, Autotelic Inc. billed the Company for personnel and service expenses Autotelic Inc. incurred on behalf of the Company. For the nine months ended September 30, 2018 and 2017, Autotelic Inc. billed a total of $777,928 and $492,406, including personnel costs of $370,520 and $386,954, respectively. An unpaid balance of $99,896 and $730,629 is included in due to related party in the accompanying balance sheet as of September 30, 2018 and December 31, 2017, respectively.

 

In April 2018, and in connection with the closing of our private placement on that date, we entered into a Compromise and Settlement Agreement with Autotelic Inc. pursuant to which we agreed to issue to Autotelic Inc. an aggregate of 162.59 shares of Series E Preferred Stock and Warrants to purchase up to 1,345,040 shares of common stock to satisfy accrued and unpaid fees in the aggregate amount of approximately $739,772, and other liabilities, owed to Autotelic Inc. as of March 31, 2018 pursuant to the MSA. The securities that were issued to Autotelic Inc., which were issued upon the closing described above, have the same terms and conditions as the securities that were issued to investors in the offering (See Note 5). The warrants have a five-year term, an exercise price of $0.55, and have a fair value of $1,494,469 resulting in a loss on settlement of debt of $754,697.

 

Resignation and Appointment of Officer and Directors 

 

On April 27, 2018, our Board of Directors (the “Board”) increased the size of the entire Board from five (5) directors to seven (7) directors, and it appointed each of Erik Emerson and Tim Boris to fill the vacancies created thereby.

 

In May 2018, each of Philip C. Ranker and Philippe P. Calais, Ph.D. resigned as members of the Board, and all committees thereof, effective immediately. In connection with their resignations: (i) each of Mr. Ranker and Dr. Calais released us from all claims arising prior to the date of his resignation; (ii) we granted to Mr. Ranker fully-vested options to purchase up to 200,000 shares of our common stock at an exercise price equal to $0.98 per share of common stock; and (iii) we granted to Dr. Calais fully-vested options to purchase up to 80,000 shares of our common stock at an exercise price equal to $0.98 per share of common stock. The foregoing options are exercisable for a period of five years from the grant date.

 

In May 2018, the Board accepted the resignation of Joseph W. Ramelli, our Chief Executive Officer, whereby Mr. Ramelli resigned as an officer of our company, and as a director and/or officer of any and all subsidiaries of our company, effective immediately, to pursue other opportunities. In connection with his resignation, Mr. Ramelli released us from all claims arising prior to the date of his resignation and affirmed his obligations to be bound by the restrictive covenants contained in the employment agreement between Mr. Ramelli and our company dated February 2, 2017, and we: (i) agreed to make severance payments to Mr. Ramelli in the amount of $60,000 to be paid over a six (6) month period; and (ii) granted to Mr. Ramelli fully-vested options, exercisable for a period of five years from the grant date, to purchase up to 100,000 shares of our common stock at an exercise price equal to $0.98 per share of common stock. In May 2018, the Board appointed Vuong Trieu, a director of the Company and former Executive Chairman, to serve as our Interim Chief Executive Officer, to replace Mr. Ramelli, effective with Mr. Ramelli’s departure. In his capacity as Interim Chief Executive Officer, Dr. Trieu received a salary in the amount of $20,000 per month. Dr. Trieu resigned from the position of Interim Chief Executive Officer on June 18, 2018.

 

On June 18, 2018, the Board appointed Robert C. Moscato, Jr., to serve as our Chief Executive Officer effective immediately. In connection with the appointment of Mr. Moscato as Chief Executive Officer, Dr. Trieu resigned as Interim Chief Executive Officer, and also from his position as Executive Chairman of our company, effective immediately.

 

On June 18, 2018, the Board appointed Uli Hacksell, Ph.D.to serve as a member of the Board, and as Chairman of the Board, effective July 1, 2018. Dr. Hacksell agreed to devote half of his business time to Adhera.

 

On June 28, 2018, the Board appointed Mr. Moscato to serve as a member of the Board, effective July 1, 2018.

 

We entered into an employment agreement with R. Eric Teague pursuant to which Mr. Teague began serving as our Chief Financial Officer on September 24, 2018. In connection with the appointment of Mr. Teague as our Chief Financial Officer, Amit Shah, our prior Chief Financial Officer, resigned from such position, effective September 24, 2018.

 

15

 

 

Issuance of Preferred Stock and Warrants to Directors

 

In April 2018, and in connection with the closing of our private placement on that date, we entered into Compromise and Settlement Agreements with four of the then current members of our Board of Directors and one former member of our Board of Directors pursuant to which we agreed to issue to such directors an aggregate of 58.25 shares of Series E Preferred Stock and Warrants to purchase up to 436,875 shares of common stock to satisfy accrued and unpaid fees owed to such directors for service as members of the Board of Directors during the period ending on December 31, 2017 in the aggregate amount of approximately $291,250. The securities that were issued to the directors, which were issued upon the closing of our private placement described above, have the same terms and conditions as the securities that were issued to investors in the offering.

 

Omnibus Settlement Agreement with Vuong Trieu, Ph.D. and Affiliated Entities

 

On October 1, 2018, we entered into an Omnibus Settlement Agreement (the “Settlement Agreement”) with Vuong Trieu, Ph.D., our former interim Chief Executive Officer, Executive Chairman and Chairman of our Board of Directors (the “Board”), Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. At the same time, and in connection therewith, we also entered into an Agreement and Release with each of Dr. Trieu and Falguni Trieu (the “Individual Releases”), and entered into an Agreement and Release with each of Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. (collectively, the “Entity Releases”). We also delivered a release (the “Company Release”) to Dr. Trieu, Ms. Trieu, Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. Pursuant to the Settlement Agreement, we agreed to make a payment to Dr. Trieu in the amount of $10,000 in consideration for Dr. Trieu entering into the Individual Releases between Dr. Trieu and our company. Dr. Trieu also agreed to sell, and we agreed to purchase, from Dr. Trieu for cancellation an aggregate of 500,000 shares of our common stock in consideration of an aggregate purchase price of $250,000. Additionally, each of Dr. Trieu, Autotelic Inc., Autotelic LLC, Oncotelic, Inc. and LipoMedics, Inc. agreed to certain restrictions on sale, transfer or assignment of our common stock.

 

Furthermore: (i) we and Autotelic Inc. agreed that the Master Services Agreement, dated as of November 15, 2016, by and between our company and Autotelic Inc., shall be terminated as of October 31, 2018; (ii) we and Autotelic BIO agreed that the Term Sheet, entered into as of January 11, 2018, by and between our company and Autotelic BIO, shall be terminated immediately; (iii) we and Oncotelic, Inc. confirmed that the License Agreement, dated July 17, 2017, by and between our company and Oncotelic Inc. was terminated effective May 15, 2018; and (iv) we and Lipomedics, Inc. agreed that the License Agreement, dated as of February 6, 2016, by and between our company and Lipomedics, Inc. would remain in effect.

 

Under the Settlement Agreement, we and Autotelic LLC agreed with respect to the License Agreement, dated as of November 15, 2016, by and between our company and Autotelic LLC, that such License Agreement shall continue, provided that Autotelic LLC shall be licensee and have a license to, without representation or warranty, nasal apomorphine and nasal scopolamine and related intellectual property in addition to nasal insulin, and Autotelic LLC shall not be a licensee or have a license to Familial Adenomatous Polyposis or CEQ508 and related intellectual property.

 

Pursuant to the Individual Releases, each of Dr. Trieu and Ms. Trieu, our former Director of Business Development and the spouse of Dr. Trieu, agreed to release us from all claims arising prior to the date of the Release Agreements. Pursuant to the Entity Releases, each of Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. agreed to release us from all claims arising prior to the date of the applicable Entity Release. Pursuant to the Company Release, we agreed to release each of Dr. Trieu, Ms. Trieu, Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. from all claims arising prior to the date of the Company Release.

 

Transactions with BioMauris, LLC

 

During the nine months ended September 30, 2018, the company paid a total of $473,397 for services provided by BioMauris, LLC, of which Erik Emerson, our Chief Commercial Officer and a director of Adhera, is Executive Chairman. A total of $45,546 was due BioMauris, LLC as of September 30, 2018.

 

Note 5 - Notes Payable

 

Following is a breakdown of notes payable as of September 30, 2018 and December 31, 2017:

 

   September 30, 2018   December 31, 2017 
         
Notes payable  $-   $97,523 
Convertible notes payable   -    346,700 
Total notes payable  $-   $444,223 
           
Notes payable - related parties   -   $93,662 
Convertible notes payable - related parties (net of debt discount of $0 and $113,170 as of September 30, 2018 and December 31, 2017, respectively)   -    1,368,378 
Total notes payable - related parties  $-   $1,462,040 

 

Note Payable - Service Provider

 

In December 2016, we entered into an Agreement and Promissory Note with a law firm for past services performed totaling $121,523. The note called for monthly payments of $6,000 per month, beginning with an initial payment on March 31, 2017. The note was unsecured and non-interest bearing. The note was paid in full in May 2018. The balance due on the note was $0 and $97,523 as of September 30, 2018 and December 31, 2017, respectively.

 

16

 

 

Note Purchase Agreement and Amendment

 

In July 2017, we entered into an amendment agreement (the “Amendment Agreement”) with the holders (such holders, the “June 2016 Noteholders”) of the promissory notes that we issued in June 2016 to the June 2016 Noteholders (the “2016 Notes”) with respect to the 2016 Notes and the warrants to purchase shares of our common stock that are held by the June 2016 Noteholders and that were originally issued pursuant to a certain Note and Warrant Purchase Agreement dated as of February 10, 2012 by and among Adhera, MDRNA, Cequent and the purchasers identified on the signature pages thereto (as amended from time to time), to, among other things, extend the maturity date of the 2016 Notes to December 31, 2017, to provide for the issuance of consideration securities at a cost of $375,000 (“Consideration Securities”) and to extend the price protection applicable to certain of the warrants held by the June 2016 Noteholders with respect to dilutive offerings afforded thereunder to February 10, 2020. Refer to our Form 10-Q for the six months ended June 30, 2017 for a more detailed discussion and additional terms for the 2016 Notes.

 

In April 2018, and in connection with the closing of our private placement on that date, we issued to the June 2016 Noteholders an aggregate of 71.46 shares of Series E Preferred Stock and Warrants to purchase up to 535,950 shares of common stock as a result of the conversion of the 2016 Notes. As a result of the conversion of the 2016 Notes and the issuance of the securities to the June 2016 Noteholders, the entire unpaid principal balance of the 2016 Notes, and the accrued and unpaid interest thereon, has been satisfied in full, and such notes are no longer outstanding.

 

In addition, in April 2018, and in connection with the closing of our private placement on that date, we issued to the June 2016 Noteholders an aggregate of 75 shares of Series E Preferred Stock and Warrants to purchase up to 562,500 shares of common stock in full and complete satisfaction of our obligations to issue $375,000 worth of Consideration Securities to the June 2016 Noteholders pursuant to the Amendment Agreement.

 

As of September 30, 2018 and December 31, 2017, the accrued interest expense on the 2016 Notes amounted to $0 and $46,700, respectively, with a total balance of principal and interest of $0 and $346,700, respectively.

 

2017 Bridge Note Financing

 

In June 2017, we issued convertible promissory notes (the “2017 Notes”) in the aggregate principal amount of $400,000 to 10 investors pursuant to a Note Purchase Agreement (the “Note Purchase Agreement”) that we entered into with such investors (the “June 2017 Noteholders”). The 2017 Notes bear interest at a rate of five percent (5%) per annum and are due and payable at any time on or after the earlier of (i) June 1, 2018 and (ii) the occurrence of an event of default (as defined in the Note Purchase Agreement). Our then Executive Chairman and our Chief Science Officer were each investors in the 2017 Notes.

 

As of September 30, 2018 and December 31, 2017, the accrued interest expense on the 2017 Notes amounted to $0 and $11,365, with a total balance of principal and interest of $0 and $411,365, respectively, and is included in notes payable - related parties on the accompanying balance sheet.

 

In April 2018, and in connection with the closing of our private placement on that date, we issued to the June 2017 Noteholders an aggregate of 74.17 shares of Series E Preferred Stock and Warrants to purchase up to 505,705 shares of common stock (and also paid to such holders an aggregate of $56 thousand in cash) as full and complete satisfaction of the unpaid principal balance (and accrued but unpaid interest thereon) owed by us to the June 2017 Noteholders under the 2017 Notes. As a result of the conversion of the 2017 Notes and the issuance of the securities to the June 2016 Noteholders (and payment of cash), the entire unpaid principal balance of the 2017 Notes, and the accrued and unpaid interest thereon, has been satisfied in full, and such notes are no longer outstanding. The securities that were issued to the June 2017 Noteholders have the same terms and conditions as the securities that were issued to investors in the offering.

 

Convertible Notes Payable

 

In July 2016, IThena issued convertible promissory notes with an aggregate principal balance of $50,000 to certain related-party investors. Borrowings under each of these convertible notes bore interest at 3% per annum and these notes mature on September 30, 2018. Upon the completion of certain funding events, IThena had the right to convert the outstanding principal amount of these notes into shares of IThena’s common stock. The notes were assumed by Autotelic Inc. on November 15, 2016 as part of its acquisition of the technology asset (IT-101).

 

17

 

 

In November 2017, the Company issued a convertible promissory note with a related party (a trust affiliated with Isaac Blech, a member of our Board of Directors) for $500,000 (the “Blech Note”), with annual interest at 8%, maturing on March 31, 2018, and convertible at the price equal to any financing transaction involving the sale by the Company of its equity securities yielding aggregate gross proceeds to the Company of not less than $5 million. The note included warrants to purchase 66,667 shares of the Company’s common stock, with a 5-year term and an exercise price of $0.75.

 

In April 2018, and in connection with the closing of our private placement on that date, we issued to the trust an aggregate of 103.18 shares of Series E Preferred Stock and Warrants to purchase up to 777,750 shares of common stock as a result of the conversion of the Blech Note in the original principal amount of $500,000. As a result of the conversion of the Blech Note and the issuance of the securities to the holder thereof, the entire unpaid principal balance of the Blech Note, and the accrued and unpaid interest thereon, has been satisfied in full, and the Blech Note is no longer outstanding. The securities that were issued to the holder of the Blech Note have the same terms and conditions as the securities that were issued to investors in the offering.

 

The Blech Note included a debt discount of $162,210 consisting of loan costs of $50,000 and the fair value of the warrants of $112,210. Total amortization of this debt discount was $113,171 for the nine months ended September 30, 2018, with a remaining unamortized value of $0. Total principal and interest was $0 and $504,274 as of September 30, 2018 and December 31, 2017, respectively, and is included in notes payable - related parties on the accompanying balance sheet.

 

Convertible Notes Payable, Dr. Trieu

 

In connection with the Merger, Adhera entered into a Line Letter dated November 15, 2016 with Dr. Trieu for an unsecured line of credit in an amount not to exceed $540,000, to be used for current operating expenses. Dr. Trieu has advanced the full $540,000 under the Line Letter as of December 31, 2017. The line of credit was convertible at any time into shares of the Company’s common stock at a price of $1.77 per share.

 

In April 2018, and in connection with the closing of our private placement on that date, we issued to Dr. Trieu 114.63 shares of Series E Preferred Stock and Warrants to purchase up to 859,725 shares of common stock as full and complete satisfaction of the unpaid principal balance (and accrued but unpaid interest thereon) owed by us to Dr. Trieu under the Line of Credit. As such, the Line of Credit was terminated in April 2018. The securities that were issued to Dr. Trieu have the same terms and conditions as the securities that were issued to investors in the offering.

 

Accrued interest on the Line Letter was $0 and $25,836 as of September 30, 2018 and December 31, 2017, respectively, and is included in notes payable - related parties on the accompanying consolidated balance sheets.

 

Line Letter with Autotelic, Inc.

 

In April 2017, the Company entered into a Line Letter with Autotelic Inc. for an unsecured line of credit in an amount not to exceed $500,000, to be used for current operating expenses. Autotelic Inc. is a stockholder of IThenaPharma that became the holder of 525,535 shares of Adhera common stock as a result of the Merger, and an entity of which Dr. Trieu serves as Chairman of the Board. Autotelic Inc. was to consider requests for advances under the Line Letter until September 1, 2017. Autotelic Inc. had the right at any time for any reason in its sole and absolute discretion to terminate the line of credit available under the Line Letter or to reduce the maximum amount available thereunder without notice. Advances made under the Line Letter bear interest at the rate of five percent (5%) per annum, are evidenced by the Demand Promissory Note issued to Autotelic Inc., and are due and payable upon demand by Autotelic, Inc. Autotelic Inc. advanced funds after September 1, 2017 but is no longer considering additional requests for advances as of December 31, 2017.

 

In April 2018, and in connection with the closing of our private placement on that date, we issued to Autotelic Inc. 19 shares of Series E Preferred Stock and Warrants to purchase up to 142,500 shares of common stock as full and complete satisfaction of the unpaid principal balance (and accrued but unpaid interest thereon) owed by us to Autotelic Inc. under the Line of Credit, of which $90,816 had been drawn down as of the date of the closing described above. As such, in April 2018, the line of credit with Autotelic Inc was terminated. The securities that were issued to Autotelic Inc. have the same terms and conditions as the securities that were issued to investors in the offering.

 

18

 

 

The balance under the line was $0 and $93,662, including accrued interest of $0 and $2,847 as of September 30, 2018 and December 31, 2017, respectively, and is included in notes payable - related parties on the accompanying consolidated balance sheet.

 

Note 6 - Stockholders’ Equity

 

Preferred Stock

 

Adhera has authorized 100,000 shares of preferred stock for issuance and has designated 1,000 shares as Series B Preferred Stock (“Series B Preferred”) and 90,000 shares as Series A Junior Participating Preferred Stock (“Series A Preferred”). No shares of Series B Preferred or Series A Preferred are outstanding. In March 2014, Adhera designated 1,200 shares as Series C Convertible Preferred Stock (“Series C Preferred”). In August 2015, Adhera designated 220 shares as Series D Convertible Preferred Stock (“Series D Preferred”). In April 2018, Adhera designated 3,500 shares of Series E Convertible Preferred Stock. In July 2018, Adhera designated 2,200 shares of Series F Convertible Preferred Stock.

 

Series C Preferred

 

Each share of Series C Preferred has a stated value of $5,000 per share, has a $5,100 liquidation preference per share, has voting rights of 666.67 votes per share, and is convertible into shares of common stock at a conversion price of $7.50 per share. In September 2017, an investor converted 270 shares of Series C Preferred stock into 180,000 shares of our common stock.

 

In June 2018, an investor converted 650 shares of Series C Preferred stock into 433,334 shares of our common stock.

 

As of September 30, 2018 and December 31, 2017, 100 and 750 shares, respectively, of Series C Preferred remained outstanding.

 

Series D Preferred

 

In August 2015, Adhera entered into a Securities Purchase Agreement with certain investors pursuant to which Adhera sold 220 shares of Series D Preferred and warrants to purchase up to 344,000 shares of Adhera’s common stock at an initial exercise price of $4.00 per share before August 2021, for an aggregate purchase price of $1.1 million. Each share of Series D Preferred has a stated value of $5,000 per share, has a liquidation preference of $300 per share, has voting rights of 1,250 votes per share and is convertible into shares of common stock at a conversion price of $4.00 per share. The Series D Preferred is initially convertible into an aggregate of 275,000 shares of Adhera’s common stock, subject to certain limitations and adjustments, has a 5% stated dividend rate, is not redeemable and has voting rights on an as-converted basis.

 

In May 2018, an investor converted 20 shares of Series D Preferred into 25,000 shares of common stock.

 

As of September 30, 2018 and December 31, 2017, 40 and 60 shares, respectively, of Series D Preferred remained outstanding.

 

Series E Convertible Preferred Stock Private Placement

 

In April and May 2018, we entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 2,812 shares of our Series E convertible preferred stock (the “Preferred Stock”), at a purchase price of $5,000 per share of Preferred Stock. Each share of Preferred Stock is initially convertible into shares of our common stock at a conversion price of $0.50 per share of common stock. In addition, each investor received a 5-year warrant (the “Warrants”, and collectively with the Preferred Stock, the “Securities”) to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Preferred Stock purchased by such investor at an exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. The Preferred Stock accrues 8% dividends per annum and are payable in cash or stock at the Company’s discretion. The Preferred Stock has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights as described in the Certificate of Designation of Preferences, Rights and Limitations of the Preferred Stock, which we filed with the Secretary of State of Delaware in April 2018. The Warrants have full-ratchet anti-dilution protection, are exercisable for a period of five years and contain customary exercise limitations.

 

19

 

 

We received net proceeds of approximately $12.2 million from the sale of the Preferred Stock, after deducting placement agent fees and estimated expenses payable by us of approximately $2.0 million associated with such closing. We intend to use the proceeds of the offering for funding our commercial operations to the sale and promotion of our Prestalia product, working capital needs, capital expenditures, the repayment of certain liabilities and other general corporate purposes. In connection with the private placement described above, we also issued to the placement agent for such private placement a Warrant to purchase 2,958,460 shares of our common stock.

 

We accrued dividends on the Series E Preferred Stock of $351,897 for the three months ended September 30, 2018 and $622,530 for the nine months ended September 30, 2018. No similar dividends were accrued for the same periods of 2017.  

 

Series F Convertible Preferred Share Private Placement

 

In July 2018, we entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 308 shares of our Series F convertible preferred stock (the “Preferred Stock”), at a purchase price of $5,000 per share of Preferred Stock. Each share of Preferred Stock is initially convertible into shares of our common stock at a conversion price of $0.50 per share of common stock. In addition, each investor received a 5-year warrant (the “Warrants”, and collectively with the Preferred Stock, the “Securities”) to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Preferred Stock purchased by such investor at an exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. The Preferred Stock accrues 8% dividends per annum and are payable in cash or stock at the Company’s discretion. The Preferred Stock has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights as described in the Certificate of Designation of Preferences, Rights and Limitations of the Preferred Stock, which we filed with the Secretary of State of Delaware in July 2018. The Warrants have full-ratchet anti-dilution protection, are exercisable for a period of five years and contain customary exercise limitations. 

 

We received proceeds of approximately $1.3 million from the sale of the Securities, after deducting placement agent fees and estimated expenses payable by us of approximately $180,000 associated with such closing. We intend to use the proceeds of the offering for funding our commercial operations to the sale and promotion of our Prestalia product, working capital needs, capital expenditures, the repayment of certain liabilities and other general corporate purposes. In connection with the private placement described above, we also issued to the placement agent for such private placement a Warrant to purchase 308,000 shares of our common stock. The Warrant has a five-year term and an exercise price of $0.55 per share.

 

We accrued dividends on the Series F Preferred Stock of $27,327 for the 3 months and nine months ended September 30, 2018. No similar dividends were accrued for the same periods of 2017.  

 

Stock Option Grants

 

In July 2018, we granted our Chief Executive Officer, Robert Moscato, Jr., 1,500,000 stock options; Uli Hacksell, Ph. D., the Chairman of our Board, 1,000,000 stock options, Erik Emerson, our Chief Commercial Officer, 1,125,000 stock options, and Jay Schwartz, our VP of Operations, 250,000 stock options.

 

In September 2018, we granted our Chief Financial Officer, Eric Teague, 450,000 stock options.

 

Common Stock

 

Our common stock currently trades on the OTCQB tier of the OTC Markets under the symbol “ATRX”. We currently have 10,761,684 shares of our common stock outstanding.

 

Stock Issuances

 

In addition to the common stock and preferred stock issuances described above, we issued the following shares of the Company’s common stock during the nine months ended September 30, 2018.

 

20

 

 

As discussed in Note 8, in May 2018, we issued to Novosom 51,988 shares of our common stock as additional consideration pursuant to the Asset Purchase Agreement, dated as of July 27, 2010, between our company and Novosom. Such shares were due to Novosom as a result of the receipt by our company of a license fee under the License Agreement that we entered into with Lipomedics Inc. in February 2017.

 

As discussed in Note 9, in April 2018, we entered into a Stipulation of Settlement with Vaya Pharma and issued a total of 210,084 shares of our common stock with a fair value of $250,000.

 

In May 2018, an investor converted 20 shares of Series D Preferred into 25,000 shares of common stock.

 

In June 2018, an investor converted 650 shares of Series C Preferred stock into 433,334 shares of our common stock.

 

Warrants

 

As of September 30, 2018, there were 35,646,829 warrants outstanding, with a weighted average exercise price of $0.79 per share, and annual expirations as follows:

 

Expiring in 2018   - 
Expiring in 2019   600,000 
Expiring in 2020   1,189,079 
Expiring in 2021   343,750 
Expiring in 2022   29,202,227 
Expiring thereafter   4,311,773 
    35,646,829 

 

The above includes 29,135,560 warrants issued in April and May 2018 in connection with our Series E Preferred Stock offering with a fair value of $31,106,896 and 2,618,000 warrants issued with our Series F Preferred Stock offering with a fair value of $1,313,684 which are reflected in additional paid-in capital and additional paid in capital-warrants on the accompanying condensed consolidated statement of stockholders’ equity. The warrants have a five-year term and an exercise price of $0.55. There was no expense related to these warrants.

 

Additionally, the above includes 1,345,040 warrants issued to Autotelic, Inc. in April 2018 to satisfy accrued and unpaid fees in the aggregate amount of approximately $739,772, and other liabilities, owed to Autotelic Inc. as of March 31, 2018. The warrants have a five-year term, an exercise price of $0.55, and have a fair value of $1,494,469 resulting in a loss on settlement of liability of $754,697.

 

The above includes price adjustable warrants totaling 1,895,013 which are described more fully in our 2017 Annual Report on Form 10-K.

 

A total of 339,702 warrants expired during the nine months ended September 30, 2018.

 

Note 7 - Stock Incentive Plans

 

Stock Options

 

Stock option activity was as follows:

 

   Options Outstanding 
   Shares   Weighted
Average
Exercise Price		 
Outstanding, December 31, 2017   745,707   $8.84 
Options granted   4,724,000    0.67 
Options expired / forfeited   (88,750)   67.40 
Outstanding, September 30, 2018   5,380,957    0.86 
Exercisable, September 30, 2018   1,638,991   $0.93 

 

21

 

 

The following table summarizes additional information on Adhera’s stock options outstanding at September 30, 2018:

 

    Options Outstanding   Options Exercisable 
Range of
Exercise
Prices		   Number Outstanding   Weighted- Average Remaining Contractual Life (Years)   Weighted Average Exercise Price   Number Exercisable   Weighted Average Exercise Price 
$0.98    4,705,000    9.39   $0.67    1,467,500   $0.73 
$1.00    7,000    3.13   $1.00    7,000   $1.06 
 $1.50 - $1.80    521,107    8.64   $1.79    136,641   $1.78 
 $2.60 - $8.20    135,200    3.78   $2.77    15,200   $4.48 
 $10.70 - $22.00    12,650    1.00   $10.92    12,650   $10.92 
                            
 Totals    5,380,957    9.15   $0.86    1,638,991   $0.93 

 

Weighted-Average Exercisable Remaining Contractual Life (Years) 8.22

 

In January 2018, the Company granted a total of 19,000 stock options to directors and officers for services. The options have an exercise price of $1.56 and a five-year term.

 

In May 2018, the Company granted a total of 380,000 stock options to directors and officers for services. The options have an exercise price of $0.98 and a five-year term.

 

In July 2018, we granted our Chief Executive Officer, 1,500,000 stock options; Uli Hacksell, Ph.D., the Chairman of our Board, 1,000,000 stock options; and Erik Emerson, our Chief Commercial Officer, 1,125,000 stock options at an exercise prices of $0.66 per share with a 10-year term.

 

In July 2018, we granted our SVP of Commercial Operations 250,000 stock options at an exercise price of $0.575 per share with a 10-year term.

 

In September 2018 we granted our Chief Financial Officer 450,000 stock options at an exercise price of $0.55 per share with a 10-year term.

 

As of September 30, 2018, we had $523,943 of total unrecognized compensation expense related to unvested stock options. Total expense related to stock options was $1,307,046 and $218,295 for the nine months ended September 30, 2018 and 2017, respectively, and $814,008 and $5,109 for the three months ended September 30, 2018 and 2017, respectively.

 

As of September 30, 2018, the intrinsic value of options outstanding or exercisable was $0 as there were no options outstanding with an exercise price less than $0.54, the per share closing market price of our common stock at that date.

 

Note 8 - Intellectual Property and Collaborative Agreements

 

Novosom Agreements

 

In July 2010, Adhera entered into an asset purchase agreement with Novosom Verwaltungs GmbH (“Novosom”), pursuant to which Adhera acquired intellectual property for Novosom’s SMARTICLES-based liposomal delivery system.  In May 2018, we issued to Novosom 51,988 shares of our common stock, with a fair value of $75,000, as additional consideration pursuant to the Asset Purchase Agreement. Such shares were due to Novosom as a result of the receipt by our company of a license fee under the License Agreement that we entered into with Lipomedics Inc. in February 2017.

 

22

 

 

Arrangements with LipoMedics

 

In February 2017, we entered into a License Agreement (the “License Agreement”) with LipoMedics, pursuant to which, among other things, we provided to LipoMedics a license to our SMARTICLES platform for further development of Lipomedics’s proprietary phospholipid nanoparticles that can deliver protein, small molecule drugs, and peptides. These are not currently being developed at Adhera and Adhera has no IP around these products. On the same date, we also entered into a Stock Purchase Agreement with LipoMedics pursuant to which we issued to LipoMedics an aggregate of 86,207 shares of our common stock for a total purchase price of $250,000.

 

Under the terms of the License Agreement, we could receive success-based milestones based on commercial sales of licensed products. In addition, if LipoMedics determines to pursue further development and commercialization of products under the License Agreement, LipoMedics agreed, in connection therewith, to purchase shares of our common stock for an aggregate purchase price of $500,000, with the purchase price for each share of common stock being the greater of $2.90 or the volume weighted average price of our common stock for the thirty (30) trading days immediately preceding the date on which LipoMedics notifies us that it intends to pursue further development or commercialization of a licensed product.

 

If LipoMedics breaches the License Agreement, we shall have the right to terminate the License Agreement effective sixty (60) days following delivery of written notice to LipoMedics specifying the breach, if LipoMedics fails to cure such material breach within such sixty (60) day period.

 

Vuong Trieu, Ph.D. is the Chairman of the Board and Chief Operating Officer of LipoMedics.

 

In consideration Lipomedics agreed to the following fee schedule: 1) Evaluations License Fee. Simultaneous with the execution and delivery of the License Agreement, Lipomedics shall enter into a Stock Purchase Agreement in form and substance reasonably acceptable to Adhera and Lipomedics, pursuant to which Adhera will sell to Lipomedics shares of the common stock of Adhera for an aggregate purchase price of $0.25 million, with the purchase price for each share of Adhera common stock being $2.90. 2) Commercial License Fee. Unless the License Agreement is earlier terminated, within thirty (30) days following Lipomedics’s delivery of an Evaluation Notice advising that it intends to pursue, or cause to be pursued, further development and commercialization of Licensed Products. 3) For up to and including three Licensed Products, Lipomedics shall pay to Adhera a milestone (collectively the “Sales Milestones”) of $10 million upon reaching Commercial Sales in the Territory in any given twelve month period equal to or greater than $500 million for a given Licensed Product and of $20 million upon reaching Commercial Sales in any given twelve month period equal to or greater than $1 million for such Licensed Product, such payments to be made within thirty (30) days following the month in which such Commercial Sale targets are met.

 

Arrangements with Oncotelic Inc.

 

In July 2017, we entered into a License Agreement (the “License Agreement”) with Oncotelic, Inc. (“Oncotelic”) pursuant to which, among other things, we provided to Oncotelic a license to our SMARTICLES platform for the delivery of antisense DNA therapeutics, as well as a license to our conformationally restricted nucleotide (“CRN”) technology with respect to TGF-Beta. Under the terms of the License Agreement, Oncotelic also agreed to purchase 49,019 shares of our common stock for an aggregate purchase price of $0.25 million ($5.10 per share), with such purchase and sale to be made pursuant to a Stock Purchase Agreement to be entered into between us and Oncotelic within thirty (30) days following the date of the License Agreement. Oncotelic has not completed the purchase of the stock and we have not been able to reach to a definitive agreement, as such we have terminated the agreement.

 

23

 

 

Agreement with Autotelic BIO

 

On January 11, 2018, we entered into a binding agreement with Autotelic BIO (“ATB”) pursuant to which, among other things, and subject to the satisfaction of certain conditions on or prior to January 15, 2019, we shall grant to ATB a perpetual exclusive right of development and marketing of our IT-103 product candidate, which is a fixed dose combination of celecoxib and olmesartan medoxomil, at the currently approved dose/approved indications only for celecoxib (100 mg, 200mg and 400mg) for combined hypertension and arthritis only, with such right extending throughout the entire world (excluding the United States and Canada, and the territories of such countries). The grant of the license would be memorialized in a definitive license agreement to be entered into between the parties. On October 1, 2018, we and ATB agreed to terminate this arrangement.

 

Autotelic LLC, an entity that owns approximately 22% of the issued and outstanding shares of our common stock and of which Dr. Trieu serves as Chief Executive Officer, owns approximately 19% of the issued and outstanding shares of the common stock of ATB.

 

License of DiLA2 Assets

 

On March 16, 2018, Adhera entered into a Licensing Agreement, whereby Adhera granted exclusive rights to the company’s DiLA2 delivery system in exchange for an upfront payment of $200,000 and further potential future consideration dependent upon event and sales-based milestones. Under the terms of the agreement, Adhera has agreed to assign ownership of the intellectual property associated with the DiLA2 delivery system to the purchaser. The Company has yet to complete certain performance obligations under the agreement and accordingly has deferred the recognition of revenue from the sale of the asset until such obligations are fulfilled.

 

Asset Purchase Agreement

 

In July 2017, Adhera entered into an Asset Purchase Agreement with Symplmed Pharmaceuticals LLC and its wholly-owned subsidiary Symplmed Technologies, LLC pursuant to which the Company purchased from the Sellers, for an aggregate purchase price of $75,000 in cash, certain specified assets of the Sellers relating to the Sellers’ patented technology platform known as DyrctAxess that offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to help achieve optimal care (see Note 3).

 

Note 9 - Commitments and Contingencies

 

Amendment to Agreement with Windlas Healthcare Private Limited

 

On August 17, 2017, we entered into an amendment (the “Amendment”) of that certain Pharmaceutical Development Agreement dated as of March 30, 2017 by and between Windlas Healthcare Private Limited (“Windlas”) and our company (the “Development Agreement”), relating to the development by Windlas of certain pharmaceutical products to be used for conducting clinical trials or for regulatory submissions, as more fully described therein. Pursuant to the Amendment, we and Windlas agreed to amend the Development Agreement to reflect our agreement to issue to Windlas, and Windlas’ agreement to accept from us, in lieu of cash payments with respect to forty percent (40%) of the total amount reflected on invoices sent from time to time by Windlas to us, shares of our common stock having an aggregate value equal to forty percent (40%) of such invoiced amount (with the remaining portion of the invoiced amount being paid in cash). The maximum value of common stock that may be issued to Windlas pursuant to the Development Agreement (as modified by the Amendment) is $2 million. The parties also agreed that the foregoing payment arrangement would apply to any Contract Manufacturing and Supply Agreement (or similar agreement) relating to the manufacturing of commercial batches of the products covered by the Development Agreement that may be entered into between the parties.

 

Litigation 

 

Because of the nature of our activities, we are subject to claims and/or threatened legal actions, which arise out of the normal course of business. Other than the disclosure below, as of the date of this filing, we are not aware of any pending lawsuits against us, our officers or our directors.

 

24

 

 

We had been named on a complaint filed in New York State as a defendant in the matter entitled Vaya Pharma, Inc. v. Symplmed Technologies, Inc., Symplmed Pharmaceuticals, Inc., Erik Emerson and Marina Biotech, Inc. While this complaint had been filed in the Supreme Court of the State of New York, we had not been legally served. The complaint alleged, in relevant part, that: (i) the sale by Symplmed Pharmaceuticals, Inc. of its assets related to its Prestalia product, and the sale by Symplmed Technologies, Inc. of its assets related to its DyrctAxess platform, should be set aside pursuant to New York law as they were consummated without fair consideration to the sellers (the “Symplmed Defendants”), and thereby had the effect of fraudulently depriving the creditors of the Symplmed Defendants, including Vaya Pharma, Inc., of funds that could have been used to pay their debts; and (ii) we were liable, as successor, for any and all claims by Vaya Pharma, Inc. against the Symplmed Defendants, though pursuant to the agreement we are only contractually responsible for liabilities that accrue after the parties entered into the agreement for Prestalia and any liabilities that existed prior to the agreement are contractually held by Symplmed. In April 2018, we entered into a Stipulation of Settlement requiring us to issue to Vaya Pharma 210,084 shares of our common stock with a fair value of $250,000, which shares were issued in April of 2018. We accrued $0 and $250,000, as of September 30, 2018 and December 31, 2017, respectively, and such amount was included in accrued expenses on the accompanying consolidated balance sheets. 

 

Note 10 - Subsequent Events

 

Except for the event(s) discussed below, there were no subsequent events that required recognition or disclosure. The Company evaluated subsequent events through the date the financial statements were issued and filed with the Securities and Exchange Commission.

 

On November 9, 2018, we entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 73 shares of our Series F convertible preferred stock, par value of $0.01 per share (the “Preferred Stock”), at a purchase price of $5,000 per share of Preferred Stock. Each share of Preferred stock is initially convertible into shares of our common stock at a conversion price of $0.50 per share of common Stock. In addition, each investor received a 5-year warrant to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Preferred Stock purchased by such investor at an exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. We received total net proceeds of approximately $0.31 million from the issuance of the securities described above, after deducting placement agent fees and estimated expenses payable by us associated with such closing.

 

As discussed in Note 4, on October 1, 2018, we entered into a Settlement Agreement with Vuong Trieu, Ph.D., our former interim Chief Executive Officer, Executive Chairman and Chairman of our Board of Directors, which incuded the Company repurchasing 500,000 shares of our common stock from Dr. Trieu.

 

In October 2018, an investor converted 2 shares of Series E convertible preferred stock into 20,000 shares of our common stock.

 

25

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

This Quarterly Report on Form 10-Q includes a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) that reflect management’s current views with respect to future events and financial performance. The following discussion should be read in conjunction with the financial statements and related notes contained in our Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (“SEC”) on April 17, 2018. Forward-looking statements are projections in respect of future events or financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology.

 

Forward-looking statements are inherently subject to risks and uncertainties, many of which we cannot predict with accuracy and some of which we might not even anticipate. Although we believe that the expectations reflected in such forward-looking statements are based upon reasonable assumptions at the time made, we can give no assurance that such expectations will be achieved. Future events and actual results, financial and otherwise, may differ materially from the results discussed in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements after the date of this Quarterly Report on Form 10-Q or to conform them to actual results, new information, future events or otherwise, except as otherwise required by securities and other applicable laws.

 

The following factors, among others, could cause our or our industry’s future results to differ materially from historical results or those anticipated:

 

●our continued ability to obtain additional funding for our company, whether pursuant to a capital raising transaction arising from the sale of our securities, a strategic transaction or otherwise;
●our ability to attract and/or maintain research, development, commercialization and manufacturing partners;
●the ability of our company and/or a partner to successfully complete product research and development, including pre-clinical and clinical studies and commercialization;
●the ability of our company and/or a partner to obtain required governmental approvals, including product and patent approvals;
●the ability of our company and/or a partner to develop and commercialize products that can compete favorably with those of our competitors;
●the timing of costs and expenses related to the research and development programs of our company and/or our partners;
●the timing and recognition of revenue from milestone payments and other sources not related to product sales;
●our ability to obtain suitable facilities in which to conduct our planned business operations on acceptable terms and on a timely basis;
●our ability to satisfy our disclosure obligations under the Exchange Act, as amended, and to maintain the registration of our common stock thereunder;
●our ability to attract and retain qualified officers, employees and consultants as necessary; and
●costs associated with any product liability claims, patent prosecution, patent infringement lawsuits and other lawsuits.

 

These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” set forth in our Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC on April 17, 2018, any of which may cause our company’s or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These risks may cause our or our industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements.

 

26

 

 

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity or performance. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. We are under no duty to update any forward-looking statements after the date of this report to conform these statements to actual results.

 

As used in this quarterly report and unless otherwise indicated, the terms “we,” “us,” “our” or the “Company” refer to Adhera Therapeutics, Inc., a Delaware corporation, and its wholly-owned subsidiaries, MDRNA Research, Inc., Cequent Pharmaceuticals, Inc., Atossa Healthcare, Inc., and IthenaPharma, Inc. Unless otherwise specified, all dollar amounts are expressed in United States dollars. Our common stock is currently listed on the OTC Market, OTCQB tier, under the symbol “ATRX.”

 

Corporate Overview

 

Nature of Business

 

We are an emerging specialty pharmaceutical company leveraging an innovative distribution model and technologies to improve the quality of care for patients in the United States suffering from chronic and acute diseases in the United States. Adhera is focused on fixed dose combination (“FDC”) therapies in hypertension, with plans to expand the portfolio of drugs commercialize include other therapeutic areas.

 

We began marketing Prestalia®, a single-pill FDC of perindopril arginine (an angiotensin-converting-enzyme) inhibitor and amlodipine besylate (a calcium channel blocker), which was approved by the U.S. Food and Drug Administration (“FDA”) in June of 2018. Prestalia was developed in coordination with Servier, a French pharmaceutical conglomerate, that sells the formulation outside the United States under the brand name - Viacoram. Prestalia is distributed through the DyrectAxess platform which we acquired from Symplmed and its wholly-owned subsidiary, Symplmed Technologies, LLC in 2017. DyrectAxess is a patented technology platform, also known as Total Care®, that offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to achieve optimal care.

 

By combining Prestalia, DyrectAxess, and a specialty pharma network, we have created a proprietary platform for drug adherence and the effective treatment of hypertension, improving the distribution of FDC hypertensive drugs, such as our FDA-approved product Prestalia, devices for therapeutic drug monitoring (e.g., blood pressure and other cardiac monitors), as well as patient counseling and prescription reminder services.

 

During the nine months ended September 30, 2018, we received proceeds of approximately $12.2 million from the sale of our newly created Series E Convertible Preferred Stock (the “Series E Preferred Stock”), net of fees and expenses. The use of funds from the raise will be on the commercialization of Prestalia, funding working capital, capital expenditure needs, payment of certain liabilities and other general corporate requirements. We plan to license or divest our other pharmaceutical assets and halt any other FDC development programs since they no longer align with our focus on the treatment of hypertension.

 

27

 

 

Recent Developments During the Three Months Ended September 30, 2018

 

Sales of Series F Convertible Preferred Stock

 

On July 12, 2018, we entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 308 shares of our Series F convertible preferred stock, par value of $0.01 per share (the “Series F Stock”), at a purchase price of $5,000 per share of Series F Stock. Each share of Series F Stock is initially convertible into shares of our common stock at a conversion price of $0.50 per share of common stock. In addition, each investor received a 5-year warrant to purchase 0.75 shares of our common stock for each share of our common stock issuable upon the conversion of the Series F Stock purchased by such investor at an exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. We received total gross proceeds of approximately $1.54 million from the issuance of the securities described above, prior to deducting placement agent fees and estimated expenses payable by us associated with such closing. Our intended use of the proceeds is for funding operations, working capital needs, capital expenditures, the repayment of certain liabilities and other general corporate purposes in pursuit of advancing our commercial, clinical and preclinical efforts, including advancing our commercial operations relating to the sale and promotion of Prestalia® product.

 

Change of Corporate Offices

 

On September 10, 2018, we entered into a Standard Form Office Lease with ROC III Fairlead Imperial Center, LLC, with respect to office space located at 4721 Emperor Boulevard, Suite 350, Durham, North Carolina 27703, for a three year term. Starting on October 1, 2018, our executive offices have been located at such address. We no longer maintain an address at 17870 Castleton Street, Suite 250, City of Industry, California 91748.

 

Appointment of R. Eric Teague as Chief Financial Officer

 

We entered into an employment agreement with R. Eric Teague (the “Teague Agreement”) pursuant to which Mr. Teague began serving as our Chief Financial Officer on September 24, 2018. In connection with the appointment of Mr. Teague as our Chief Financial Officer, Amit Shah, our prior Chief Financial Officer, resigned from such position, effective September 24, 2018.

 

Mr. Teague’s base salary under the Teague Agreement, which provides for a three year term, is initially $285,000 per year, subject to review and adjustment by us from time to time. Starting in 2019, Mr. Teague shall be eligible for an annual discretionary cash bonus with a target of 35% of his base salary, subject to his achievement of any applicable performance targets and goals. Mr. Teague was also granted options to purchase up to 450,000 shares of our common stock, which options shall vest according to the terms of the Teague Agreement.

 

Omnibus Settlement Agreement with Vuong Trieu, Ph.D. and Affiliated Entities

 

On October 1, 2018, we entered into an Omnibus Settlement Agreement (the “Settlement Agreement”) with Vuong Trieu, Ph.D., our former interim Chief Executive Officer, Executive Chairman and Chairman of our Board of Directors (the “Board”), Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. At the same time, and in connection therewith, we also entered into an Agreement and Release with each of Dr. Trieu and Falguni Trieu (the “Individual Releases”), and entered into an Agreement and Release with each of Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. (collectively, the “Entity Releases”). We also delivered a release (the “Company Release”) to Dr. Trieu, Ms. Trieu, Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. Pursuant to the Settlement Agreement, we agreed to make a payment to Dr. Trieu in the amount of $10,000 in consideration for Dr. Trieu entering into the Individual Releases between Dr. Trieu and our company. Dr. Trieu also agreed to sell, and we agreed to purchase, from Dr. Trieu for cancellation an aggregate of 500,000 shares of our common stock in consideration of an aggregate purchase price of $250,000. Additionally, each of Dr. Trieu, Autotelic Inc., Autotelic LLC, Oncotelic, Inc. and LipoMedics, Inc. agreed to certain restrictions on sale, transfer or assignment of our common stock.

 

28

 

 

Furthermore: (i) we and Autotelic Inc. agreed that the Master Services Agreement, dated as of November 15, 2016, by and between our company and Autotelic Inc., shall be terminated as of October 31, 2018; (ii) we and Autotelic BIO agreed that the Term Sheet, entered into as of January 11, 2018, by and between our company and Autotelic BIO, shall be terminated immediately; (iii) we and Oncotelic, Inc. confirmed that the License Agreement, dated July 17, 2017, by and between our company and Oncotelic Inc. was terminated effective May 15, 2018; and (iv) we and Lipomedics, Inc. agreed that the License Agreement, dated as of February 6, 2016, by and between our company and Lipomedics, Inc. would remain in effect.

 

Under the Settlement Agreement, we and Autotelic LLC agreed with respect to the License Agreement, dated as of November 15, 2016, by and between our company and Autotelic LLC, that such License Agreement shall continue, provided that Autotelic LLC shall be licensee and have a license to, without representation or warranty, nasal apomorphine and nasal scopolamine and related intellectual property in addition to nasal insulin, and Autotelic LLC shall not be a licensee or have a license to Familial Adenomatous Polyposis or CEQ508 and related intellectual property.

 

Pursuant to the Individual Releases, each of Dr. Trieu and Ms. Trieu, our former Director of Business Development and the spouse of Dr. Trieu, agreed to release us from all claims arising prior to the date of the Release Agreements. Pursuant to the Entity Releases, each of Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. agreed to release us from all claims arising prior to the date of the applicable Entity Release. Pursuant to the Company Release, we agreed to release each of Dr. Trieu, Ms. Trieu, Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. from all claims arising prior to the date of the Company Release.

 

Resignation of Directors and Officers

 

On October 1, 2018, in connection with the Settlement Agreement, Dr. Trieu resigned as a member of the Board, and of the Board of Directors of each of our subsidiaries, effective immediately. In addition, and in connection with the continuing reorganization of management following our recent financing transactions, Larn Hwang, Ph.D., our former Chief Scientific Officer, Mihir Munsif, our former Chief Operating Officer, and Peter Weinstein, our former Chief Legal Officer, have resigned as officers of our company. We have contracted with an outside consulting firm to provide Chief Scientific Officer services as required by us, we have moved the roles and responsibilities of the Chief Operating Officer to the commercial team, and we anticipate that Mr. Weinstein will continue to provide legal services to us through his private practice.

 

Appointment of Director

 

On October 1, 2018, Nancy R. Phelan was appointed to serve as a member of our Board of Directors, effective immediately.

 

Amendments to Certificate of Incorporation

 

On October 4, 2018, we filed a Certificate of Amendment to our Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to change our name from “Marina Biotech, Inc.” to “Adhera Therapeutics, Inc.” The change of our name became effective on October 9, 2018. Following the change of our name from Marina Biotech, Inc. to Adhera Therapeutics, Inc., our common stock began trading on the OTCQB tier of the OTC Markets under the symbol “ATRX”.

 

Results of Operations

 

Comparison of the Three Months Ended September 30, 2018 to the Three Months Ended September 30, 2017

 

Net Sales

 

Net sales was $76,186 for the three months ended September 30, 2018, and represents revenues from the sale of Prestalia. We had no sales during the three months ended September 30, 2017. As the Company has yet to complete certain performance obligations under a licensing agreement for the sale of our DiLA2 assets, we have deferred the recognition of revenue of $200,000 until such obligations are fulfilled. The majority of our licensing deals provide for clinical and regulatory milestones, so significant revenues could result from the existing licenses, but are uncertain as to timing or probability. We will continue to seek research and development collaborations as well as licensing transactions to fund business operations.

 

Cost of Sales

 

Cost of sales was $7,760 for the three months ended September 30, 2018, and represents cost of sales from the sale of Prestalia. We had no sales or cost of sales during the three months ended September 30, 2017.

 

29

 

 

Operating Expenses

 

Our operating expenses for the three months ended September 30, 2018 are summarized as follows in comparison to our expenses for the three months ended September 30, 2017.

 

   Three Months Ended 
   September 30, 2018   September 30, 2017 
         
Sales, marketing and commercial operations  $870,926   $- 
Research and development   -    232,896 
General and administrative expenses   2,140,992    680,063 
Amortization   41,937    123,038 
Goodwill and intangible assets impairment   4,794,030    - 
Total operating expenses  $7,847,885   $1,035,997 

 

Sales, Marketing and Commercial Operations

 

Sales, marketing and commercial operations expense increased by approximately $0.8 million primarily due to launch activities related to the launch of Prestalia.

 

Research and Development

 

Research and development (“R&D”) expense decreased by approximately $0.2 million, as compared to the three months ended September 30, 2017 due to the Company’s primary focus transitioning from research and development activities to sales, marketing and commercial operations activities effective April 2018.

 

General and Administrative

 

General and administrative (“G&A”) expense increased by approximately $1.5 million for the three months ended September 30, 2018, as compared to the three months ended September 30, 2017, primarily due to an increase in stock option and payroll expense.

 

Amortization Expense

 

Amortization expenses relate to amortization of intangible assets acquired in the November 15, 2016 merger and the asset purchases on June 5, 2017 and July 21, 2017, with an aggregate estimated fair value of $3.1 million (reduced by the impairment loss of $1,291,200 described below).

 

Goodwill and intangible assets impairment

 

During the three months ended September 30, 2018, the Company determined that goodwill was impaired and, as a result, a loss on impairment of $3,502,830 was recognized for the three and nine-month periods ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company’s strategic objectives. There was no such loss on impairment for the three months ended September 30, 2017.

 

During the three months ended September 30, 2018, the Company determined that the intangible asset from the Merger was impaired and as a result, a loss on impairment of $1,291,200 was recognized and for the three months ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company’s strategic objectives . There was no such loss on impairment for the three months ended September 30, 2017.

 

Other Expense

 

   Three Months Ended 
   September 30, 2018   September 30, 2017 
Interest expense  $-   $(24,301)
Change in fair value liability of warrants   -    7,442 
Change in fair value of derivative liability        -    80,672 
Total other expense, net  $-   $63,813 

 

Total net other expense for the three months ended September 30, 2018 decreased $63,813 compared to the three months ended September 30, 2017 due to the repayment of debt during the three months ended June 30, 2018.

 

30

 

 

Comparison of the Nine Months Ended September 30, 2018 to the Nine Months Ended September 30, 2017

 

Net Sales

 

Net sales was $76,186 for the nine months ended September 30, 2018, and represents revenues from the sale of Prestalia. We had no sales during the nine months ended September 30, 2017. As the Company has yet to complete certain performance obligations under a licensing agreement for the sale of our DiLA2 assets, we have deferred the recognition of revenue of $200,000 until such obligations are fulfilled. The majority of our licensing deals provide for clinical and regulatory milestones, so significant revenues could result from the existing licenses, but are uncertain as to timing or probability. We will continue to seek research and development collaborations as well as licensing transactions to fund business operations.

 

Cost of Sales

 

Cost of sales was $7,760 for the nine months ended September 30, 2018, and represents cost of sales from the sale of Prestalia. We had no sales or cost of sales during the nine months ended September 30, 2017.

 

Operating Expenses

 

Our expenses for the nine months ended September 30, 2018 are summarized as follows in comparison to our expenses for the nine months ended September 30, 2017.

 

   Nine Months Ended 
   September 30, 2018   September 30, 2017 
         
Sales, marketing and commercial operations  $

3,456,871

   $- 
Research and development   173,256    746,221 
General and administrative expenses   4,119,988    1,878,301 
Amortization   288,460    327,642 
Goodwill and intangible assets impairment   4,794,030    - 
Total operating expenses  $12,832,605   $2,952,164 

 

Sales, marketing and commercial operations

 

Sales, marketing and commercial operations expense increased by approximately $3.4 million primarily due to launch activities related to the launch of Prestalia and related activities.

 

Research and Development

 

Research and development (“R&D”) expense decreased by approximately $0.6 million, as compared to the nine months ended September 30, 2017 due to the Company’s primary focus transitioning from research and development activities to sales, marketing and commercial operations activities effective April 2018.

 

General and Administrative

 

General and administrative (“G&A”) expense increased by approximately $2.2 million for the nine months ended September 30, 2018, as compared to the nine months ended September 30, 2017, primarily due to a charge of approximately $1.3 million related to share based compensation and an increase in payroll expenses.

 

Amortization Expense

 

Amortization expenses relate to amortization of intangible assets acquired in the November 15, 2016 merger and the asset purchases on June 5, 2017 and July 21, 2017, with an aggregate estimated fair value of approximately $3.1 million (reduced by the impairment loss of approximately $1,291,200 described below).

 

Goodwill and intangible assets impairment

 

During the nine months ended September 30, 2018, the Company determined that goodwill was impaired and, as a result, a loss on impairment of $3,502,830 was recognized for the nine-month period ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company’s strategic objectives . There was no such loss on impairment for the nine months ended September 30, 2017.

 

During the three months ended September 30, 2018, the Company determined that the intangible asset from the Merger was impaired and as a result, a loss on impairment of $1,291,200 was recognized for the three and nine-month periods ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company’s strategic objectives . There was no such loss on impairment for the nine months ended September 30, 2017.

 

31

 

 

Other Expense

 

   Nine Months Ended 
   September 30, 2018   September 30, 2017 
Interest expense  $149,900   $51,575 
Change in fair value liability of warrants   -    106,345 
Loss on settlement   874,697    - 
Change in fair value of derivative liability   -    115,271 
Total other expense, net  $1,024,597   $273,191 

 

Total net other expense for the nine months ended September 30, 2018 increased approximately $0.8 million compared to the nine months ended September 30, 2017. The increase is primarily attributable to the loss on settlement of debt incurred of approximately $0.9 million during the nine months ended September 30, 2018, primarily due to a non-cash loss of approximately $0.8 million related to warrants issued to Autotelic, Inc. to satisfy outstanding liabilities where the fair value of the warrants exceeded the value of liabilities settled as part of the Series E Preferred Stock private placement. Additionally, there was an increase in interest expense of approximately $0.2 million from new notes and lines of credit taken in 2017. Such debt and accrued interest thereon was settled as part of the Series E Preferred Stock private placement. There was no gain or loss on the change in fair value liability of warrants during the nine months ended September 30, 2018 due to the adoption of Accounting Standards Update 2017-11 in November 2017 relating to the issuance of financial statements that include down round provisions utilizing the modified retrospective approach.

 

Liquidity & Capital Resources

 

Working Capital

 

   September 30, 2018   December 31, 2017 
Current assets  $7,454,372   $124,943 
Current liabilities   (2,185,238)   (5,735,503)
Working capital (deficiency)  $5,269,134   $(5,610,560)

 

Working capital as of September 30, 2018 was approximately $5.3 million as compared to negative working capital of approximately $5.6 million as of December 31, 2017. As of September 30, 2018, current assets were approximately $7.5 million, primarily attributable to an increase in cash of approximately $6.4 million primarily due to the issuance of Series E and F Preferred stock. As of December 31, 2017, current assets were approximately $0.1 million primarily attributable to cash of approximately $0.1 million.

 

As of September 30, 2018, current liabilities were approximately $2.2 million, comprised of accounts payable of approximately $0.9 million, accrued expenses of approximately $1.0 million and deferred revenue of $0.2 million. Comparatively, as of December 31, 2017, current liabilities were $5.7 million, primarily consisting of approximately $1.0 million of accounts payable, accrued expenses of approximately $1.5 million and notes payable of approximately $1.9 million. Current liabilities decreased by approximately $3.6 million, which was primarily attributable to the settlement of notes payable and other liabilities of approximately $3.4 million by converting such debt and liabilities into the initial round of financing under the Series E Convertible Preferred Stock private placement in April of 2018 and paying accrued fees payable of approximately $0.3 million.

 

32

 

 

Cash Flows and liquidity

 

   Nine Months Ended 
   September 30, 2018   September 30, 2017 
         
Net cash used in operating activities  $(7,013,516)  $(923,202)
Net cash used in investing activities   (28,795)   (375,000)
Net cash provided by financing activities   13,442,060    1,201,531 
Increase (decrease) in cash  $6,399,749   $(96,671)

 

Net cash used in Operating Activities

 

Net cash used in operating activities was approximately $7.0 million during the nine months ended September 30, 2018. This was primarily due to the net loss of approximately $13.8 million, partially offset by goodwill and intangible asset impairment of approximately $4.8 million and non-cash loss on settlement of approximately $0.9 million.

 

Comparatively, net cash used in operating activities was approximately $0.9 million during the nine months ended September 30, 2017. This was primarily due to the net loss of approximately $2.3 million offset by non-cash charges of approximately $0.7 million and change in working capital of approximately $0.9 million. The non-cash charges were comprised of approximately $0.1 million of share based compensation, $0.1 million of services paid in company stock, amortization of intangibles of approximately $0.2 million and fair value of warrants liability and derivatives of approximately $0.3 million.

 

Net cash used in Investing Activities

 

Net cash used in investing activities during the nine months ended September 30, 2018 was due to purchase of furniture of approximately $29 thousand as compared to $0.3 million to purchase intangible assets during the nine months ended September 30, 2017.

 

Net cash provided by Financing Activities

 

Net cash provided by financing activities of approximately $13.4 million during the nine months ended September 30, 2018 was primarily due to the approximately $12.2 million received from the sale of our Series E Preferred Stock, net of fees, and approximately $1.3 million received from the sales of our Series F Preferred Stock, net of fees, offset partially by approximately $0.1 million for repayment of a debt. Correspondingly, during the nine months ended September 30, 2017, net cash provided by financing activities was approximately $1.2 million. This was primarily attributable to proceeds of approximately $0.25 million from the sale of common stock, approximately $0.8 million from borrowings on third party and related party notes payable, and approximately $0.2 million from the exercise of common stock warrants.

 

We may need to raise additional operating capital in calendar year 2018 in order to maintain our operations and to realize our business plan. Without additional sources of cash and/or the deferral, reduction, or elimination of significant planned expenditures, we may not have the cash resources to continue as a going concern thereafter.

 

Future Financing

 

We will require additional funds to implement the growth strategy for our business. As mentioned above, we have, in the past, raised additional capital to supplement our commercialization, clinical development and operational expenses. We will need to raise additional funds required through equity financing, debt financing, strategic alliances or other sources, which may result in further dilution in the equity ownership of our shares. There can be no assurance that additional financing will be available when needed or, if available, that it can be obtained on commercially reasonable terms. If we will not be able to obtain the additional financing on a timely basis as required, or generate significant material revenues from operations, we will not be able to meet our other obligations as they become due and will be forced to scale down or perhaps even cease our operations.

 

33

 

 

Off-Balance Sheet Arrangements

 

As of September 30, 2018, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of SEC Regulation S-K.

 

Critical Accounting Policies and Estimates

 

Our significant accounting policies are more fully described in the notes to our financial statements included herein for the period ended September 30, 2018 and in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017.

 

New and Recently Adopted Accounting Pronouncements

 

Any new and recently adopted accounting pronouncements are more fully described in Note 1 to our financial statements included herein for the period ended September 30, 2018.

 

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4 CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our senior management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Management identified material weaknesses in internal control over financial reporting as described under the heading “Management Report on Internal Control” contained in Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Form 10-K”), which have not been fully remediated, and therefore our principal executive officer and our principal financial officer concluded that, as of September 30, 2018, our disclosure controls and procedures were not effective.

 

Internal Control Over Financial Reporting

 

Management has reported to the Board of Directors and the Audit Committee thereof material weaknesses described under the heading “Management Report on Internal Control” contained in Item 9A of the 2017 Form 10-K. The material weaknesses discussed therein have not been fully remediated. There have been no changes in our internal control over financial reporting or in other factors during the fiscal quarter ended September 30, 2018 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. To remediate the material weakness identified in our 2017 Form 10-K, we plan to hire additional experienced accounting and other personnel to assist with filings and financial record keeping (in addition to our hiring of Eric Teague to serve as our Chief Financial Officer commencing in September 2018), and to take additional steps to improve our financial reporting systems and enhance our existing policies, procedures and controls, as resources allow.

 

Because of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

 

34

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

Our Prestalia product is currently involved in a paragraph IV challenge regarding patents issued to perindopril arginine. This challenge, which is currently pending in the United States District Court for the District of Delaware (No. 1:17-cv-00276), is captioned Apotex Inc. and Apotex Corp. v. Symplmed Pharmaceuticals, LLC and Les Laboratories Servier. The challengers (Apotex Inc. and Apotex Corp. (“Apotex”)) have filed an Abbreviated New Drug Application seeking FDA approval to market a generic version of Prestalia and included a Paragraph (IV) certification. In the litigation, Apotex seeks a declaratory judgment that no valid claims of the two patents Symplmed listed in the FDA Orange Book as having claims covering Prestalia, U.S. Patent No. 6,696,481 and 7,846,961, will be infringed by the Apotex proposed generic version of Prestalia and that the claims of those patents are invalid. The challenge is designed to provide Apotex with an opportunity to enter the market with a generic version of Prestalia, ahead of the expiration of the patents with claims covering that product. Apotex entered into negotiations with Symplmed Pharmaceuticals, LLC (which entity sold its assets relating to Prestalia to us in June 2017, including its License and Commercialization Agreement with Les Laboratories Servier) and Les Laboratories Servier (which entity owns or controls intellectual property rights relating to pharmaceutical products containing as an active pharmaceutical ingredient perindopril in combination with other active pharmaceutical ingredients, which rights have been licensed to Symplmed Pharmaceuticals) to resolve the challenge in the second quarter of 2017, and such parties, along with us, have come to a general agreement on terms that will result in a delay to the challengers’ ability to enter the market with a generic version of Prestalia, while still providing the challenger with the right to enter the market prior to the expiration of the patent covering such product. The term sheet memorializing such terms is pending execution in a final settlement agreement. In the meantime, the District Court has entered an order extending the time for the defendants to respond to Apotex’s Complaint. Resolution of the Apotex litigation continues with alignment from all parties, including Servier, Apotex, Symplmed and Adhera. Necessary extensions have been agreed upon and final resolution is anticipated this year.

 

ITEM 1A. RISK FACTORS

 

An investment in our common stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (the “Annual Report”), as filed with the SEC on April 17, 2018, in addition to other information contained in those documents and reports that we have filed with the SEC pursuant to the Securities Act and the Exchange Act since the date of the filing of the Annual Report, including, without limitation, this Quarterly Report on Form 10-Q, in evaluating our company and its business before purchasing shares of our common stock. Our business, operating results and financial condition could be adversely affected due to any of those risks.

 

35

 

 

Item 6. Exhibits

 

Exhibit No.   Description
3.1   Certificate of Amendment of the Restated Certificate of Incorporation of Adhera Therapeutics, Inc. (filed as Exhibit 3.1 to our Current Report on Form 8-K dated October 9, 2018, and incorporated herein by reference).
     
3.2   Certificate of Designation of Preferences, rights and Limitations of the Series F Convertible Preferred Stock of Adhera Therapeutics, Inc. (filed as Exhibit 3.1 to our Current Report on Form 8-K dated July 11, 2018, and incorporated herein by reference).
     
4.1   Form of Common Stock Purchase Warrant issued by Adhera Therapeutics, Inc. to the purchasers of its Series F Convertible Preferred Stock (filed as Exhibit 4.1 to our Current Report on Form 8-K dated July 11, 2018, and incorporated herein by reference).
     
10.1   Employment Agreement, dated as of September 24, 2018, by and between Adhera Therapeutics, Inc. and R. Eric Teague (filed as Exhibit 10.1 to our Current Report on Form 8-K dated September 24, 2018, and incorporated herein by reference).
     
10.2   Omnibus Settlement Agreement, dated as of September 28, 2018, by and among Adhera Therapeutics, Inc., Vuong Trieu, Ph.D., Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. (filed as Exhibit 10.1 to our Current Report on Form 8-K dated October 3, 2018, and incorporated herein by reference).
     
31.1   Certification of our Principal Executive Officer pursuant to Rule 13a-14 and 15d-14 under the Securities Exchange Act of 1934, as amended. (1)
     
31.2   Certification of our Principal Financial Officer pursuant to Rule 13a-14 and 15d-14 under the Securities Exchange Act of 1934, as amended. (1)
     
32.1   Certification of our Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (2)
     
32.2   Certification of our Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (2)
     
101INS   XBRL Instance Document (1)
     
101SCH   XBRL Taxonomy Extension Schema Document (1)
     
101CAL   XBRL Taxonomy Extension Calculation Linkbase Document (1)
     
101DEF   XBRL Taxonomy Extension Definition Linkbase Document (1)
     
101LAB   XBRL Taxonomy Extension Label Linkbase Document (1)
     
101PRE   XBRL Taxonomy Extension Presentation Linkbase Document (1)
(1)   Filed herewith.
(2)   Furnished herewith.

 

36

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ADHERA THERAPEUTICS, INC.
     
Date: November 19, 2018 By: /s/ Robert C. Moscato, Jr.
    Robert C. Moscato, Jr.
    Chief Executive Officer
    (Principal Executive Officer)
     
Date: November 19, 2018   /s/ Eric Teague
    Eric Teague
    Chief Financial Officer
    (Principal Financial Officer and Principal Accounting Officer)

 

37

 

 

 EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

ADHERA THERAPEUTICS, INC.

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Robert C. Moscato, Jr., certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Adhera Therapeutics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:
   
  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

By: /s/ Robert C. Moscato, Jr.  
  Robert C. Moscato, Jr.  
  Chief Executive Officer  
  (Principal Executive Officer)  
Date: November 19, 2018  

 

   
 

 

 EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

ADHERA THERAPEUTICS, INC.

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Eric Teague, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Adhera Therapeutics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:
   
  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

By: /s/ Eric Teague  
  Eric Teague  
  Chief Financial Officer  
  (Principal Financial Officer and Principal Accounting Officer)  
Date: November 19, 2018  

 

   
 

 

 EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

ADHERA THERAPEUTICS, INC.

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Quarterly Report on Form 10-Q of Adhera Therapeutics, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

By: /s/ Robert C. Moscato, Jr.  
  Robert C. Moscato, Jr.  
  Chief Executive Officer  
  (Principal Executive Officer)  
Date: November 19, 2018  

 

   
 

 

 EX-32.2 5 ex32-2.htm

 

Exhibit 32.2

 

ADHERA THERAPEUTICS, INC.

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Quarterly Report on Form 10-Q of Adhera Therapeutics, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

By: /s/ Eric Teague  
  Eric Teague  
  Chief Financial Officer  
  (Principal Financial Officer and Principal Accounting Officer)  
Date: November 19, 2018  

 

   
 

 EX-101.INS 6 atrx-20180930.xml XBRL INSTANCE FILE 0000737207 2018-01-01 2018-09-30 0000737207 2016-12-31 0000737207 2017-12-31 0000737207 ATRX:SeriesCconvertiblePreferredStockMember 2018-09-30 0000737207 ATRX:SeriesCconvertiblePreferredStockMember 2017-12-31 0000737207 ATRX:SeriesDConvertiblePreferredStockMember 2018-09-30 0000737207 ATRX:SeriesDConvertiblePreferredStockMember 2017-12-31 0000737207 ATRX:StockOptionsOutstandingMember 2018-01-01 2018-09-30 0000737207 ATRX:WarrantsMember 2018-01-01 2018-09-30 0000737207 ATRX:SharesToBeIssuedUponConversionOfNotesPayableMember 2018-01-01 2018-09-30 0000737207 ATRX:StockOptionsOutstandingMember 2017-01-01 2017-09-30 0000737207 ATRX:WarrantsMember 2017-01-01 2017-09-30 0000737207 ATRX:SharesToBeIssuedUponConversionOfNotesPayableMember 2017-01-01 2017-09-30 0000737207 us-gaap:SeriesBPreferredStockMember 2018-09-30 0000737207 us-gaap:SeriesAPreferredStockMember 2018-09-30 0000737207 us-gaap:SeriesCPreferredStockMember 2014-03-31 0000737207 us-gaap:SeriesDPreferredStockMember 2015-08-31 0000737207 ATRX:SecuritiesPurchaseAgreementMember us-gaap:SeriesDPreferredStockMember 2015-08-30 2015-08-31 0000737207 ATRX:SecuritiesPurchaseAgreementMember us-gaap:SeriesDPreferredStockMember 2015-08-31 0000737207 us-gaap:WarrantMember 2018-09-30 0000737207 ATRX:RangeOneMember 2018-09-30 0000737207 ATRX:RangeOneMember 2018-01-01 2018-09-30 0000737207 ATRX:RangeTwoMember 2018-09-30 0000737207 ATRX:RangeTwoMember 2018-01-01 2018-09-30 0000737207 ATRX:RangeThreeMember 2018-09-30 0000737207 ATRX:RangeThreeMember 2018-01-01 2018-09-30 0000737207 ATRX:RangeFourMember 2018-09-30 0000737207 ATRX:RangeFourMember 2018-01-01 2018-09-30 0000737207 ATRX:RangeFiveMember 2018-09-30 0000737207 ATRX:RangeFiveMember 2018-01-01 2018-09-30 0000737207 ATRX:MasterServicesAgreementMember 2018-09-30 0000737207 ATRX:MasterServicesAgreementMember 2018-01-01 2018-09-30 0000737207 ATRX:MasterServicesAgreementMember ATRX:RelatedPartyMember 2018-01-01 2018-09-30 0000737207 ATRX:AutotelicMember 2018-01-01 2018-09-30 0000737207 ATRX:AutotelicMember 2017-01-01 2017-09-30 0000737207 ATRX:PromissoryNoteMember 2016-12-31 0000737207 us-gaap:CommonStockMember 2017-12-31 0000737207 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000737207 us-gaap:RetainedEarningsMember 2017-12-31 0000737207 ATRX:DirectorAndOfficersMember 2017-01-31 0000737207 ATRX:DirectorAndOfficersMember 2018-01-01 2018-01-31 0000737207 ATRX:LicenseAgreementMember ATRX:LipoMedicsMember 2017-02-01 2017-02-28 0000737207 ATRX:MergerMember 2018-09-30 0000737207 ATRX:PrestaliaMember 2018-09-30 0000737207 ATRX:MergerMember 2018-01-01 2018-09-30 0000737207 ATRX:PrestaliaMember 2018-01-01 2018-09-30 0000737207 ATRX:PurchaseAgreementMember ATRX:SymplmedPharmaceuticalsLLCMember 2017-06-01 2017-06-30 0000737207 ATRX:PurchaseAgreementMember ATRX:SymplmedPharmaceuticalsLLCMember 2017-09-30 0000737207 ATRX:PromissoryNoteMember 2017-03-30 2017-03-31 0000737207 ATRX:NotePurchaseAgreementMember ATRX:TenInvestorsMember 2017-09-30 0000737207 ATRX:NotesPayableMember 2017-12-31 0000737207 ATRX:LicenseAgreementMember ATRX:OncotelicIncMember 2017-07-01 2017-07-31 0000737207 ATRX:PurchaseAgreementMember ATRX:SymplmedPharmaceuticalsLLCMember 2017-07-01 2017-07-31 0000737207 ATRX:DyrctAxessMember 2018-09-30 0000737207 ATRX:DyrctAxessMember 2018-01-01 2018-09-30 0000737207 us-gaap:InvestorMember us-gaap:SeriesCPreferredStockMember 2017-09-01 2017-09-30 0000737207 ATRX:PharmaceuticalDevelopmentAgreementMember 2018-01-01 2018-09-30 0000737207 ATRX:PharmaceuticalDevelopmentAgreementMember srt:MaximumMember 2018-01-01 2018-09-30 0000737207 ATRX:TwoThousandAndFourteenLongTermIncentivePlanMember ATRX:ChiefCommercialOfficerMember 2018-01-01 2018-09-30 0000737207 2017-09-30 0000737207 2017-01-01 2017-09-30 0000737207 ATRX:SymplmedTechnologiesLLCMember 2017-07-31 0000737207 ATRX:ConvertiblePromissoryNotesMember 2016-07-31 0000737207 ATRX:ConvertiblePromissoryNotesMember 2016-07-01 2016-07-31 0000737207 ATRX:ConvertiblePromissoryNotesMember 2017-11-30 0000737207 ATRX:ConvertiblePromissoryNotesMember 2017-11-01 2017-11-30 0000737207 ATRX:ConvertiblePromissoryNotesMember 2018-01-01 2018-09-30 0000737207 ATRX:ConvertiblePromissoryNotesMember 2018-09-30 0000737207 ATRX:LineLetterMember ATRX:ExecutiveChairmanMember 2016-11-15 0000737207 ATRX:LineLetterMember ATRX:DrTrieuMember 2017-12-31 0000737207 ATRX:LineLetterMember ATRX:DrTrieuMember 2016-11-15 0000737207 ATRX:LineLetterMember ATRX:AutotelicIncMember 2017-04-30 0000737207 ATRX:LineLetterMember ATRX:AutotelicIncMember 2017-04-01 2017-04-30 0000737207 ATRX:LineLetterMember ATRX:AutotelicIncMember 2018-09-30 0000737207 ATRX:LineLetterMember ATRX:AutotelicIncMember 2018-01-01 2018-09-30 0000737207 ATRX:LicensingAgreementMember 2018-03-15 2018-03-16 0000737207 ATRX:LicenseAgreementMember 2017-07-31 0000737207 ATRX:ConvertibleNotePayableMember 2017-12-31 0000737207 ATRX:NotesPayableRelatedPartiesMember 2017-12-31 0000737207 ATRX:ConvertibleNotesPayableRelatedPartiesMember 2017-12-31 0000737207 ATRX:ConvertibleNotePayableMember 2018-09-30 0000737207 ATRX:NotesPayableRelatedPartiesMember 2018-09-30 0000737207 ATRX:ConvertibleNotesPayableRelatedPartiesMember 2018-09-30 0000737207 ATRX:SubscriptionAgreementsMember us-gaap:WarrantMember 2018-07-31 0000737207 ATRX:SeriesEConvertiblePreferredStockMember 2018-04-30 0000737207 2018-09-30 0000737207 2017-01-01 2017-12-31 0000737207 ATRX:NotesPayableMember 2018-09-30 0000737207 ATRX:AmendmentAgreementMember ATRX:FebruaryTenTwoThousandAndTweleveMember 2017-07-01 2017-07-31 0000737207 ATRX:NotesOneMember 2018-09-30 0000737207 ATRX:NotesOneMember 2017-12-31 0000737207 ATRX:NotesOneMember 2018-01-01 2018-09-30 0000737207 us-gaap:SeriesCPreferredStockMember 2018-09-30 0000737207 us-gaap:SeriesCPreferredStockMember 2018-01-01 2018-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2018-09-30 0000737207 ATRX:NotesTwoMember 2018-09-30 0000737207 ATRX:NotesTwoMember 2017-12-31 0000737207 ATRX:NotesTwoMember 2018-01-01 2018-09-30 0000737207 ATRX:ConvertiblePromissoryNotesMember 2017-12-31 0000737207 ATRX:VayaPharmaIncMember 2018-04-01 2018-04-30 0000737207 ATRX:CompromiseAndSettlementAgreementsMember ATRX:BoardOfDirectorsMember 2018-04-30 0000737207 ATRX:CompromiseAndSettlementAgreementsMember ATRX:BoardOfDirectorsMember 2018-04-01 2018-04-30 0000737207 ATRX:AssetPurchaseAgreementMember ATRX:NovosomVerwaltungsGmbHMember 2018-05-01 2018-05-31 0000737207 2017-07-01 2017-09-30 0000737207 2018-07-01 2018-09-30 0000737207 ATRX:SeriesEConvertiblePreferredStockMember 2018-04-01 2018-04-30 0000737207 ATRX:SeriesEConvertiblePreferredStockMember 2018-05-01 2018-05-31 0000737207 ATRX:SeriesEConvertiblePreferredStockMember 2018-09-30 0000737207 ATRX:SeriesEConvertiblePreferredStockMember 2017-12-31 0000737207 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0000737207 us-gaap:CommonStockMember 2018-09-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000737207 ATRX:AdditionalPaidInCapitalWarrantsMember 2018-01-01 2018-09-30 0000737207 ATRX:AdditionalPaidInCapitalWarrantsMember 2017-12-31 0000737207 ATRX:AdditionalPaidInCapitalWarrantsMember 2018-09-30 0000737207 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0000737207 us-gaap:RetainedEarningsMember 2018-09-30 0000737207 ATRX:SeriesFConvertiblePreferredStockMember 2018-07-01 2018-07-31 0000737207 ATRX:SubscriptionAgreementsMember ATRX:SeriesFConvertiblePreferredStockMember 2018-07-01 2018-07-31 0000737207 ATRX:SubscriptionAgreementsMember ATRX:SeriesFConvertiblePreferredStockMember 2018-07-31 0000737207 ATRX:LicensingAgreementMember 2018-01-01 2018-09-30 0000737207 ATRX:RestrictedCommonStockMember 2018-01-01 2018-09-30 0000737207 ATRX:RestrictedCommonStockMember 2017-01-01 2017-09-30 0000737207 ATRX:SettlementAgreementWithAutotelicIncMember us-gaap:SeriesEPreferredStockMember 2018-04-01 2018-04-30 0000737207 ATRX:SettlementAgreementWithAutotelicIncMember srt:MaximumMember 2018-04-30 0000737207 us-gaap:WarrantMember 2018-01-01 2018-09-30 0000737207 ATRX:PhilipCRankerMember 2018-05-01 2018-05-31 0000737207 ATRX:PhilipCRankerMember 2018-05-31 0000737207 ATRX:PhilippePCalaisMember 2018-05-01 2018-05-31 0000737207 ATRX:PhilippePCalaisMember 2018-05-31 0000737207 ATRX:JosephWRamelliMember 2018-05-01 2018-05-31 0000737207 ATRX:JosephWRamelliMember 2018-05-31 0000737207 ATRX:DrTrieuMember 2018-01-01 2018-09-30 0000737207 ATRX:CompromiseAndSettlementAgreementsMember ATRX:BoardOfDirectorsMember 2017-12-30 2017-12-31 0000737207 ATRX:BioMaurisLLCMember 2018-01-01 2018-09-30 0000737207 us-gaap:PrivatePlacementMember 2018-04-01 2018-04-30 0000737207 us-gaap:PrivatePlacementMember 2018-04-30 0000737207 us-gaap:PrivatePlacementMember ATRX:JuneTwoThousandSixteenNoteholdersMember 2018-04-01 2018-04-30 0000737207 us-gaap:PrivatePlacementMember ATRX:JuneTwoThousandSixteenNoteholdersMember 2018-04-30 0000737207 ATRX:NotesOneMember 2017-01-01 2017-12-31 0000737207 ATRX:NotesTwoMember 2017-01-01 2017-12-31 0000737207 ATRX:NotePurchaseAgreementMember us-gaap:PrivatePlacementMember 2018-04-01 2018-04-30 0000737207 ATRX:NotePurchaseAgreementMember 2018-04-30 0000737207 us-gaap:ConvertibleNotesPayableMember 2018-04-01 2018-04-30 0000737207 us-gaap:ConvertibleNotesPayableMember 2018-04-30 0000737207 ATRX:LineLetterMember ATRX:DrTrieuMember 2018-04-01 2018-04-30 0000737207 ATRX:LineLetterMember ATRX:DrTrieuMember 2018-04-30 0000737207 ATRX:LineLetterMember 2017-12-31 0000737207 ATRX:LineLetterMember 2018-09-30 0000737207 ATRX:LineLetterMember ATRX:AutotelicIncMember 2018-04-30 0000737207 ATRX:LineLetterMember ATRX:AutotelicIncMember 2018-04-01 2018-04-30 0000737207 ATRX:LineLetterMember ATRX:AutotelicIncMember 2017-12-31 0000737207 ATRX:LineLetterMember ATRX:AutotelicIncMember 2018-01-01 2018-12-31 0000737207 us-gaap:InvestorMember us-gaap:SeriesCPreferredStockMember 2018-01-01 2018-06-30 0000737207 us-gaap:InvestorMember us-gaap:SeriesDPreferredStockMember 2018-05-01 2018-05-31 0000737207 ATRX:SubscriptionAgreementsMember ATRX:SeriesEConvertiblePreferredStockMember 2018-04-01 2018-05-31 0000737207 ATRX:SubscriptionAgreementsMember ATRX:SeriesEConvertiblePreferredStockMember us-gaap:WarrantMember 2018-05-31 0000737207 ATRX:SubscriptionAgreementsMember us-gaap:PrivatePlacementMember 2018-05-31 0000737207 ATRX:SubscriptionAgreementsMember us-gaap:PrivatePlacementMember 2018-04-01 2018-05-31 0000737207 ATRX:SeriesEConvertiblePreferredStockMember 2018-01-01 2018-09-30 0000737207 ATRX:SeriesEConvertiblePreferredStockMember 2018-07-01 2018-09-30 0000737207 ATRX:VayaPharmaLLCMember 2018-04-01 2018-04-30 0000737207 ATRX:WarrantsMember us-gaap:SeriesEPreferredStockMember 2018-04-01 2018-05-31 0000737207 ATRX:WarrantsMember 2018-05-31 0000737207 ATRX:WarrantsMember ATRX:AutotelicIncMember 2018-04-01 2018-05-31 0000737207 us-gaap:WarrantMember ATRX:AutotelicIncMember 2018-09-30 0000737207 us-gaap:WarrantMember ATRX:AutotelicIncMember 2018-01-01 2018-09-30 0000737207 ATRX:DirectorAndOfficersMember 2018-05-01 2018-05-31 0000737207 ATRX:DirectorAndOfficersMember 2018-05-31 0000737207 ATRX:RobertMoscatoJrMember 2018-07-01 2018-07-31 0000737207 ATRX:UliHacksellMember 2018-07-01 2018-07-31 0000737207 ATRX:ErikEmersonMember 2018-07-01 2018-07-31 0000737207 2018-05-01 2018-05-31 0000737207 ATRX:ExecutiveChairmanMember 2018-09-30 0000737207 us-gaap:ChiefExecutiveOfficerMember 2018-09-30 0000737207 2018-07-01 2018-07-31 0000737207 ATRX:BioMaurisLLCMember 2018-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2018-01-01 2018-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2017-12-31 0000737207 2018-11-19 0000737207 ATRX:SeriesFConvertiblePreferredStockMember 2017-12-31 0000737207 ATRX:SeriesFConvertiblePreferredStockMember 2018-09-30 0000737207 us-gaap:SeriesFPreferredStockMember 2018-01-01 2018-09-30 0000737207 us-gaap:SeriesFPreferredStockMember 2018-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2018-01-01 2018-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2017-01-01 2017-09-30 0000737207 us-gaap:SeriesFPreferredStockMember 2018-01-01 2018-09-30 0000737207 us-gaap:SeriesFPreferredStockMember 2017-01-01 2017-09-30 0000737207 ATRX:SeriesFConvertiblePreferredStockMember 2018-07-31 0000737207 ATRX:SeriesFConvertiblePreferredStockMember 2018-01-01 2018-09-30 0000737207 ATRX:SeriesFConvertiblePreferredStockMember 2018-07-01 2018-09-30 0000737207 ATRX:SeriesFConvertiblePreferredStockMember 2017-07-01 2017-09-30 0000737207 ATRX:SeriesFConvertiblePreferredStockMember 2017-01-01 2017-09-30 0000737207 ATRX:VPOfOperationsMember 2018-07-01 2018-07-31 0000737207 ATRX:EricTeagueMember 2018-01-01 2018-09-30 0000737207 ATRX:WarrantsMember us-gaap:SeriesFPreferredStockMember 2018-04-01 2018-05-31 0000737207 2018-07-31 0000737207 ATRX:SVPOfCommercialOperationsMember 2018-07-01 2018-07-31 0000737207 ATRX:SVPOfCommercialOperationsMember 2018-07-31 0000737207 us-gaap:ChiefFinancialOfficerMember 2018-01-01 2018-09-30 0000737207 us-gaap:ChiefFinancialOfficerMember 2018-09-30 0000737207 us-gaap:SeriesFPreferredStockMember 2017-12-31 0000737207 ATRX:PurchaseAgreementMember ATRX:SymplmedPharmaceuticalsLLCMember 2018-07-01 2018-09-30 0000737207 ATRX:PurchaseAgreementMember ATRX:SymplmedPharmaceuticalsLLCMember 2018-09-30 0000737207 ATRX:OmnibusSettlementAgreementMember ATRX:DrTrieuMember 2018-10-01 0000737207 ATRX:OmnibusSettlementAgreementMember ATRX:DrTrieuMember 2018-09-26 2018-10-01 0000737207 us-gaap:SeriesCPreferredStockMember 2017-01-01 2017-12-31 0000737207 us-gaap:SeriesDPreferredStockMember 2018-01-01 2018-09-30 0000737207 us-gaap:SeriesDPreferredStockMember 2017-01-01 2017-12-31 0000737207 us-gaap:SubsequentEventMember ATRX:SubscriptionAgreementsMember 2018-11-08 2018-11-09 0000737207 us-gaap:SubsequentEventMember ATRX:SubscriptionAgreementsMember ATRX:SeriesFConvertiblePreferredStockMember 2018-11-09 0000737207 us-gaap:SubsequentEventMember ATRX:SubscriptionAgreementsMember us-gaap:CommonStockMember 2018-11-09 0000737207 us-gaap:SubsequentEventMember ATRX:SubscriptionAgreementsMember us-gaap:WarrantMember 2018-11-09 0000737207 us-gaap:SubsequentEventMember ATRX:SubscriptionAgreementsMember us-gaap:WarrantMember 2018-11-08 2018-11-09 0000737207 ATRX:SeriesEConvertiblePreferredStockAndWarrantsMember 2018-04-01 2018-05-31 0000737207 us-gaap:SubsequentEventMember ATRX:SettlementAgreementMember ATRX:DrTrieuMember 2018-09-29 2018-10-01 0000737207 us-gaap:SubsequentEventMember ATRX:InvestorsMember ATRX:SeriesEConvertiblePreferredStockAndWarrantsMember 2018-09-29 2018-10-31 0000737207 us-gaap:SubsequentEventMember ATRX:InvestorsMember us-gaap:CommonStockMember 2018-09-29 2018-10-31 0000737207 us-gaap:CommonStockMember 2018-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 10-Q 2018-09-30 false --12-31 Non-accelerated Filer 105347 106378 8676 6506127 0.01 0.01 0.01 0.01 0.01 5000 0.75 0.01 5000 0.01 0.01 5000 5000 0.01 0.01 0.01 100000 1200 1200 220 220 100000 3500 3500 2200 2200 100 750 40 60 3490 0 0 308 100 750 40 60 3490 0 0 308 0.006 0.006 180000000 180000000 10521728 11241684 10521728 11241684 10761684 106345 112210 -7442 1494469 31106896 1494469 1313684 -13788776 -3226155 -972184 -7779459 -13788776 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="text-transform: uppercase"><b>Note 7 &#8212; Stock Incentive Plans</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stock option activity was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Options Outstanding</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Shares</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font><br /> <font style="font-size: 10pt"><b>Average</b></font><br /> <font style="font-size: 10pt"><b>Exercise Price</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%"><font style="font-size: 10pt">Outstanding, December 31, 2017</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">745,707</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">8.84</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Options granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,724,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.67</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Options expired / forfeited</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(88,750</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">67.40</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Outstanding, September 30, 2018</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,380,957</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">0.86</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Exercisable, September 30, 2018</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,638,991</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.93</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table summarizes additional information on Adhera&#8217;s stock options outstanding at September 30, 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Options Outstanding</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Options Exercisable</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Range of </b></font><br /> <font style="font-size: 10pt"><b>Exercise </b></font><br /> <font style="font-size: 10pt"><b>Prices</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number Outstanding</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted- Average Remaining Contractual Life (Years)</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted Average Exercise Price</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number Exercisable</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted Average Exercise Price</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">$0.98</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font-size: 10pt">4,705,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font-size: 10pt">9.39</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 13%; text-align: right"><font style="font-size: 10pt">0.67</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font-size: 10pt">1,467,500</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 13%; text-align: right"><font style="font-size: 10pt">0.73</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">$1.00</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3.13</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.00</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.06</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">$1.50 &#8211; $1.80</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">521,107</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">8.64</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.79</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">136,641</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.78</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">$2.60 &#8211; $8.20</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">135,200</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3.78</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">2.77</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">15,200</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4.48</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">$10.70 &#8211; $22.00</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">12,650</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1.00</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10.92</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">12,650</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10.92</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Totals</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,380,957</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9.15</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.86</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,638,991</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.93</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Weighted-Average Exercisable Remaining Contractual Life (Years) 8.22</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In January 2018, the Company granted a total of 19,000 stock options to directors and officers for services. The options have an exercise price of $1.56 and a five-year term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2018, the Company granted a total of 380,000 stock options to directors and officers for services. The options have an exercise price of $0.98 and a five-year term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2018, we granted our Chief Executive Officer, 1,500,000 stock options; Uli Hacksell, Ph.D., the Chairman of our Board, 1,000,000 stock options; and Erik Emerson, our Chief Commercial Officer, 1,125,000 stock options at an exercise prices of $0.66 per share with a 10-year term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2018 we granted our SVP of Commercial Operations 250,000 stock options at an exercise price of $0.575 per share with a 10-year term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In September 2018 we granted our Chief Financial Officer 450,000 stock options at an exercise price of $0.55 per share with a 10-year term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of September 30, 2018, we had $523,943 of total unrecognized compensation expense related to unvested stock options. Total expense related to stock options was $1,307,046 and $218,295 for the nine months ended September 30, 2018 and 2017, respectively, and $814,008 and $5,109 for the three months ended September 30, 2018 and 2017, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of September 30, 2018, the intrinsic value of options outstanding or exercisable was $0 as there were no options outstanding with an exercise price less than $0.54, the per share closing market price of our common stock at that date.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="text-transform: uppercase"><b>Note 8 &#8212; Intellectual Property and Collaborative Agreements</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Novosom Agreements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2010, Adhera entered into an asset purchase agreement with Novosom Verwaltungs GmbH (&#8220;Novosom&#8221;), pursuant to which Adhera acquired intellectual property for Novosom&#8217;s SMARTICLES-based liposomal delivery system.&#160; In May 2018, we issued to Novosom 51,988 shares of our common stock, with a fair value of $75,000, as additional consideration pursuant to the Asset Purchase Agreement. Such shares were due to Novosom as a result of the receipt by our company of a license fee under the License Agreement that we entered into with Lipomedics Inc. in February 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Arrangements with LipoMedics</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In February 2017, we entered into a License Agreement (the &#8220;License Agreement&#8221;) with LipoMedics, pursuant to which, among other things, we provided to LipoMedics a license to our SMARTICLES platform for further development of Lipomedics&#8217;s proprietary phospholipid nanoparticles that can deliver protein, small molecule drugs, and peptides. These are not currently being developed at Adhera and Adhera has no IP around these products. On the same date, we also entered into a Stock Purchase Agreement with LipoMedics pursuant to which we issued to LipoMedics an aggregate of 86,207 shares of our common stock for a total purchase price of $250,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the terms of the License Agreement, we could receive success-based milestones based on commercial sales of licensed products. In addition, if LipoMedics determines to pursue further development and commercialization of products under the License Agreement, LipoMedics agreed, in connection therewith, to purchase shares of our common stock for an aggregate purchase price of $500,000, with the purchase price for each share of common stock being the greater of $2.90 or the volume weighted average price of our common stock for the thirty (30) trading days immediately preceding the date on which LipoMedics notifies us that it intends to pursue further development or commercialization of a licensed product.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If LipoMedics breaches the License Agreement, we shall have the right to terminate the License Agreement effective sixty (60) days following delivery of written notice to LipoMedics specifying the breach, if LipoMedics fails to cure such material breach within such sixty (60) day period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Vuong Trieu, Ph.D. is the Chairman of the Board and Chief Operating Officer of LipoMedics.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In consideration Lipomedics agreed to the following fee schedule: 1) Evaluations License Fee. Simultaneous with the execution and delivery of the License Agreement, Lipomedics shall enter into a Stock Purchase Agreement in form and substance reasonably acceptable to Adhera and Lipomedics, pursuant to which Adhera will sell to Lipomedics shares of the common stock of Adhera for an aggregate purchase price of $0.25 million, with the purchase price for each share of Adhera common stock being $2.90. 2) Commercial License Fee. Unless the License Agreement is earlier terminated, within thirty (30) days following Lipomedics&#8217;s delivery of an Evaluation Notice advising that it intends to pursue, or cause to be pursued, further development and commercialization of Licensed Products. 3) For up to and including three Licensed Products, Lipomedics shall pay to Adhera a milestone (collectively the &#8220;Sales Milestones&#8221;) of $10 million upon reaching Commercial Sales in the Territory in any given twelve month period equal to or greater than $500 million for a given Licensed Product and of $20 million upon reaching Commercial Sales in any given twelve month period equal to or greater than $1 million for such Licensed Product, such payments to be made within thirty (30) days following the month in which such Commercial Sale targets are met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Arrangements with Oncotelic Inc.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2017, we entered into a License Agreement (the &#8220;License Agreement&#8221;) with Oncotelic, Inc. (&#8220;Oncotelic&#8221;) pursuant to which, among other things, we provided to Oncotelic a license to our SMARTICLES platform for the delivery of antisense DNA therapeutics, as well as a license to our conformationally restricted nucleotide (&#8220;CRN&#8221;) technology with respect to TGF-Beta. Under the terms of the License Agreement, Oncotelic also agreed to purchase 49,019 shares of our common stock for an aggregate purchase price of $0.25 million ($5.10 per share), with such purchase and sale to be made pursuant to a Stock Purchase Agreement to be entered into between us and Oncotelic within thirty (30) days following the date of the License Agreement. Oncotelic has not completed the purchase of the stock and we have not been able to reach to a definitive agreement, as such we have terminated the agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Agreement with Autotelic BIO</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 11, 2018, we entered into a binding agreement with Autotelic BIO (&#8220;ATB&#8221;) pursuant to which, among other things, and subject to the satisfaction of certain conditions on or prior to January 15, 2019, we shall grant to ATB a perpetual exclusive right of development and marketing of our IT-103 product candidate, which is a fixed dose combination of celecoxib and olmesartan medoxomil, at the currently approved dose/approved indications only for celecoxib (100 mg, 200mg and 400mg) for combined hypertension and arthritis only, with such right extending throughout the entire world (excluding the United States and Canada, and the territories of such countries). The grant of the license would be memorialized in a definitive license agreement to be entered into between the parties. On October 1, 2018, we and ATB agreed to terminate this arrangement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Autotelic LLC, an entity that owns approximately 22% of the issued and outstanding shares of our common stock and of which Dr. Trieu serves as Chief Executive Officer, owns approximately 19% of the issued and outstanding shares of the common stock of ATB.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>License of DiLA<sup>2</sup> Assets</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 16, 2018, Adhera entered into a Licensing Agreement, whereby Adhera granted exclusive rights to the company&#8217;s DiLA<sup>2 </sup>delivery system in exchange for an upfront payment of $200,000 and further potential future consideration dependent upon event and sales-based milestones. Under the terms of the agreement, Adhera has agreed to assign ownership of the intellectual property associated with the DiLA<sup>2</sup> delivery system to the purchaser. The Company has yet to complete certain performance obligations under the agreement and accordingly has deferred the recognition of revenue from the sale of the asset until such obligations are fulfilled.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Asset Purchase Agreement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In July 2017, Adhera entered into an Asset Purchase Agreement with Symplmed Pharmaceuticals LLC and its wholly-owned subsidiary Symplmed Technologies, LLC pursuant to which the Company purchased from the Sellers, for an aggregate purchase price of $75,000 in cash, certain specified assets of the Sellers relating to the Sellers&#8217; patented technology platform known as DyrctAxess that offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to help achieve optimal care (see Note 3).</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="text-transform: uppercase"><b>Note 9 &#8211; Commitments and Contingencies</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Amendment to Agreement with Windlas Healthcare Private Limited</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 17, 2017, we entered into an amendment (the &#8220;Amendment&#8221;) of that certain Pharmaceutical Development Agreement dated as of March 30, 2017 by and between Windlas Healthcare Private Limited (&#8220;Windlas&#8221;) and our company (the &#8220;Development Agreement&#8221;), relating to the development by Windlas of certain pharmaceutical products to be used for conducting clinical trials or for regulatory submissions, as more fully described therein. Pursuant to the Amendment, we and Windlas agreed to amend the Development Agreement to reflect our agreement to issue to Windlas, and Windlas&#8217; agreement to accept from us, in lieu of cash payments with respect to forty percent (40%) of the total amount reflected on invoices sent from time to time by Windlas to us, shares of our common stock having an aggregate value equal to forty percent (40%) of such invoiced amount (with the remaining portion of the invoiced amount being paid in cash). The maximum value of common stock that may be issued to Windlas pursuant to the Development Agreement (as modified by the Amendment) is $2 million. The parties also agreed that the foregoing payment arrangement would apply to any Contract Manufacturing and Supply Agreement (or similar agreement) relating to the manufacturing of commercial batches of the products covered by the Development Agreement that may be entered into between the parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Litigation</i>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Because of the nature of our activities, we are subject to claims and/or threatened legal actions, which arise out of the normal course of business. Other than the disclosure below, as of the date of this filing, we are not aware of any pending lawsuits against us, our officers or our directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We had been named on a complaint filed in New York State as a defendant in the matter entitled <i>Vaya Pharma, Inc. v. Symplmed Technologies, Inc., Symplmed Pharmaceuticals, Inc., Erik Emerson and Marina Biotech, Inc.</i> While this complaint had been filed in the Supreme Court of the State of New York, we had not been legally served. The complaint alleged, in relevant part, that: (i) the sale by Symplmed Pharmaceuticals, Inc. of its assets related to its Prestalia product, and the sale by Symplmed Technologies, Inc. of its assets related to its DyrctAxess platform, should be set aside pursuant to New York law as they were consummated without fair consideration to the sellers (the &#8220;Symplmed Defendants&#8221;), and thereby had the effect of fraudulently depriving the creditors of the Symplmed Defendants, including Vaya Pharma, Inc., of funds that could have been used to pay their debts; and (ii) we were liable, as successor, for any and all claims by Vaya Pharma, Inc. against the Symplmed Defendants, though pursuant to the agreement we are only contractually responsible for liabilities that accrue after the parties entered into the agreement for Prestalia and any liabilities that existed prior to the agreement are contractually held by Symplmed. In April 2018, we entered into a Stipulation of Settlement requiring us to issue to Vaya Pharma 210,084 shares of our common stock with a fair value of $250,000, which shares were issued in April of 2018. We accrued $0 and $250,000, as of September 30, 2018 and December 31, 2017, respectively, and such amount was included in accrued expenses on the accompanying consolidated balance sheets.&#160;</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="text-transform: uppercase"><b>Note 10 - Subsequent Events</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Except for the event(s) discussed below, there were no subsequent events that required recognition or disclosure. The Company evaluated subsequent events through the date the financial statements were issued and filed with the Securities and Exchange Commission.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 9, 2018, we entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 73 shares of our Series F convertible preferred stock, par value of $0.01 per share (the &#8220;Preferred Stock&#8221;), at a purchase price of $5,000 per share of Preferred Stock. Each share of Preferred stock is initially convertible into shares of our common stock at a conversion price of $0.50 per share of common Stock. In addition, each investor received a 5-year warrant to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Preferred Stock purchased by such investor at an exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. We received total net proceeds of approximately $0.31 million from the issuance of the securities described above, after deducting placement agent fees and estimated expenses payable by us associated with such closing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As discussed in Note 4, on October 1, 2018, we entered into a Settlement Agreement with Vuong Trieu, Ph.D., our former interim Chief Executive Officer, Executive Chairman and Chairman of our Board of Directors, which incuded the Company repurchasing 500,000 shares of our common stock from Dr. Trieu.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In October 2018, an investor converted 2 shares of Series E convertible preferred stock into 20,000 shares of our common stock.</p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Expiring in 2018</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 79%; text-align: justify"><font style="font-size: 10pt">Expiring in 2019</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">600,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Expiring in 2020</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,189,079</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Expiring in 2021</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">343,750</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Expiring in 2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">29,202,227</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Expiring thereafter</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">4,311,773</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">35,646,829</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Stock option activity was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Options Outstanding</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Shares</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font><br /> <font style="font-size: 10pt"><b>Average</b></font><br /> <font style="font-size: 10pt"><b>Exercise Price</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%"><font style="font-size: 10pt">Outstanding, December 31, 2017</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">745,707</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">8.84</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Options granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4,724,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.67</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Options expired / forfeited</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(88,750</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">67.40</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Outstanding, September 30, 2018</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,380,957</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">0.86</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Exercisable, September 30, 2018</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,638,991</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.93</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 275000 180000 100 210084 58.25 51988 162.59 71.46 75 74.17 103.18 114.63 19 433334 25000 210084 51988 750 40 60 73 500000 2000000 250000 250000 75000 220 49019 308 2812 250000 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table summarizes additional information on Adhera&#8217;s stock options outstanding at September 30, 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Options Outstanding</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Options Exercisable</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Range of </b></font><br /> <font style="font-size: 10pt"><b>Exercise </b></font><br /> <font style="font-size: 10pt"><b>Prices</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number Outstanding</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted- Average Remaining Contractual Life (Years)</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted Average Exercise Price</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number Exercisable</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted Average Exercise Price</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">$0.98</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font-size: 10pt">4,705,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font-size: 10pt">9.39</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 13%; text-align: right"><font style="font-size: 10pt">0.67</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: right"><font style="font-size: 10pt">1,467,500</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 13%; text-align: right"><font style="font-size: 10pt">0.73</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">$1.00</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3.13</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.00</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,000</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.06</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">$1.50 &#8211; $1.80</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">521,107</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">8.64</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.79</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">136,641</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.78</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">$2.60 &#8211; $8.20</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">135,200</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3.78</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">2.77</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">15,200</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4.48</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">$10.70 &#8211; $22.00</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">12,650</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1.00</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10.92</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">12,650</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10.92</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; padding-left: 10pt"><font style="font-size: 10pt">Totals</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,380,957</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9.15</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.86</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,638,991</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.93</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 2018 448243 63127 8413823 -8028707 6113443 35 64700 -5399004 33915049 -22467340 3 444223 97523 346700 5100 5100 300 300 5000 5000 5000 5000 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="text-transform: uppercase"><b>Note 3 &#8211; Intangible Assets</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Acquisition of Prestalia &#38; DyrctAxess</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2017, we entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Symplmed Pharmaceuticals LLC (&#8220;Symplmed&#8221;) pursuant to which we purchased from Symplmed, for aggregate consideration of approximately $620,000 (consisting of $300,000 in cash plus the assumption of certain liabilities of Symplmed in the amount of approximately $320,000), Symplmed&#8217;s assets relating to a single-pill FDC of perindopril arginine and amlodipine besylate known as Prestalia&#174; (&#8220;Prestalia&#8221;), that has been approved by the FDA for the treatment of hypertension. In addition, as part of the transactions contemplated by the Purchase Agreement: (i) Symplmed agreed to transfer to us, not later than 150 days following the closing date, the New Drug Applications for the approval of Prestalia as a new drug by the FDA; and (ii) Symplmed assigned to us all of its rights and obligations under that certain Amended and Restated License and Commercialization Agreement by and between Symplmed and Les Laboratoires Servier (&#8220;Servier&#8221;) dated January 2012, pursuant to which Symplmed has an exclusive license from Servier to manufacture, have manufactured, develop, promote, market, distribute and sell Prestalia in the U.S. (and its territories and possessions) in consideration of regulatory and sales-based milestone payments and royalty payments based on net sales. Management has determined that this acquisition was deemed an asset purchase under FASB ASC 805.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The purchase price of $620,000 was allocated based on a preliminary estimate of the fair value of the assets acquired and was included in intangible assets as of December 31, 2017. During the three months ended September 30, 2018, the allocation of the purchase price was finalized which resulted in $160,800 of the price being allocated to raw materials received from Symplmed, and the remaining $459,200 being allocated to intangible assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, we hired our current Chief Commercial Officer, who was the President and Chief Executive Officer of Symplmed, which appointment became effective in June 2017. We also agreed in such offer letter to issue 60,000 restricted shares of our common stock under our 2014 Long-Term Incentive Plan to our Chief Commercial Officer, with all of such shares vesting on the six (6) month anniversary of the date of grant. These shares were fully vested on December 31, 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In furtherance of the acquisition and commercialization of Prestalia, in July 2017 we acquired from Symplmed and its wholly-owned subsidiary, Symplmed Technologies, LLC, certain of the intellectual property assets related to the patented technology platform known as DyrctAxess, also known as Total Care, that offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to help achieve optimal care for $75,000 in cash.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Intangible Asset Summary</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table summarizes the estimated fair values as of September 30, 2018 of the identifiable intangible assets acquired, their useful life, and method of amortization:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Estimated </b></font><br /> <font style="font-size: 10pt"><b>Fair Value</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Estimated<br /> Useful Life<br /> (Years)</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Annual </b></font><br /> <font style="font-size: 10pt"><b>Amortization </b></font><br /> <font style="font-size: 10pt"><b>Expense</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%"><font style="font-size: 10pt">Intangible asset from the Merger</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">590,267</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">4.17</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">97,450</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Intangible asset - Prestalia</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">459,200</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5.25</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">94,177</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Intangible asset &#8211; DyrctAxess</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">75,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">12.84</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,357</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,124,467</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">196,984</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of September 30, 2018, the Company determined that the intangible asset from the Merger was impaired and, as a result, a loss on impairment of approximately $1,291,200 was recognized for the three and nine months ended September 30, 2018 (see Note 1).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The net intangible asset was $815,514, net of accumulated amortization of $308,953, as of September 30, 2018. Amortization expense was $288,460 and $327,642 for the nine months ended September 30, 2018 and 2017, respectively, and $41,937 and $123,038 for the three months ended September 30, 2018 and 2017, respectively.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="text-transform: uppercase"><b>Note 4 - Related Party Transactions</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Due to Related Party</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company and other related entities have&#160; had a commonality of ownership and/or management control, and as a result, the reported operating results and /or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company had a Master Services Agreement (&#8220;MSA&#8221;) with Autotelic Inc&#160;., a related party that is partly-owned by one of the Company&#8217;s Board members, namely Vuong Trieu, Ph.D., effective November 15, 2016. Autotelic Inc. currently owns less than 5% of the Company. The MSA states that Autotelic Inc. will provide business functions and services to the Company and allows Autotelic Inc. to charge the Company for these expenses paid on its behalf. The MSA includes personnel costs allocated based on amount of time incurred and other services such as consultant fees, clinical studies, conferences and other operating expenses incurred on behalf of the Company. The MSA requires a 90-day written termination notice in the event either party requires to terminate such services. We and Autotelic Inc. have agreed to terminate the MSA effective October 31, 2018. Dr. Trieu resigned as a director of our company effective October 1, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the period commencing November 15, 2016 (the &#8220;Effective Date&#8221;) and ending on the date that the Company had completed an equity offering of either common or preferred stock in which the gross proceeds therefrom is no less than $10 million (the &#8220;Equity Financing Date&#8221;), the Company shall pay Autotelic the following compensation: cash in an amount equal to the actual labor cost (paid on a monthly basis), plus 100% markup in warrants for shares of the Company&#8217;s common stock with a strike price equal to the fair market value of the Company&#8217;s common stock at the time said warrants are issued. The Company shall also pay Autotelic for the services provided by third party contractors plus 20% mark up. The warrant price per share will be calculated based on the Black-Scholes model.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After the Equity Financing Date, the Company shall pay Autotelic Inc. a cash amount equal to the actual labor cost plus 100% mark up of provided services and 20% mark up of provided services by third party contractors or material used in connection with the performance of the contracts, including but not limited to clinical trial, non-clinical trial, Contract Manufacturing Organizations (&#8220;CMO&#8221;), FDA regulatory process, Contract Research Organizations (&#8220;CRO&#8221;) and Chemistry and Manufacturing Controls (&#8220;CMC&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In accordance with the MSA, Autotelic Inc. billed the Company for personnel and service expenses Autotelic Inc. incurred on behalf of the Company. For the nine months ended September 30, 2018 and 2017, Autotelic Inc. billed a total of $777,928 and $492,406, including personnel costs of $370,520 and $386,954, respectively. An unpaid balance of $99,896 and $730,629 is included in due to related party in the accompanying balance sheet as of September 30, 2018 and December 31, 2017, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2018, and in connection with the closing of our private placement on that date, we entered into a Compromise and Settlement Agreement with Autotelic Inc. pursuant to which we agreed to issue to Autotelic Inc. an aggregate of 162.59 shares of Series E Preferred Stock and Warrants to purchase up to 1,345,040 shares of common stock to satisfy accrued and unpaid fees in the aggregate amount of approximately $739,772, and other liabilities, owed to Autotelic Inc. as of March 31, 2018 pursuant to the MSA. The securities that were issued to Autotelic Inc., which were issued upon the closing described above, have the same terms and conditions as the securities that were issued to investors in the offering (See Note 5). The warrants have a five-year term, an exercise price of $0.55, and have a fair value of $1,494,469 resulting in a loss on settlement of debt of $754,697.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Resignation and Appointment of Officer and Directors</i>&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="background-color: white">On April 27, 2018, our Board of Directors (the &#8220;Board&#8221;) increased the size of the entire Board from five (5) directors to seven (7) directors, and it appointed each of Erik Emerson and Tim Boris to fill the vacancies created thereby. </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2018, each of Philip C. Ranker and Philippe P. Calais, Ph.D. resigned as members of the Board, and all committees thereof, effective immediately. In connection with their resignations: (i) each of Mr. Ranker and Dr. Calais released us from all claims arising prior to the date of his resignation; (ii) we granted to Mr. Ranker fully-vested options to purchase up to 200,000 shares of our common stock at an exercise price equal to $0.98 per share of common stock; and (iii) we granted to Dr. Calais fully-vested options to purchase up to 80,000 shares of our common stock at an exercise price equal to $0.98 per share of common stock. The foregoing options are exercisable for a period of five years from the grant date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2018, the Board accepted the resignation of Joseph W. Ramelli, our Chief Executive Officer, whereby Mr. Ramelli resigned as an officer of our company, and as a director and/or officer of any and all subsidiaries of our company, effective immediately, to pursue other opportunities. In connection with his resignation, Mr. Ramelli released us from all claims arising prior to the date of his resignation and affirmed his obligations to be bound by the restrictive covenants contained in the employment agreement between Mr. Ramelli and our company dated February 2, 2017, and we: (i) agreed to make severance payments to Mr. Ramelli in the amount of $60,000 to be paid over a six (6) month period; and (ii) granted to Mr. Ramelli fully-vested options, exercisable for a period of five years from the grant date, to purchase up to 100,000 shares of our common stock at an exercise price equal to $0.98 per share of common stock. In May 2018, the Board appointed Vuong Trieu, a director of the Company and former Executive Chairman, to serve as our Interim Chief Executive Officer, to replace Mr. Ramelli, effective with Mr. Ramelli&#8217;s departure. In his capacity as Interim Chief Executive Officer, Dr. Trieu received a salary in the amount of $20,000 per month. Dr. Trieu resigned from the position of Interim Chief Executive Officer on June 18, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="background-color: white">On June 18, 2018, the Board appointed Robert C. Moscato, Jr., to serve as our Chief Executive Officer effective immediately. In connection with the appointment of Mr. Moscato as Chief Executive Officer, Dr. Trieu resigned as Interim Chief Executive Officer, and also from his position as Executive Chairman of our company, effective immediately.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="background-color: white">On June 18, 2018, the Board appointed Uli Hacksell, Ph.D.to serve as a member of the Board, and as Chairman of the Board, effective July 1, 2018. Dr. Hacksell agreed to devote half of his business time to Adhera. </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="background-color: white">On June 28, 2018, the Board appointed Mr. Moscato to serve as a member of the Board, effective July 1, 2018.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We entered into an employment agreement with R. Eric Teague pursuant to which Mr. Teague began serving as our Chief Financial Officer on September 24, 2018. In connection with the appointment of Mr. Teague as our Chief Financial Officer, Amit Shah, our prior Chief Financial Officer, resigned from such position, effective September 24, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Issuance of Preferred Stock and Warrants to Directors</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In April 2018, and in connection with the closing of our private placement on that date, we entered into Compromise and Settlement Agreements with four of the then current members of our Board of Directors and one former member of our Board of Directors pursuant to which we agreed to issue to such directors an aggregate of 58.25 shares of Series E Preferred Stock and Warrants to purchase up to 436,875 shares of common stock to satisfy accrued and unpaid fees owed to such directors for service as members of the Board of Directors during the period ending on December 31, 2017 in the aggregate amount of approximately $291,250. The securities that were issued to the directors, which were issued upon the closing of our private placement described above, have the same terms and conditions as the securities that were issued to investors in the offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Omnibus Settlement Agreement with Vuong Trieu, Ph.D. and Affiliated Entities</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 1, 2018, we entered into an Omnibus Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Vuong Trieu, Ph.D., our former interim Chief Executive Officer, Executive Chairman and Chairman of our Board of Directors (the &#8220;Board&#8221;), Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. At the same time, and in connection therewith, we also entered into an Agreement and Release with each of Dr. Trieu and Falguni Trieu (the &#8220;Individual Releases&#8221;), and entered into an Agreement and Release with each of Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. (collectively, the &#8220;Entity Releases&#8221;). We also delivered a release (the &#8220;Company Release&#8221;) to Dr. Trieu, Ms. Trieu, Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. Pursuant to the Settlement Agreement, we agreed to make a payment to Dr. Trieu in the amount of $10,000 in consideration for Dr. Trieu entering into the Individual Releases between Dr. Trieu and our company. Dr. Trieu also agreed to sell, and we agreed to purchase, from Dr. Trieu for cancellation an aggregate of 500,000 shares of our common stock in consideration of an aggregate purchase price of $250,000. Additionally, each of Dr. Trieu, Autotelic Inc., Autotelic LLC, Oncotelic, Inc. and LipoMedics, Inc. agreed to certain restrictions on sale, transfer or assignment of our common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Furthermore: (i) we and Autotelic Inc. agreed that the Master Services Agreement, dated as of November 15, 2016, by and between our company and Autotelic Inc., shall be terminated as of October 31, 2018; (ii) we and Autotelic BIO agreed that the Term Sheet, entered into as of January 11, 2018, by and between our company and Autotelic BIO, shall be terminated immediately; (iii) we and Oncotelic, Inc. confirmed that the License Agreement, dated July 17, 2017, by and between our company and Oncotelic Inc. was terminated effective May 15, 2018; and (iv) we and Lipomedics, Inc. agreed that the License Agreement, dated as of February 6, 2016, by and between our company and Lipomedics, Inc. would remain in effect.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the Settlement Agreement, we and Autotelic LLC agreed with respect to the License Agreement, dated as of November 15, 2016, by and between our company and Autotelic LLC, that such License Agreement shall continue, provided that Autotelic LLC shall be licensee and have a license to, without representation or warranty, nasal apomorphine and nasal scopolamine and related intellectual property in addition to nasal insulin, and Autotelic LLC shall not be a licensee or have a license to Familial Adenomatous Polyposis or CEQ508 and related intellectual property.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the Individual Releases, each of Dr. Trieu and Ms. Trieu, our former Director of Business Development and the spouse of Dr. Trieu, agreed to release us from all claims arising prior to the date of the Release Agreements. Pursuant to the Entity Releases, each of Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. agreed to release us from all claims arising prior to the date of the applicable Entity Release. Pursuant to the Company Release, we agreed to release each of Dr. Trieu, Ms. Trieu, Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. from all claims arising prior to the date of the Company Release.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Transactions with BioMauris, LLC</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">During the nine months ended September 30, 2018, the company paid a total of $473,397 for services provided by BioMauris, LLC, of which Erik Emerson, our Chief Commercial Officer and a director of Adhera, is Executive Chairman. A total of $45,546 was due BioMauris, LLC as of September 30, 2018.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table summarizes the estimated fair values as of September 30, 2018 of the identifiable intangible assets acquired, their useful life, and method of amortization:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Estimated </b></font><br /> <font style="font-size: 10pt"><b>Fair Value</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Estimated<br /> Useful Life<br /> (Years)</b></p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Annual </b></font><br /> <font style="font-size: 10pt"><b>Amortization </b></font><br /> <font style="font-size: 10pt"><b>Expense</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%"><font style="font-size: 10pt">Intangible asset from the Merger</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">590,267</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">4.17</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">97,450</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Intangible asset - Prestalia</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">459,200</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5.25</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">94,177</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Intangible asset &#8211; DyrctAxess</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">75,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">12.84</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,357</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,124,467</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">196,984</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> 60000 0000737207 250000 75000 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended September 30,</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Stock options outstanding</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">5,380,957</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">233,400</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Warrants</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">35,646,829</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,492,945</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Shares to be issued upon conversion of notes payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">315,746</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Restricted common stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">70,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Series E Preferred Stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">34,900,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Series F Preferred Stock</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3,080,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">79,007,786</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,112,091</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 1462040 93662 1368378 800 6399749 -96671 13442060 1201531 250000 -7013516 -923202 313393 299166 -641157 637642 -122229 419494 429679 -125098 54000 1307046 218295 400000 5000000 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="text-transform: uppercase"><b>Note 5 &#8211; Notes Payable</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following is a breakdown of notes payable as of September 30, 2018 and December 31, 2017:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2017</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 60%"><font style="font-size: 10pt">Notes payable</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">97,523</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Convertible notes payable</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">346,700</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total notes payable</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">444,223</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Notes payable &#8211; related parties</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">93,662</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Convertible notes payable &#8211; related parties (net of debt discount of $0 and $113,170 as of September 30, 2018 and December 31, 2017, respectively)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,368,378</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total notes payable &#8211; related parties</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,462,040</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Note Payable &#8211; Service Provider</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In December 2016, we entered into an Agreement and Promissory Note with a law firm for past services performed totaling $121,523. The note called for monthly payments of $6,000 per month, beginning with an initial payment on March 31, 2017. The note was unsecured and non-interest bearing. The note was paid in full in May 2018. The balance due on the note was $0 and $97,523 as of September 30, 2018 and December 31, 2017, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Note Purchase Agreement and Amendment</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2017, we entered into an amendment agreement (the &#8220;Amendment Agreement&#8221;) with the holders (such holders, the &#8220;June 2016 Noteholders&#8221;) of the promissory notes that we issued in June 2016 to the June 2016 Noteholders (the &#8220;2016 Notes&#8221;) with respect to the 2016 Notes and the warrants to purchase shares of our common stock that are held by the June 2016 Noteholders and that were originally issued pursuant to a certain Note and Warrant Purchase Agreement dated as of February 10, 2012 by and among Adhera, MDRNA, Cequent and the purchasers identified on the signature pages thereto (as amended from time to time), to, among other things, extend the maturity date of the 2016 Notes to December 31, 2017, to provide for the issuance of consideration securities at a cost of $375,000 (&#8220;Consideration Securities&#8221;) and to extend the price protection applicable to certain of the warrants held by the June 2016 Noteholders with respect to dilutive offerings afforded thereunder to February 10, 2020. Refer to our Form 10-Q for the six months ended June 30, 2017 for a more detailed discussion and additional terms for the 2016 Notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In April 2018, and in connection with the closing of our private placement on that date, we issued to the June 2016 Noteholders an aggregate of 71.46 shares of Series E Preferred Stock and Warrants to purchase up to 535,950 shares of common stock as a result of the conversion of the 2016 Notes. As a result of the conversion of the 2016 Notes and the issuance of the securities to the June 2016 Noteholders, the entire unpaid principal balance of the 2016 Notes, and the accrued and unpaid interest thereon, has been satisfied in full, and such notes are no longer outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In addition, in April 2018, and in connection with the closing of our private placement on that date, we issued to the June 2016 Noteholders an aggregate of 75 shares of Series E Preferred Stock and Warrants to purchase up to 562,500 shares of common stock in full and complete satisfaction of our obligations to issue $375,000 worth of Consideration Securities to the June 2016 Noteholders pursuant to the Amendment Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of September 30, 2018 and December 31, 2017, the accrued interest expense on the 2016 Notes amounted to $0 and $46,700, respectively, with a total balance of principal and interest of $0 and $346,700, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>2017 Bridge Note Financing</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2017, we issued convertible promissory notes (the &#8220;2017 Notes&#8221;) in the aggregate principal amount of $400,000 to 10 investors pursuant to a Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;) that we entered into with such investors (the &#8220;June 2017 Noteholders&#8221;). The 2017 Notes bear interest at a rate of five percent (5%) per annum and are due and payable at any time on or after the earlier of (i) June 1, 2018 and (ii) the occurrence of an event of default (as defined in the Note Purchase Agreement). Our then Executive Chairman and our Chief Science Officer were each investors in the 2017 Notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of September 30, 2018 and December 31, 2017, the accrued interest expense on the 2017 Notes amounted to $0 and $11,365, with a total balance of principal and interest of $0 and $411,365, respectively, and is included in notes payable &#8211; related parties on the accompanying balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In April 2018, and in connection with the closing of our private placement on that date, we issued to the June 2017 Noteholders an aggregate of 74.17 shares of Series E Preferred Stock and Warrants to purchase up to 505,705 shares of common stock (and also paid to such holders an aggregate of $56 thousand in cash) as full and complete satisfaction of the unpaid principal balance (and accrued but unpaid interest thereon) owed by us to the June 2017 Noteholders under the 2017 Notes. As a result of the conversion of the 2017 Notes and the issuance of the securities to the June 2016 Noteholders (and payment of cash), the entire unpaid principal balance of the 2017 Notes, and the accrued and unpaid interest thereon, has been satisfied in full, and such notes are no longer outstanding. The securities that were issued to the June 2017 Noteholders have the same terms and conditions as the securities that were issued to investors in the offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Convertible Notes Payable</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2016, IThena issued convertible promissory notes with an aggregate principal balance of $50,000 to certain related-party investors. Borrowings under each of these convertible notes bore interest at 3% per annum and these notes mature on September 30, 2018. Upon the completion of certain funding events, IThena had the right to convert the outstanding principal amount of these notes into shares of IThena&#8217;s common stock. The notes were assumed by Autotelic Inc. on November 15, 2016 as part of its acquisition of the technology asset (IT-101).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In November 2017, the Company issued a convertible promissory note with a related party (a trust affiliated with Isaac Blech, a member of our Board of Directors) for $500,000 (the &#8220;Blech Note&#8221;), with annual interest at 8%, maturing on March 31, 2018, and convertible at the price equal to any financing transaction involving the sale by the Company of its equity securities yielding aggregate gross proceeds to the Company of not less than $5 million. The note included warrants to purchase 66,667 shares of the Company&#8217;s common stock, with a 5-year term and an exercise price of $0.75.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In April 2018, and in connection with the closing of our private placement on that date, we issued to the trust an aggregate of 103.18 shares of Series E Preferred Stock and Warrants to purchase up to 777,750 shares of common stock as a result of the conversion of the Blech Note in the original principal amount of $500,000. As a result of the conversion of the Blech Note and the issuance of the securities to the holder thereof, the entire unpaid principal balance of the Blech Note, and the accrued and unpaid interest thereon, has been satisfied in full, and the Blech Note is no longer outstanding. The securities that were issued to the holder of the Blech Note have the same terms and conditions as the securities that were issued to investors in the offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Blech Note included a debt discount of $162,210 consisting of loan costs of $50,000 and the fair value of the warrants of $112,210. Total amortization of this debt discount was $113,171 for the nine months ended September 30, 2018, with a remaining unamortized value of $0. Total principal and interest was $0 and $504,274 as of September 30, 2018 and December 31, 2017, respectively, and is included in notes payable &#8211; related parties on the accompanying balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Convertible Notes Payable, Dr. Trieu</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the Merger, Adhera entered into a Line Letter dated November 15, 2016 with Dr. Trieu for an unsecured line of credit in an amount not to exceed $540,000, to be used for current operating expenses. Dr. Trieu has advanced the full $540,000 under the Line Letter as of December 31, 2017. The line of credit was convertible at any time into shares of the Company&#8217;s common stock at a price of $1.77 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In April 2018, and in connection with the closing of our private placement on that date, we issued to Dr. Trieu 114.63 shares of Series E Preferred Stock and Warrants to purchase up to 859,725 shares of common stock as full and complete satisfaction of the unpaid principal balance (and accrued but unpaid interest thereon) owed by us to Dr. Trieu under the Line of Credit. As such, the Line of Credit was terminated in April 2018. The securities that were issued to Dr. Trieu have the same terms and conditions as the securities that were issued to investors in the offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Accrued interest on the Line Letter was $0 and $25,836 as of September 30, 2018 and December 31, 2017, respectively, and is included in notes payable - related parties on the accompanying consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Line Letter with Autotelic, Inc.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2017, the Company entered into a Line Letter with Autotelic Inc. for an unsecured line of credit in an amount not to exceed $500,000, to be used for current operating expenses. Autotelic Inc. is a stockholder of IThenaPharma that became the holder of 525,535 shares of Adhera common stock as a result of the Merger, and an entity of which Dr. Trieu serves as Chairman of the Board. Autotelic Inc. was to consider requests for advances under the Line Letter until September 1, 2017. Autotelic Inc. had the right at any time for any reason in its sole and absolute discretion to terminate the line of credit available under the Line Letter or to reduce the maximum amount available thereunder without notice. Advances made under the Line Letter bear interest at the rate of five percent (5%) per annum, are evidenced by the Demand Promissory Note issued to Autotelic Inc., and are due and payable upon demand by Autotelic, Inc. Autotelic Inc. advanced funds after September 1, 2017 but is no longer considering additional requests for advances as of December 31, 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April 2018, and in connection with the closing of our private placement on that date, we issued to Autotelic Inc. 19 shares of Series E Preferred Stock and Warrants to purchase up to 142,500 shares of common stock as full and complete satisfaction of the unpaid principal balance (and accrued but unpaid interest thereon) owed by us to Autotelic Inc. under the Line of Credit, of which $90,816 had been drawn down as of the date of the closing described above. As such, in April 2018, the line of credit with Autotelic Inc was terminated. The securities that were issued to Autotelic Inc. have the same terms and conditions as the securities that were issued to investors in the offering.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The balance under the line was $0 and $93,662, including accrued interest of $0 and $2,847 as of September 30, 2018 and December 31, 2017, respectively, and is included in notes payable - related parties on the accompanying consolidated balance sheet.</p> 31404 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="text-transform: uppercase"><b>Note 6 &#8211; Stockholders&#8217; Equity</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Preferred Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Adhera has authorized 100,000 shares of preferred stock for issuance and has designated 1,000 shares as Series B Preferred Stock (&#8220;Series B Preferred&#8221;) and 90,000 shares as Series A Junior Participating Preferred Stock (&#8220;Series A Preferred&#8221;). No shares of Series B Preferred or Series A Preferred are outstanding. In March 2014, Adhera designated 1,200 shares as Series C Convertible Preferred Stock (&#8220;Series C Preferred&#8221;). In August 2015, Adhera designated 220 shares as Series D Convertible Preferred Stock (&#8220;Series D Preferred&#8221;). In April 2018, Adhera designated 3,500 shares of Series E Convertible Preferred Stock. In July 2018, Adhera designated 2,200 shares of Series F Convertible Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series C Preferred</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each share of Series C Preferred has a stated value of $5,000 per share, has a $5,100 liquidation preference per share, has voting rights of 666.67 votes per share, and is convertible into shares of common stock at a conversion price of $7.50 per share. In September 2017, an investor converted 270 shares of Series C Preferred stock into 180,000 shares of our common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2018, an investor converted 650 shares of Series C Preferred stock into 433,334 shares of our common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of September 30, 2018 and December 31, 2017, 100 and 750 shares, respectively, of Series C Preferred remained outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series D Preferred</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August 2015, Adhera entered into a Securities Purchase Agreement with certain investors pursuant to which Adhera sold 220 shares of Series D Preferred and warrants to purchase up to 344,000 shares of Adhera&#8217;s common stock at an initial exercise price of $4.00 per share before August 2021, for an aggregate purchase price of $1.1 million. Each share of Series D Preferred has a stated value of $5,000 per share, has a liquidation preference of $300 per share, has voting rights of 1,250 votes per share and is convertible into shares of common stock at a conversion price of $4.00 per share. The Series D Preferred is initially convertible into an aggregate of 275,000 shares of Adhera&#8217;s common stock, subject to certain limitations and adjustments, has a 5% stated dividend rate, is not redeemable and has voting rights on an as-converted basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2018, an investor converted 20 shares of Series D Preferred into 25,000 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of September 30, 2018 and December 31, 2017, 40 and 60 shares, respectively, of Series D Preferred remained outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series E Convertible Preferred Stock Private Placement </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April and May 2018, we entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 2,812 shares of our Series E convertible preferred stock (the &#8220;Preferred Stock&#8221;), at a purchase price of $5,000 per share of Preferred Stock. Each share of Preferred Stock is initially convertible into shares of our common stock at a conversion price of $0.50 per share of common stock. In addition, each investor received a 5-year warrant (the &#8220;Warrants&#8221;, and collectively with the Preferred Stock, the &#8220;Securities&#8221;) to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Preferred Stock purchased by such investor at an exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. The Preferred Stock accrues 8% dividends per annum and are payable in cash or stock at the Company&#8217;s discretion. The Preferred Stock has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights as described in the Certificate of Designation of Preferences, Rights and Limitations of the Preferred Stock, which we filed with the Secretary of State of Delaware in April 2018. The Warrants have full-ratchet anti-dilution protection, are exercisable for a period of five years and contain customary exercise limitations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We received net proceeds of approximately $12.2 million from the sale of the Preferred Stock, after deducting placement agent fees and estimated expenses payable by us of approximately $2.0 million associated with such closing. We intend to use the proceeds of the offering for funding our commercial operations to the sale and promotion of our Prestalia product, working capital needs, capital expenditures, the repayment of certain liabilities and other general corporate purposes. In connection with the private placement described above, we also issued to the placement agent for such private placement a Warrant to purchase 2,958,460 shares of our common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We accrued dividends on the Series E Preferred Stock of $351,897 for the three months ended September 30, 2018 and $622,530 for the nine months ended September 30, 2018. No similar dividends were accrued for the same periods of 2017.&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series F Convertible Preferred Share Private Placement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">In July 2018, we entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 308 shares of our Series F convertible preferred stock (the &#8220;Preferred Stock&#8221;), at a purchase price of $5,000 per share of Preferred Stock. Each share of Preferred Stock is initially convertible into shares of our common stock at a conversion price of $0.50 per share of common stock. In addition, each investor received a 5-year warrant (the &#8220;Warrants&#8221;, and collectively with the Preferred Stock, the &#8220;Securities&#8221;) to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Preferred Stock purchased by such investor at an exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. The Preferred Stock accrues 8% dividends per annum and are payable in cash or stock at the Company&#8217;s discretion. The Preferred Stock has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights as described in the Certificate of Designation of Preferences, Rights and Limitations of the Preferred Stock, which we filed with the Secretary of State of Delaware in July 2018. The Warrants have full-ratchet anti-dilution protection, are exercisable for a period of five years and contain customary exercise limitations.</font><font style="font-size: 9pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We received proceeds of approximately $1.3 million from the sale of the Securities, after deducting placement agent fees and estimated expenses payable by us of approximately $180,000 associated with such closing. We intend to use the proceeds of the offering for funding our commercial operations to the sale and promotion of our Prestalia product, working capital needs, capital expenditures, the repayment of certain liabilities and other general corporate purposes. In connection with the private placement described above, we also issued to the placement agent for such private placement a Warrant to purchase 308,000 shares of our common stock. The Warrant has a five-year term and an exercise price of $0.55 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">We accrued dividends on the Series F Preferred Stock of $27,327 for the 3 months and nine months ended September 30, 2018. No similar dividends were accrued for the same periods of 2017.</font><font style="font-size: 9pt">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Option Grants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2018, we granted our Chief Executive Officer, Robert Moscato, Jr., 1,500,000 stock options; Uli Hacksell, Ph. D., the Chairman of our Board, 1,000,000 stock options, Erik Emerson, our Chief Commercial Officer, 1,125,000 stock options, and Jay Schwartz, our VP of Operations, 250,000 stock options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In September 2018, we granted our Chief Financial Officer, Eric Teague, 450,000 stock options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Common Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our common stock currently trades on the OTCQB tier of the OTC Markets under the symbol &#8220;ATRX&#8221;. We currently have 10,761,684 shares of our common stock outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Issuances</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to the common stock and preferred stock issuances described above, we issued the following shares of the Company&#8217;s common stock during the nine months ended September 30, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As discussed in Note 8, in May 2018, we issued to Novosom 51,988 shares of our common stock as additional consideration pursuant to the Asset Purchase Agreement, dated as of July 27, 2010, between our company and Novosom. Such shares were due to Novosom as a result of the receipt by our company of a license fee under the License Agreement that we entered into with Lipomedics Inc. in February 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As discussed in Note 9, in April 2018, we entered into a Stipulation of Settlement with Vaya Pharma and issued a total of 210,084 shares of our common stock with a fair value of $250,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2018, an investor converted 20 shares of Series D Preferred into 25,000 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In June 2018, an investor converted 650 shares of Series C Preferred stock into 433,334 shares of our common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Warrants</i></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of September 30, 2018, there were 35,646,829 warrants outstanding, with a weighted average exercise price of $0.79 per share, and annual expirations as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Expiring in 2018</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 79%; text-align: justify"><font style="font-size: 10pt">Expiring in 2019</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">600,000</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Expiring in 2020</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,189,079</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Expiring in 2021</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">343,750</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Expiring in 2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">29,202,227</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Expiring thereafter</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">4,311,773</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">35,646,829</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The above includes 29,135,560 warrants issued in April and May 2018 in connection with our Series E Preferred Stock offering with a fair value of $31,106,896 and 2,618,000&#160; warrants issued with our Series F Preferred Stock offering with a fair value of $1,313,684 which are reflected in additional paid-in capital and additional paid in capital-warrants on the accompanying condensed consolidated statement of stockholders&#8217; equity. The warrants have a five-year term and an exercise price of $0.55. There was no expense related to these warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, the above includes 1,345,040 warrants issued to Autotelic, Inc. in April 2018 to satisfy accrued and unpaid fees in the aggregate amount of approximately $739,772, and other liabilities, owed to Autotelic Inc. as of March 31, 2018. The warrants have a five-year term, an exercise price of $0.55, and have a fair value of $1,494,469 resulting in a loss on settlement of liability of $754,697.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The above includes price adjustable warrants totaling 1,895,013 which are described more fully in our 2017 Annual Report on Form 10-K.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A total of 339,702 warrants expired during the nine months ended September 30, 2018.</p> 113171 113171 976714 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following is a breakdown of notes payable as of September 30, 2018 and December 31, 2017:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>September 30, 2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2017</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 60%"><font style="font-size: 10pt">Notes payable</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">97,523</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Convertible notes payable</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">346,700</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total notes payable</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">444,223</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Notes payable &#8211; related parties</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">93,662</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Convertible notes payable &#8211; related parties (net of debt discount of $0 and $113,170 as of September 30, 2018 and December 31, 2017, respectively)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,368,378</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total notes payable &#8211; related parties</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,462,040</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 79007786 5380957 35646829 233400 2492945 315746 3112091 70000 34900000 3080000 344000 66667 0.75 436875 308000 1345040 535950 562500 505705 777750 859725 142500 0.75 2958460 P4Y2M1D P5Y2M30D P12Y10M3D 620000 200000 200000 300000 75000 815514 459200 308953 590267 459200 75000 1124467 97450 94177 5357 196984 0.05 10000000 0.20 777928 492406 370520 386954 121523 400000 50000 500000 0.05 0.03 0.08 2018-09-30 2018-03-31 2017-12-31 0 46700 0 11365 25836 0 6000 97523 0 56000 1.77 0.50 500000 P5Y 4.00 0.55 0.75 0.55 0.55 0.55 0.55 0.55 113170 162210 0 0 540000 500000 540000 0 93662 0 2847 525535 0.05 1000 90000 1200 220 3500 2200 4.00 7.50 0.50 0.50 270 650 20 2 20000 1100000 0.05 0.08 0.08 5.10 35646829 P5Y P5Y 600000 1189079 343750 29202227 4311773 35646829 4724000 19000 380000 1500000 1000000 1125000 250000 450000 250000 450000 1.56 0.98 0.98 0.98 0.575 0.55 P5Y P5Y P10Y P10Y P10Y 523943 1307046 218295 5109 814008 745707 5380957 8.84 0.86 0.67 67.40 1.50 2.60 10.70 0.98 1.00 1.80 8.20 22.00 4705000 7000 521107 135200 12650 5380957 P9Y1M24D P9Y4M20D P3Y1M16D P8Y7M21D P3Y9M11D P1Y 0.67 1.00 1.79 2.77 10.92 0.86 1467500 7000 136641 15200 12650 1638991 0.73 1.06 1.78 4.48 10.92 0.93 86207 2.90 0.40 250000 0 730629 99896 45546 10000 300 5100 0.79 13600000 10000000 2000000 1400000 1300000 12200000 voting rights of 1,250 votes per share voting rights of 666.67 votes per share Q3 36729 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="text-transform: uppercase"><b>Note 1 - Nature of Operations, Basis of Presentation and Significant Accounting Policies</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Business Overview</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Adhera Therapeutics, Inc. (formerly known as Marina Biotech, Inc.) and its wholly-owned subsidiaries, MDRNA Research, Inc. (&#8220;MDRNA&#8221;), Cequent Pharmaceuticals, Inc. (&#8220;Cequent&#8221;), Atossa Healthcare, Inc. (&#8220;Atossa&#8221;), and IthenaPharma, Inc. (&#8220;Ithena&#8221;) (collectively &#8220;Adhera,&#8221;, the &#8220;Company&#8221;, &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) is an emerging specialty pharmaceutical company leveraging innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic and acute diseases. Adhera is focused on fixed dose combination (&#8220;FDC&#8221;) therapies in hypertension, with plans to expand the portfolio of drugs we commercialize to include other therapeutic areas.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We began marketing Prestalia<sup>&#174;</sup>, a single-pill FDC of perindopril arginine (an angiotensin-converting-enzyme) inhibitor and amlodipine besylate (a calcium channel blocker), which was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in June of 2018. Prestalia was developed in coordination with Servier, a French pharmaceutical conglomerate, that sells the formulation outside the United States under the brand name - Viacoram. Prestalia is distributed through the DyrectAxess platform which we acquired in 2017. DyrectAxess is a patented&#160; technology platform, also known as Total Care<sup>&#174;</sup>, that offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to achieve optimal care.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">By combining Prestalia, DyrectAxess, and a specialty pharma network, we have created proprietary platform for drug adherence and the effective treatment of hypertension, improving the distribution of FDC hypertensive drugs, such as our FDA-approved product Prestalia, devices for therapeutic drug monitoring (e.g., blood pressure and other cardiac monitors), as well as patient counseling and prescription reminder services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 15, 2016, Adhera entered into, and consummated the transactions contemplated by, an Agreement and Plan of Merger between and among IthenaPharma, Inc., a Delaware corporation (&#8220;IThena&#8221;), IThena Acquisition Corporation, a Delaware corporation and wholly-owned subsidiary of Adhera (&#8220;Merger Sub&#8221;), and a representative of the stockholders of IThena (the &#8220;Merger Agreement&#8221;), pursuant to which IThena merged into Merger Sub (the &#8220;Merger&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As reported in our Annual Report on Form 10-K, in April 2018, we raised in excess of $10 million, net of fees and expenses, from a private placement of our newly created Series E Convertible Preferred Stock (See Recent Developments: Series E Convertible Preferred Stock Private Placement Offering below). Further, in May 2018, we raised an additional $2 million, net of fees and expenses, from the private placement. In July 2018, we raised $1.3 million net of fees and expenses, from a private placement of our newly created Series F Convertible Preferred Stock. The use of funds from the raise will be on the commercialization of Prestalia, funding working capital, capital expenditure needs, payment of certain liabilities and other general corporate requirements. We plan to license or divest our other pharmaceutical assets and halt any other FDC development programs, since they no longer align with our focus on the treatment of hypertension.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Change of Company Name and OTC Markets Symbol</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On October 4, 2018, we filed a Certificate of Amendment to the Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware to change the name of our company from &#8220;Marina Biotech, Inc.&#8221; to &#8220;Adhera Therapeutics, Inc.&#8221; The change of name was effective October 9, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Following the name change from Marina Biotech, Inc. to Adhera Therapeutics, Inc., the common stock, par value $0.006 per share, of the Company began trading on the OTCQB tier of the OTC Markets under the symbol &#8220;ATRX&#8221;.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Reverse Stock Split</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August 2017, we filed a Certificate of Amendment of our Amended and Restated Certificate of Incorporation to effect a one-for-ten reverse split of our issued and outstanding shares of common stock. Our common stock commenced trading on the OTCQB tier of the OTC Markets on a split-adjusted basis on Thursday, August 3, 2017. Unless indicated otherwise, all share and per share information included in these financial statements and Notes to the Consolidated Financial Statements give effect to the reverse split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Basis of Presentation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for complete audited financial statements. The accompanying unaudited financial information should be read in conjunction with the audited consolidated financial statements, including the notes thereto, as of and for the year ended December 31, 2017, included in our 2017 Annual Report on Form 10-K filed with the SEC. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the nine months ended September 30, 2018 are not necessarily indicative of the results for the year ending December 31, 2018 or for any future period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Principles of Consolidation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The consolidated financial statements include the accounts of IThena and Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 10pt"><i>Going Concern and Management&#8217;s Liquidity Plans</i></font><font style="font-size: 9pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The accompanying condensed consolidated financial statements have been prepared on the basis that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At September 30, 2018, we had a significant accumulated deficit of approximately $22 million and working capital of approximately $5 million. Our operating activities consume the majority of our cash resources. We anticipate that we will continue to incur operating losses as we execute our commercialization plans for Prestalia, as well as strategic and business development initiatives. In addition, we have had and will continue to have negative cash flows from operations, at least into the near future. We have previously funded, and plan to continue funding, our losses primarily through the sale of common and preferred stock, combined with or without warrants, the sale of notes, cash generated from the outlicensing or sale of our licensed assets and, to a lesser extent, equipment financing facilities and secured loans. However, we cannot be certain that we will be able to obtain such funds required for our operations at terms acceptable to us or at all.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In April and May 2018, we raised approximately $12.2 million net proceeds from a private placement of shares of our Series E Convertible Preferred Stock, and warrants to purchase shares of our common stock. Further, in July 2018, we raised an additional $1.4 million net proceeds from the private placement of our Series F Convertible Preferred Stock. For our assessment as of September 30, 2018, we have considered the amount raised and we believe that the $13.6 million will provide us the ability to continue as a going concern for one year from the issuance date of this Form 10-Q. We may continue to attempt to obtain future financing or engage in strategic transactions which may require us to curtail our operations. We cannot predict, with certainty, the outcome of our actions to generate liquidity, including the availability of additional equity or debt financing, or whether such actions would generate the expected liquidity as currently planned.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Summary of Significant Accounting Policies</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include valuation allowance for deferred income tax assets, legal contingencies and fair value of financial instruments. Actual results could differ materially from such estimates under different assumptions or circumstances.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We consider the fair value of cash, accounts payable, due to related parties, notes payable, notes payable to related parties, accounts receivable and accrued liabilities not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"><font style="font-size: 10pt">Level 1:</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><font style="font-size: 10pt">Level 2:</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><font style="font-size: 10pt">Level 3:</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our cash is subject to fair value measurement and is determined by Level 1 inputs. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. There were no liabilities measured at fair value as of September 30, 2018 or December 31, 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Goodwill and Intangible Assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company periodically reviews the carrying value of intangible assets, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company&#8217;s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit&#8217;s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit&#8217;s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of September 30, 2018, the Company determined that goodwill was impaired and, as a result, a loss on impairment of $3,502,830 was recognized for the three and nine-month periods ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company&#8217;s strategic objectives&#160;. There was no such loss on impairment for the year ended December 31, 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Impairment of Long-Lived Assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We review all of our long-lived assets for impairment indicators throughout the year and perform detailed testing whenever impairment indicators are present. In addition, we perform detailed impairment testing for indefinite-lived intangible assets, at least annually, at December 31. When necessary, we record charges for impairments. Specifically:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, we compare the undiscounted amount of the projected cash flows associated with the asset, or asset group, to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate; and</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">For indefinite-lived intangible assets, such as acquired in-process R&#38;D assets, each year and whenever impairment indicators are present, we determine the fair value of the asset and record an impairment loss for the excess of book value over fair value, if any.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of September 30, 2018, the Company determined that the intangible asset from the merger was impaired and, as a result, a loss on impairment of $1,291,200 was recognized for the three and nine-month periods ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company&#8217;s strategic objectives&#160;. There was no such loss on impairment for the year ended December 31, 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Revenue Recognition</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has adopted the new revenue recognition guidelines in accordance with ASC 606, <i>Revenue from Contracts with Customers </i>(ASC 606), effective with the quarter ended March 31, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt">The Company sells its medicines primarily to wholesale distributors and specialty pharmacy providers. These customers subsequently resell the Company&#8217;s medicines to health care patients. In addition, the Company enters into arrangements with health care providers and payers that provide for government-mandated or privately-negotiated discounts and allowances related to the Company&#8217;s medicines. Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company&#8217;s contracts have a single performance obligation to transfer medicines. Accordingly, revenues from medicine sales are recognized when the customer obtains control of the Company&#8217;s medicines, which occurs at a point in time, typically upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring medicines and is generally based upon a list or fixed price less allowances for medicine returns, rebates and discounts. The Company sells its medicines to wholesale pharmaceutical distributors and pharmacies under agreements with payment terms typically less than 90 days.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt"><u>Medicine Sales Discounts and Allowances</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt">The nature of the Company&#8217;s contracts gives rise to variable consideration because of allowances for medicine returns, rebates and discounts. Allowances for medicine returns, rebates and discounts are recorded at the time of sale to wholesale pharmaceutical distributors and pharmacies. The Company applies significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, the Company will be required to make adjustments to these allowances in the future. The Company&#8217;s adjustments to gross sales are discussed further below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt"><u>Distribution Service Fees</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.5pt">The Company includes distribution service fees paid to its wholesalers for distribution and inventory management services as a reduction to revenue. The Company calculates accrued distribution service fee estimates using the most likely amount method. The Company accrues estimated distribution fees based on contractually determined amounts, typically as a percentage of revenue. Accrued distribution service fees are included in &#8220;accrued expenses&#8221; &#160;on the condensed consolidated balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.65pt"><u>Patient Access Programs</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.5pt">The Company offers discounts to patients under which the patient receives a discount on his or her prescription. In circumstances when a patient&#8217;s prescription is rejected by a third party payer, the Company will pay for the full cost of the prescription. &#160;The Company reimburses pharmacies for this discount directly or through third-party vendors. The Company reduces gross sales by the amount of actual co-pay and other patient assistance in the period based on the invoices received. The Company also records an accrual to reduce gross sales for estimated co-pay and other patient assistance on units sold to distributors or pharmacies that have not yet been prescribed/dispensed to a patient. The Company calculates accrued co-pay and other patient assistance fee estimates using the expected value method. The estimate is based on contract prices, estimated percentages of medicine that will be prescribed to qualified patients, average assistance paid based on reporting from the third-party vendors and estimated levels of inventory in the distribution channel. Accrued co-pay and other patient assistance fees are included in &#8220;accrued expenses&#8221;&#160; on the condensed consolidated balance sheet. Patient assistance programs include both co-pay assistance and fully bought down prescriptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt"><u>Sales Returns</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt">Consistent with industry practice, the Company maintains a return policy that allows customers to return medicines within a specified period prior to and subsequent to the medicine expiration date. Generally, medicines may be returned for a period beginning six months prior to its expiration date and up to one year after its expiration date. The right of return expires on the earlier of one year after the medicine expiration date or the time that the medicine is dispensed to the patient. The majority of medicine returns result from medicine dating, which falls within the range set by the Company&#8217;s policy, and are settled through the issuance of a credit to the customer. The Company calculates sales returns using the expected value method. The estimate of the provision for returns is based upon industry experience. This period is known to the Company based on the shelf life of medicines at the time of shipment.&#160; The Company records sales returns in &#8220;accrued expenses&#8221; and as a reduction of revenue. &#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt"><u>Shipping Fees</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt">The Company includes fees incurred by pharmacies for shipping medicines to patients as a reduction to revenue. The Company calculates accrued shipping fee estimates using the expected value method. The Company records accrued shipping fees in &#8220;accrued expenses&#8221; on the condensed consolidated balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt"><u>Licensing Agreements</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt">In terms of licensing agreements entered into by the Company, they typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the nine months ended September 30, 2018&#160;, Adhera entered into a Licensing Agreement, whereby Adhera granted exclusive rights to the company&#8217;s DiLA<sup>2 </sup>delivery system in exchange for an upfront payment of approximately $200,000 and further potential future consideration dependent upon event and sales-based milestones. Under the terms of the agreement, Adhera has agreed to assign ownership of the intellectual property associated with the DiLA<sup>2</sup> delivery system to the purchaser. The Company has yet to complete certain performance obligations under the agreement and accordingly has deferred the recognition of revenue from the sale of the asset until such obligations are fulfilled.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). Under the provisions of ASU 2014-09, entities should recognize revenue in an amount that reflects the consideration to which they expect to be entitled to in exchange for goods and services provided. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017. The Company adopted the provisions of this standard effective January 1, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In February 2016, the FASB issued ASU 2016 02, Leases (Topic 842) (&#8220;ASU 2016 02&#8221;). The provisions of ASU 2016 02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right of use asset and a lease liability for all leases with a term of greater than 12 months, regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases. ASU 2016 02 supersedes the previous lease standard, Topic 840, Leases. This guidance is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company&#8217;s consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Net Income (Loss) per Common Share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Basic net income (loss) per common share (after giving effect of the one for ten reverse stock split) is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period, excluding any unvested restricted stock awards. Diluted net income (loss) per share includes the effect of common stock equivalents (stock options, unvested restricted stock, and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. Net income (loss) is adjusted for the dilutive effect of the change in fair value liability for price adjustable warrants, if applicable. The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended September 30,</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Stock options outstanding</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">5,380,957</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">233,400</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Warrants</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">35,646,829</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,492,945</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Shares to be issued upon conversion of notes payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">315,746</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Restricted common stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">70,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Series E Preferred Stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">34,900,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Series F Preferred Stock</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3,080,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">79,007,786</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,112,091</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reclassification of Prior Period Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Net Income (Loss) per Common Share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Basic net income (loss) per common share (after giving effect of the one for ten reverse stock split) is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period, excluding any unvested restricted stock awards. Diluted net income (loss) per share includes the effect of common stock equivalents (stock options, unvested restricted stock, and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. Net income (loss) is adjusted for the dilutive effect of the change in fair value liability for price adjustable warrants, if applicable. The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Nine Months Ended September 30,</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2018</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><font style="font-size: 10pt">Stock options outstanding</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">5,380,957</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 18%; text-align: right"><font style="font-size: 10pt">233,400</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Warrants</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">35,646,829</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,492,945</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Shares to be issued upon conversion of notes payable</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">315,746</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Restricted common stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">70,000</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Series E Preferred Stock</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">34,900,000</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Series F Preferred Stock</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">3,080,000</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">79,007,786</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,112,091</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). Under the provisions of ASU 2014-09, entities should recognize revenue in an amount that reflects the consideration to which they expect to be entitled to in exchange for goods and services provided. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017. The Company adopted the provisions of this standard effective January 1, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In February 2016, the FASB issued ASU 2016 02, Leases (Topic 842) (&#8220;ASU 2016 02&#8221;). The provisions of ASU 2016 02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right of use asset and a lease liability for all leases with a term of greater than 12 months, regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases. ASU 2016 02 supersedes the previous lease standard, Topic 840, Leases. This guidance is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company&#8217;s consolidated financial statements.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Revenue Recognition</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has adopted the new revenue recognition guidelines in accordance with ASC 606, <i>Revenue from Contracts with Customers </i>(ASC 606), effective with the quarter ended March 31, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt">The Company sells its medicines primarily to wholesale distributors and specialty pharmacy providers. These customers subsequently resell the Company&#8217;s medicines to health care patients. In addition, the Company enters into arrangements with health care providers and payers that provide for government-mandated or privately-negotiated discounts and allowances related to the Company&#8217;s medicines. Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company&#8217;s contracts have a single performance obligation to transfer medicines. Accordingly, revenues from medicine sales are recognized when the customer obtains control of the Company&#8217;s medicines, which occurs at a point in time, typically upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring medicines and is generally based upon a list or fixed price less allowances for medicine returns, rebates and discounts. The Company sells its medicines to wholesale pharmaceutical distributors and pharmacies under agreements with payment terms typically less than 90 days.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt"><u>Medicine Sales Discounts and Allowances</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt">The nature of the Company&#8217;s contracts gives rise to variable consideration because of allowances for medicine returns, rebates and discounts. Allowances for medicine returns, rebates and discounts are recorded at the time of sale to wholesale pharmaceutical distributors and pharmacies. The Company applies significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, the Company will be required to make adjustments to these allowances in the future. The Company&#8217;s adjustments to gross sales are discussed further below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt"><u>Distribution Service Fees</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.5pt"><font style="font-size: 10pt">The Company includes distribution service fees paid to its wholesalers for distribution and inventory management services as a reduction to revenue. The Company calculates accrued distribution service fee estimates using the most likely amount method. The Company accrues estimated distribution fees based on contractually determined amounts, typically as a percentage of revenue. Accrued distribution service fees are included in &#8220;accrued expenses&#8221; </font><font style="font-size: 9pt">&#160;</font><font style="font-size: 10pt">on the condensed consolidated balance sheet.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.65pt"><u>Patient Access Programs</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-size: 10pt">The Company offers discounts to patients under which the patient receives a discount on his or her prescription. In circumstances when a patient&#8217;s prescription is rejected by a managed care vendor, the Company will pay for the full cost of the prescription. </font><font style="font-size: 9pt">&#160;</font><font style="font-size: 10pt">The Company reimburses pharmacies for this discount directly or through third-party vendors. The Company reduces gross sales by the amount of actual co-pay and other patient assistance in the period based on the invoices received. The Company also records an accrual to reduce gross sales for estimated co-pay and other patient assistance on units sold to distributors or pharmacies that have not yet been prescribed/dispensed to a patient. The Company calculates accrued co-pay and other patient assistance fee estimates using the expected value method. The estimate is based on contract prices, estimated percentages of medicine that will be prescribed to qualified patients, average assistance paid based on reporting from the third-party vendors and estimated levels of inventory in the distribution channel. Accrued co-pay and other patient assistance fees are included in &#8220;accrued expenses&#8221;</font><font style="font-size: 9pt">&#160; </font><font style="font-size: 10pt">on the condensed consolidated balance sheet. Patient assistance programs include both co-pay assistance and fully bought down prescriptions.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt"><u>Sales Returns</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt"><font style="font-size: 10pt">Consistent with industry practice, the Company maintains a return policy that allows customers to return medicines within a specified period prior to and subsequent to the medicine expiration date. Generally, medicines may be returned for a period beginning six months prior to its expiration date and up to one year after its expiration date. The right of return expires on the earlier of one year after the medicine expiration date or the time that the medicine is dispensed to the patient. The majority of medicine returns result from medicine dating, which falls within the range set by the Company&#8217;s policy, and are settled through the issuance of a credit to the customer. The Company calculates sales returns using the expected value method. The estimate of the provision for returns is based upon industry experience. This period is known to the Company based on the shelf life of medicines at the time of shipment.</font><font style="font-size: 9pt">&#160;</font> <font style="font-size: 10pt">The Company records sales returns in &#8220;accrued expenses&#8221; and as a reduction of revenue. </font><font style="font-size: 9pt">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt"><u>Shipping Fees</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt">The Company includes fees incurred by pharmacies for shipping medicines to patients as a reduction to revenue. The Company calculates accrued shipping fee estimates using the expected value method. The Company records accrued shipping fees in &#8220;accrued expenses&#8221; on the condensed consolidated balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt"><u>Licensing Agreements</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.65pt">In terms of licensing agreements entered into by the Company, they typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the nine months ended September 30, 2018&#160;, Adhera entered into a Licensing Agreement, whereby Adhera granted exclusive rights to the company&#8217;s DiLA<sup>2 </sup>delivery system in exchange for an upfront payment of approximately $200,000 and further potential future consideration dependent upon event and sales-based milestones. Under the terms of the agreement, Adhera has agreed to assign ownership of the intellectual property associated with the DiLA<sup>2</sup> delivery system to the purchaser. The Company has yet to complete certain performance obligations under the agreement and accordingly has deferred the recognition of revenue from the sale of the asset until such obligations are fulfilled.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Impairment of Long-Lived Assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We review all of our long-lived assets for impairment indicators throughout the year and perform detailed testing whenever impairment indicators are present. In addition, we perform detailed impairment testing for indefinite-lived intangible assets, at least annually, at December 31. When necessary, we record charges for impairments. Specifically:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, we compare the undiscounted amount of the projected cash flows associated with the asset, or asset group, to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate; and</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">For indefinite-lived intangible assets, such as acquired in-process R&#38;D assets, each year and whenever impairment indicators are present, we determine the fair value of the asset and record an impairment loss for the excess of book value over fair value, if any.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">As of September 30, 2018, the Company determined that the intangible asset from the merger was impaired and, as a result, a loss on impairment of $1,291,200 was recognized for the three and nine-month periods ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company&#8217;s strategic objectives</font><font style="font-size: 9pt">&#160;</font><font style="font-size: 10pt">. There was no such loss on impairment for the year ended December 31, 2017.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We consider the fair value of cash, accounts payable, due to related parties, notes payable, notes payable to related parties, accounts receivable and accrued liabilities not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"><font style="font-size: 10pt">Level 1:</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><font style="font-size: 10pt">Level 2:</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><font style="font-size: 10pt">Level 3:</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our cash is subject to fair value measurement and is determined by Level 1 inputs. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. There were no liabilities measured at fair value as of September 30, 2018 or December 31, 2017.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include valuation allowance for deferred income tax assets, legal contingencies and fair value of financial instruments. Actual results could differ materially from such estimates under different assumptions or circumstances.</p> 620000 620000 160800 375000 0 0 346700 411365 P8Y2M19D 0 0.54 0.66 1638991 0.93 35 3 60000 100000 0.98 P5Y 20000 200000 80000 739772 291250 739772 339702 180000 2000000 -874697 754697 754697 -320000 200000 -28795 -375000 13585894 12200000 90888 290000 170643 1494469 55247 3437735 32420580 649857 622530 351897 27340 27327 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reclassification of Prior Period Presentation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.</p> 473397 375000 0 504274 90816 29135560 1345040 2618000 1895013 0.22 0.19 88750 28795 375000 143834 204051 75000 The Amendment, we and Windlas agreed to amend the Development Agreement to reflect our agreement to issue to Windlas, and Windlas' agreement to accept from us, in lieu of cash payments with respect to forty percent (40%) of the total amount reflected on invoices sent from time to time by Windlas to us, shares of our common stock having an aggregate value equal to forty percent (40%) of such invoiced amount (with the remaining portion of the invoiced amount being paid in cash). P5Y P5Y P5Y P5Y 10521278 3490 11241684 308 12247325 12247297 28 2812 -31106896 31106896 3437735 3437728 7 687 433334 25000 1494469 1494469 250000 1261 248739 210084 75000 312 74688 51988 -649857 -649857 1307046 1307046 9 500000 500000 46311 46311 250000 After the Equity Financing Date, the Company shall pay Autotelic Inc. a cash amount equal to the actual labor cost plus 100% mark up of provided services and 20% mark up of provided services by third party contractors or material used in connection with the performance of the contracts, including but not limited to clinical trial, non-clinical trial, Contract Manufacturing Organizations ("CMO"), FDA regulatory process, Contract Research Organizations ("CRO") and Chemistry and Manufacturing Controls ("CMC"). true false false 10761684 250000 320000 32080 46311 1338569 1338566 3 308 -1313684 1313684 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 - OTHER ASSETS&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has deposit of approximately $200,000 with a customer which is included in prepaid expenses and other assets on the accompanying balance sheet. The deposit is for use by the customer to fund co-pay assistance for a specified period of time, with any unused amounts to then be refunded to the Company.</p> 200000 Adhera Therapeutics, Inc. ATRX In consideration Lipomedics agreed to the following fee schedule: 1) Evaluations License Fee. Simultaneous with the execution and delivery of the License Agreement, Lipomedics shall enter into a Stock Purchase Agreement in form and substance reasonably acceptable to Adhera and Lipomedics, pursuant to which Adhera will sell to Lipomedics shares of the common stock of Adhera for an aggregate purchase price of $0.25 million, with the purchase price for each share of Adhera common stock being $2.90. 2) Commercial License Fee. Unless the License Agreement is earlier terminated, within thirty (30) days following Lipomedics's delivery of an Evaluation Notice advising that it intends to pursue, or cause to be pursued, further development and commercialization of Licensed Products. 3) For up to and including three Licensed Products, Lipomedics shall pay to Adhera a milestone (collectively the "Sales Milestones") of $10 million upon reaching Commercial Sales in the Territory in any given twelve month period equal to or greater than $500 million for a given Licensed Product and of $20 million upon reaching Commercial Sales in any given twelve month period equal to or greater than $1 million for such Licensed Product, such payments to be made within thirty (30) days following the month in which such Commercial Sale targets are met. 135150 6183746 8298681 6058803 844309 3502829 2555974 815514 28795 124943 7454372 18565 448244 364851 135150 5735503 2185238 200000 320000 1139369 978733 1336518 155442 1033353 851063 6183746 8298681 -8028707 -22467340 8413823 28516045 63127 64700 10864036 9645954 9869672 11241684 -1.27 -0.33 -0.10 -0.69 800 -13788776 -3225355 -972184 -7779459 -1024597 -273191 63813 -115271 80672 149900 51575 24301 -12764179 -2952164 -1035997 -7779459 12832605 2952164 1035997 7847885 288460 327642 123038 41937 4119988 1878301 680063 2140992 173256 746221 232896 3456871 870926 68426 68426 76186 76186 4794030 4794030 3502830 3502830 1291200 1291200 320000 1291200 5000 0.75 310000 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Goodwill and Intangible Assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company periodically reviews the carrying value of intangible assets, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company&#8217;s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit&#8217;s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit&#8217;s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-size: 10pt">As of September 30, 2018, the Company determined that goodwill was impaired and, as a result, a loss on impairment of $3,502,830 was recognized for the three and nine-month periods ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company&#8217;s strategic objectives</font><font style="font-size: 9pt">&#160;</font><font style="font-size: 10pt">. There was no such loss on impairment for the year ended December 31, 2017.</font></p> 375000 160800 5000000 1300000 In addition, each investor received a 5-year warrant to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Preferred Stock purchased by such investor at an exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. 7760 7760 EX-101.SCH 7 atrx-20180930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Other Assets link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stock Incentive Plans link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Intellectual Property and Collaborative Agreements link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Stock Incentive Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Other Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Notes Payable - Summary of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Notes Payable - Summary of Notes Payable (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stockholders' Equity - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stock Incentive Plans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Stock Incentive Plans - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Stock Incentive Plans - Summary of Additional Information on Stock Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Intellectual Property and Collaborative Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 atrx-20180930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 atrx-20180930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 atrx-20180930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series C Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Antidilutive Securities [Axis] Stock Options Outstanding [Member] Warrants [Member] Shares to be Issued Upon Conversion of Notes Payable [Member] Series B Preferred Stock [Member] Series A Preferred Stock [Member] Series C Preferred Stock [Member] Series D Preferred Stock [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Securities Purchase Agreement [Member] Equity Components [Axis] Warrants [Member] Exercise Price Range [Axis] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Range Five [Member] Ownership [Axis] Master Services Agreement [Member] Related Party [Axis] Related Party [Member] Autotelic [Member] Debt Instrument [Axis] Promissory Note [Member] Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Title of Individual [Axis] Director and Officers [Member] License Agreement [Member] Lipo Medics [Member] Indefinite-lived Intangible Assets [Axis] Merger [Member] Prestalia [Member] Purchase Agreement [Member] Legal Entity [Axis] Symplmed Pharmaceuticals LLC [Member] Note Purchase Agreement [Member] 10 Investors [Member] Notes Payable [Member] Oncotelic, Inc. [Member] DyrctAxess [Member] Investor [Member] Pharmaceutical Development Agreement [Member] Range [Axis] Maximum [Member] Plan Name [Axis] 2014 Long-Term Incentive Plan [Member] Chief Commercial Officer [Member] Symplmed Technologies, LLC [Member] Convertible Promissory Notes [Member] Credit Facility [Axis] Line Letter [Member] Executive Chairman [Member] Dr. Trieu [Member] Autotelic Inc [Member] Licensing Agreement [Member] Convertible Notes Payable [Member] Notes Payable Related Parties [Member] Convertible Notes Payable Related Parties [Member] Subscription Agreements [Member] Series E Convertible Preferred Stock [Member] Amendment Agreement [Member] Report Date [Axis] February 10, 2012 [Member] Notes One [Member] Series E Preferred Stock [Member] Notes Two [Member] Vaya Pharma, Inc. [Member] Compromise and Settlement Agreements [Member] Board of Directors [Member] Asset Purchase Agreement [Member] Novosom Verwaltungs GmbH [Member] Additional Paid-In Capital - Warrants [Member] Series F Convertible Preferred Stock [Member] Restricted Common Stock [Member] Settlement Agreement with Autotelic Inc [Member] Philip C. Ranker [Member] Philippe P. Calais [Member] Joseph W. Ramelli [Member] BioMauris, LLC [Member] Sale of Stock [Axis] Private Placement [Member ] June 2016 Noteholders [Member] Convertible Notes Payable [Member] Shares to be Issued upon Conversion of Notes Payable [Member] Vaya Pharma LLC [Member] Robert Moscato Jr [Member] Uli Hacksell [Member] Erik Emerson [Member] Chief Executive Officer [Member] Series F Preferred Stock [Member] VP of Operations [Member] Eric Teague [Member] SVP of Commercial Operations [Member] Chief Financial Officer [Member] Omnibus Settlement Agreement [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Series E Convertible Preferred Stock And Warrants [Member] Settlement Agreement [Member] Investors [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS Current assets Cash Accounts receivable Inventory Prepaid expenses and other assets Total current assets Furniture and fixtures, net of depreciation Intangible assets, net of amortization Goodwill Total noncurrent assets Total assets LIABILITIESAND STOCKHOLDERS' EQUITY Current liabilities Accounts payable Due to related party, including warrant liability Accrued expenses Accrued fee payable Deferred revenue Notes payable Notes payable - related parties Total current liabilities Commitments and contingencies (Note 9) Stockholders' equity Preferred stock, $0.01 par value; 100,000 shares authorized Common stock, $0.006 par value; 180,000,000 shares authorized, 11,241,684 and 10,521,728 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively Additional paid-in capital Accumulated deficit Totalstockholders' equity Totalliabilities and stockholders' equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, liquidation preference value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Net sales Cost of sales Gross profit Operating expenses Sales, marketing and commercial operations Research and development General and administrative Amortization Goodwill and intangible assets impairment Total operating expenses Loss from operations Other expense Interest expense Change in fair value liability of warrants Loss on settlement Change in fair value of derivative liability Total other expense, net Loss before provision for income taxes Provision for income taxes Net loss Net loss per share - basic and diluted Weighted average shares outstanding Statement of Cash Flows [Abstract] Cash Flows Used in Operating Activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Share based compensation Common shares issued to third party for services Loss on settlement with issuance of common shares Loss on note settlement with issuance of preferred shares Common shares issued to license agreement Amortization of intangibles Amortization of debt discount Non-cash interest expense Loss on settlement Change in fair value liabilities for price adjustable warrants Change in fair value of derivative liability Changes in operating assets and liabilities: Accounts receivable Inventory Prepaid expenses and other assets Accounts payable Accrued expenses Accrued fee payable Deferred revenue Due to related party Net Cash Used in Operating Activities Cash Flows Used in Investing Activities: Purchase of furniture and fixtures Purchase of intangible assets Net Cash Used in Investing Activities Cash Flows Provided By Financing Activities: Proceeds from sale of preferred stock, net of offering expenses Proceeds from sale of common stock to related party Proceeds from notes payable due to related party Proceeds from convertible notes Proceeds from convertible notes due to related parties, net Proceeds from exercise of warrants for common stock Payments for notes payable Net Cash Provided by Financing Activities Net increase (decrease) in cash Cash - Beginning of Period Cash - End of Period Supplementary Cash Flow Information: Income taxes paid Non-cash Investing and Financing Activities: Issuance of warrants for liabilities, related party Common stock issued for settlement of accrued expenses Return of common stock for other assets Adjustment to goodwill Accrued interest Assumption of liabilities for acquisition of assets Preferred share settlement of debt and accrued liabilities Issuance of warrants Accrued dividends Cancellation of Series E Preferred Stock Goodwill reclassified to inventory Balance Balance, shares Issuance of Series E Preferred Stock, net of fees Issuance of Series E Preferred Stock, net of fees, shares Warrants issued with Series E Preferred Stock Issuance of Series F Preferred Stock, net of fees Issuance of Series F Preferred Stock, net of fees, shares Warrants issued with Series F Preferred Stock Warrants issued with Series F Preferred Stock, shares Issuance of Series E Preferred for debt and accounts payable Issuance of Series E Preferred for debt and accounts payable, shares Conversion of Series C Preferred stock for common stock Conversion of Series C Preferred stock for common stock, shares Conversion of Series D Preferred stock for common stock Conversion of Series D Preferred stock for common stock, shares Warrants issued for settlement of liability Shares issued for settlement of litigation Shares issued for settlement of litigation, shares Shares issued for License Agreement Shares issued for License Agreement, shares Accrued dividend Share based compensation Cancellation of Series E Preferred Stock Cancellation of Series E Preferred Stock, shares Balance Balance, shares Accounting Policies [Abstract] Nature of Operations, Basis of Presentation and Significant Accounting Policies Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Other Assets Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Related Party Transactions [Abstract] Related Party Transactions Debt Disclosure [Abstract] Notes Payable Equity [Abstract] Stockholders' Equity Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock Incentive Plans Intellectual Property and Collaborative Agreements Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Use of Estimates Fair Value of Financial Instruments Goodwill and Intangible Assets Impairment of Long-Lived Assets Revenue Recognition Recently Issued Accounting Pronouncements Net Income (Loss) Per Common Share Reclassification of Prior Period Presentation Schedule of Anti-dilutive Securities Schedule of Intangible Assets Summary of Notes Payable Schedule of Warrant Activity Schedule of Stock Option Activity Summary of Additional Information on Stock Options Outstanding Product and Service [Axis] Proceeds from private placement Proceeds from private placement, net of fees and expenses Working capital Loss on impairment of goodwill Loss on impairment of intangible assets Upfront payment Anti-dilutive securities Deposits with a customer Purchase consideration Payment to acquire business Liabilities assumed Fair value of the assets acquired Number of restricted shares of common stock Intangible asset Loss on impairment Accumulated amortization of intangible assets Estimated Fair Value, Intangible assets Estimated Useful Life, Intangible assets Annual Amortization Expense, Intangible assets Ownership interest Proceeds from common or preferred stock, gross Service provider percentage Compensation description Billed expenses Personnel cost Due to related party Number of stock issued during the period, shares Warrants to purchase common shares Accrued and unpaid fees Warrant term Exercise price of warrants Fair value of warrant Loss on settlement of debt Options to purchase share Exercise price of common shares Severance payments Exercisable period Number of exercisable options grants Exercise price of common stock Salary received amount per month Paid to related party for services Aggregate of cancellation shares Aggregate of cancellation shares, value Debt instrument face amount Debt periodic payment Notes payable Debt instrument interest rate Debt instrument maturity date Issuance of consideration securities Purchase of warrants Obligation issued amount Accrued interest expenses Interest Debt conversion price per share Notes payable to related party Gross proceeds from debt Convertible note payable Warrants terms Original principal amount Unamortization of debt discount Fair value of warrants Line of credit maximum borrowing capacity Line of credit Line of credit interest Number of common stock issued for merger Line of credit bears interest rate Line of credit drawn down amount Total notes payable Total notes payable - related parties Convertible notes payable - related parties net of debt discount Preferred stock designated, shares Preferred stock shares outstanding Preferred stock liquidation preference per share Preferred stock voting rights Common stock at a conversion price, per share Conversion of stock, shares converted Sale of stock, shares Warrants to purchase of common stock shares Common stock exercise price, per share Proceeds from exercise price of warrants to common stock Preferred stock stated dividend rate Warrant term Sale of preferred stock Placement agent fees and estimated expenses Preferred stock, dividend rate Stock option granted during the period Number shares issued, value Warrants outstanding Weighted average exercise price Warrant issued Adjustable warrants, shares Number of warrants expired Expiring in 2018 Expiring in 2019 Expiring in 2020 Expiring in 2021 Expiring in 2022 Expiring thereafter Total Weighted-average exercisable remaining contractual life (years) Options to purchase exercise price, per share Stock option weighted average period term Stock option outstanding exercise price Stock option unrecognized compensation expense Stock option expenses Stock option outstanding, intrinsic value Option outstanding Options Outstanding Beginning, Shares Options Outstanding, granted Options Outstanding, expired/ forfeited Options Outstanding Ending, Shares Options Outstanding Exercisable, Shares Options Outstanding Weighted Average Exercise Price, Beginning Options Outstanding Weighted Average Exercise Price, granted Options Outstanding Weighted Average Exercise Price, expired/ forfeited Options Outstanding Weighted Average Exercise Price, Ending Options Outstanding Exercisable Weighted Average Exercise Price Range of Exercise Prices, Lower Range of Exercise Prices, Upper Number of Options Outstanding, Shares Options Outstanding Weighted-average Remaining Contractual Life (years) Options Outstanding Weighted Average Exercise Price Number of Option Exercisable, Shares Options Exercisable Weighted Average Exercise Price Sale of common stock to related party, shares Sale of common stock to related party Number of shares issued for equity components Number of value issued for equity components Weighted average price per share Intellectual property collaboration description Purchase price, shares Purchase price Sale of stock price per share Ownership percentage Upfront payment of future consideration Commitments, description Cash payments percentage Issuance of common stock, value Issuance of common stock, shares Accrued expenses Purchase price of common stock Debt conversion price Exercise price of common stock Debt description Proceeds from issuance Stock repurchasing common stock Conversion of stock, share Accrued and Unpaid fees. Amendment Agreement [Member] Asset Purchase Agreement [Member] Autotelic Inc [Member] Autotelic [Member] Board of Directors [Member] Cash payments percentage. Chief Commercial Officer [Member] Represents class of warrant or right expiring in year one. Class Of Warrant Or Right Expiring In Year Five. Class Of Warrant Or Right Expiring In Year Four. Represents class of warrant or right expiring in year three. Represents class of warrant or right expiring in year two. Represents class of warrant or right expiring thereafter. Common shares issued for third party services. Common stock at a conversion price, per share. Compensation description. Compromise and Settlement Agreements [Member] Convertible Notes Payable [Member] Convertible Notes Payable Related Parties [Member] Convertible Promissory Notes [Member] Director And Officers [Member] Dr. Trieu [Member] DyrctAxess [Member] Erik Emerson [Member] Executive Chairman [Member] Intellectual property and collaborative agreements [Text Block] Intellectual Property Collaboration Description. Joseph W. Ramelli [Member] June 2016 Noteholders [Member] License Agreement [Member] Licensing Agreement [Member] Line Letter [Member] Lipo Medics [Member] Master Services Agreement [Member] Merger [Member] Represents value of non cash interest expense. Note Purchase Agreement [Member] Notes One [Member] Notes Payable [Member] Notes Payable Related Parties [Member] Notes Two [Member] Novosom Verwaltungs GmbH [Member] Number of warrants expired. Oncotelic, Inc. [Member] Personnel cost. Personnel service percentage. Pharmaceutical Development Agreement [Member] Philip C. Ranker [Member] Philippe P. Calais [Member] Placement agent fees and estimated expenses. Preferred Stock Designated, Shares. Preferred stock liquidation preference per share. Prestalia [Member] Proceed from convertible note, related party. Proceeds from common or preferred stock, gross. Issuance of consideration securities. Promissory Note [Member] Purchase Agreement [Member] Range Five [Member] Range Four [Member] Range One [Member] Range Three [Member] Range Two [Member] Related Party [Member] Restricted Common Stock [Member] Return of common stock for other assets. Securities Purchase Agreement [Member] Series C Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Symplmed Pharmaceuticals LLC [Member] Symplmed Technologies, LLC [Member] 10 Investors [Member] 2014 Long-Term Incentive Plan [Member] Vaya Pharma, Inc. [Member] Warrant term. Warrants [Member] Warrants Outstanding. Warrants terms. Additional Paid-In Capital - Warrants [Member] Proceeds from exercise of warrants for common stock. Issuance of warrants for liabilities, related party. Adjustment to goodwill. Preferred share settlement of debt and accrued liabilities. Issuance of warrants. Accrued dividends. Reclassification of Prior Period Presentation [Policy Text Block] July 2018 [Member] Series F Convertible Preferred Stock [Member] Subscription Agreements [Member] Stock Options Outstanding [Member] Shares to be Issued upon Conversion of Notes Payable [Member] Settlement Agreement with Autotelic Inc [Member] Paid to related party for services. BioMauris, LLC [Member] February 10, 2012 [Member] Obligation issued amount. Line of credit drawn down amount. Vaya Pharma LLC [Member] Warrant issued. Adjustable warrants, shares. Robert Moscato Jr [Member] Uli Hacksell [Member] Binding Agreement with Autotelic BIO [Member] Due to related party, including warrant liability current. Common shares issued to license agreement. Stock Issuance of Series E Preferred Stock, net of fees value. Stock Issuance of Series E Preferred Stock, net of fees, shares. Stock Issued During Period, Value Conversion of Series D Preferred stock for common stock. Stock Issued During Period, Shares Conversion of Series D Preferred stock for common stock. Warrants issued for settlement of liability. Shares issued for License Agreement. Shares issued for License Agreement, shares. Stock Issued During Period Value,Accrued dividend. Loss on settlement with issuance of common shares. Accrued interest. Cancellation of Series E Preferred Stock. Issuance of Series F Preferred Stock, net of fees. Issuance of Series F Preferred Stock, net of fees, shares. Warrants issued with Series F Preferred Stock. Warrants issued with Series F Preferred Stock, shares. VP of Operations [Member] Eric Teague [Member] SVP of Commercial Operations [Member] Loss on impairment of intangible assets. Omnibus Settlement Agreement [Member] Purchase price of common stock. Loss on note settlement with issuance of preferred shares. Goodwill reclassified to inventory. Working capital. Series E Convertible Preferred Stock And Warrants [Member] Proceeds from private placement, net of fees and expenses. Settlement Agreement [Member] Investors [Member] Warrant [Member] Assets, Current Assets, Noncurrent Assets Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Interest Expense, Other Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Accrued Salaries Increase (Decrease) in Deferred Revenue Net Cash Provided by (Used in) Operating Activities Payments to Acquire Furniture and Fixtures Payments to Acquire Intangible Assets Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Period Increase (Decrease) Shares, Outstanding Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Due to Related Parties Notes Payable [Default Label] Warrants and Rights Outstanding, Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Accrued Liabilities Shares Issued, Price Per Share EX-101.PRE 11 atrx-20180930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2018
Nov. 19, 2018
Document And Entity Information    
Entity Registrant Name Adhera Therapeutics, Inc.  
Entity Central Index Key 0000737207  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Small Business Flag true  
Entity Emerging Growth Company false  
Entity Ex Transition Period false  
Entity Common Stock, Shares Outstanding   10,761,684
Trading Symbol ATRX  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2018  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Current assets    
Cash $ 6,506,127 $ 106,378
Accounts receivable 135,150
Inventory 364,851
Prepaid expenses and other assets 448,244 18,565
Total current assets 7,454,372 124,943
Furniture and fixtures, net of depreciation 28,795
Intangible assets, net of amortization 815,514 2,555,974
Goodwill 3,502,829
Total noncurrent assets 844,309 6,058,803
Total assets 8,298,681 6,183,746
Current liabilities    
Accounts payable 851,063 1,033,353
Due to related party, including warrant liability 155,442 1,336,518
Accrued expenses 978,733 1,139,369
Accrued fee payable 320,000
Deferred revenue 200,000
Notes payable 444,223
Notes payable - related parties 1,462,040
Total current liabilities 2,185,238 5,735,503
Commitments and contingencies (Note 9)
Stockholders' equity    
Common stock, $0.006 par value; 180,000,000 shares authorized, 11,241,684 and 10,521,728 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively 64,700 63,127
Additional paid-in capital 28,516,045 8,413,823
Accumulated deficit (22,467,340) (8,028,707)
Totalstockholders' equity 6,113,443 448,243
Totalliabilities and stockholders' equity 8,298,681 6,183,746
Series C Convertible Preferred Stock [Member]    
Stockholders' equity    
Preferred stock, $0.01 par value; 100,000 shares authorized
Series D Convertible Preferred Stock [Member]    
Stockholders' equity    
Preferred stock, $0.01 par value; 100,000 shares authorized
Series E Convertible Preferred Stock [Member]    
Stockholders' equity    
Preferred stock, $0.01 par value; 100,000 shares authorized 35
Series F Convertible Preferred Stock [Member]    
Stockholders' equity    
Preferred stock, $0.01 par value; 100,000 shares authorized $ 3
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 100,000 100,000
Common stock, par value $ 0.006 $ 0.006
Common stock, shares authorized 180,000,000 180,000,000
Common stock, shares issued 11,241,684 10,521,728
Common stock, shares outstanding 11,241,684 10,521,728
Series C Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 1,200 1,200
Preferred stock, liquidation preference value $ 5,100 $ 5,100
Preferred stock, shares issued 100 750
Preferred stock, shares outstanding 100 750
Series D Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 220 220
Preferred stock, liquidation preference value $ 300 $ 300
Preferred stock, shares issued 40 60
Preferred stock, shares outstanding 40 60
Series E Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 3,500 3,500
Preferred stock, liquidation preference value $ 5,000 $ 5,000
Preferred stock, shares issued 3,490 0
Preferred stock, shares outstanding 3,490 0
Series F Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 2,200 2,200
Preferred stock, liquidation preference value $ 5,000 $ 5,000
Preferred stock, shares issued 308 0
Preferred stock, shares outstanding 308 0
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]        
Net sales $ 76,186 $ 76,186
Cost of sales 7,760   7,760  
Gross profit 68,426 68,426
Operating expenses        
Sales, marketing and commercial operations 870,926 3,456,871
Research and development 232,896 173,256 746,221
General and administrative 2,140,992 680,063 4,119,988 1,878,301
Amortization 41,937 123,038 288,460 327,642
Goodwill and intangible assets impairment 4,794,030 4,794,030
Total operating expenses 7,847,885 1,035,997 12,832,605 2,952,164
Loss from operations (7,779,459) (1,035,997) (12,764,179) (2,952,164)
Other expense        
Interest expense (24,301) (149,900) (51,575)
Change in fair value liability of warrants 7,442 (106,345)
Loss on settlement (874,697)
Change in fair value of derivative liability 80,672 (115,271)
Total other expense, net 63,813 (1,024,597) (273,191)
Loss before provision for income taxes (7,779,459) (972,184) (13,788,776) (3,225,355)
Provision for income taxes 800
Net loss $ (7,779,459) $ (972,184) $ (13,788,776) $ (3,226,155)
Net loss per share - basic and diluted $ (0.69) $ (0.10) $ (1.27) $ (0.33)
Weighted average shares outstanding 11,241,684 9,869,672 10,864,036 9,645,954
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash Flows Used in Operating Activities:    
Net loss $ (13,788,776) $ (3,226,155)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share based compensation 1,307,046 218,295
Common shares issued to third party for services 54,000
Loss on settlement with issuance of common shares 250,000
Loss on note settlement with issuance of preferred shares 375,000
Common shares issued to license agreement 75,000
Goodwill and intangible assets impairment 4,794,030
Amortization of intangibles 288,460 327,642
Amortization of debt discount 113,171
Non-cash interest expense 36,729
Loss on settlement 874,697
Change in fair value liabilities for price adjustable warrants 106,345
Change in fair value of derivative liability 115,271
Changes in operating assets and liabilities:    
Accounts receivable (135,150)
Inventory (204,051)
Prepaid expenses and other assets (429,679) 125,098
Accounts payable (122,229) 419,494
Accrued expenses (641,157) 637,642
Accrued fee payable (320,000)
Deferred revenue 200,000
Due to related party 313,393 299,166
Net Cash Used in Operating Activities (7,013,516) (923,202)
Cash Flows Used in Investing Activities:    
Purchase of furniture and fixtures (28,795)
Purchase of intangible assets (375,000)
Net Cash Used in Investing Activities (28,795) (375,000)
Cash Flows Provided By Financing Activities:    
Proceeds from sale of preferred stock, net of offering expenses 13,585,894
Proceeds from sale of common stock to related party 250,000
Proceeds from notes payable due to related party 90,888
Proceeds from convertible notes 400,000
Proceeds from convertible notes due to related parties, net 290,000
Proceeds from exercise of warrants for common stock 170,643
Payments for notes payable (143,834)
Net Cash Provided by Financing Activities 13,442,060 1,201,531
Net increase (decrease) in cash 6,399,749 (96,671)
Cash - Beginning of Period 106,378 105,347
Cash - End of Period 6,506,127 8,676
Supplementary Cash Flow Information:    
Income taxes paid 800
Non-cash Investing and Financing Activities:    
Issuance of warrants for liabilities, related party 1,494,469
Common stock issued for settlement of accrued expenses 976,714
Return of common stock for other assets 31,404
Adjustment to goodwill 55,247
Accrued interest 32,080
Assumption of liabilities for acquisition of assets 320,000
Preferred share settlement of debt and accrued liabilities 3,437,735
Issuance of warrants 32,420,580
Accrued dividends 649,857
Cancellation of Series E Preferred Stock 46,311
Goodwill reclassified to inventory $ 160,800
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($)
Series E Preferred Stock [Member]
Series F Preferred Stock [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Additional Paid-In Capital - Warrants [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2017 $ 63,127 $ 8,413,823 $ (8,028,707) $ 448,243
Balance, shares at Dec. 31, 2017 10,521,278        
Issuance of Series E Preferred Stock, net of fees $ 28 12,247,297 12,247,325
Issuance of Series E Preferred Stock, net of fees, shares 2,812        
Warrants issued with Series E Preferred Stock (31,106,896) 31,106,896
Issuance of Series F Preferred Stock, net of fees $ 3 1,338,566 1,338,569
Issuance of Series F Preferred Stock, net of fees, shares 308        
Warrants issued with Series F Preferred Stock (1,313,684) 1,313,684
Warrants issued with Series F Preferred Stock, shares        
Issuance of Series E Preferred for debt and accounts payable $ 7 3,437,728 3,437,735
Issuance of Series E Preferred for debt and accounts payable, shares 687        
Conversion of Series C Preferred stock for common stock
Conversion of Series C Preferred stock for common stock, shares 433,334        
Conversion of Series D Preferred stock for common stock
Conversion of Series D Preferred stock for common stock, shares 25,000        
Warrants issued for settlement of liability 1,494,469 1,494,469
Shares issued for settlement of litigation $ 1,261 248,739 250,000
Shares issued for settlement of litigation, shares 210,084        
Shares issued for License Agreement $ 312 74,688 75,000
Shares issued for License Agreement, shares 51,988        
Accrued dividend (649,857) (649,857)
Share based compensation 1,307,046 1,307,046
Cancellation of Series E Preferred Stock (46,311) (46,311)
Cancellation of Series E Preferred Stock, shares (9)        
Net loss (13,788,776) (13,788,776)
Balance at Sep. 30, 2018 $ 35 $ 3 $ 64,700 $ (5,399,004) $ 33,915,049 $ (22,467,340) $ 6,113,443
Balance, shares at Sep. 30, 2018 3,490 308 11,241,684        
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Nature of Operations, Basis of Presentation and Significant Accounting Policies
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Nature of Operations, Basis of Presentation and Significant Accounting Policies

Note 1 - Nature of Operations, Basis of Presentation and Significant Accounting Policies

 

Business Overview

 

Adhera Therapeutics, Inc. (formerly known as Marina Biotech, Inc.) and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IthenaPharma, Inc. (“Ithena”) (collectively “Adhera,”, the “Company”, “we,” “our,” or “us”) is an emerging specialty pharmaceutical company leveraging innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic and acute diseases. Adhera is focused on fixed dose combination (“FDC”) therapies in hypertension, with plans to expand the portfolio of drugs we commercialize to include other therapeutic areas.

 

We began marketing Prestalia®, a single-pill FDC of perindopril arginine (an angiotensin-converting-enzyme) inhibitor and amlodipine besylate (a calcium channel blocker), which was approved by the U.S. Food and Drug Administration (“FDA”) in June of 2018. Prestalia was developed in coordination with Servier, a French pharmaceutical conglomerate, that sells the formulation outside the United States under the brand name - Viacoram. Prestalia is distributed through the DyrectAxess platform which we acquired in 2017. DyrectAxess is a patented  technology platform, also known as Total Care®, that offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to achieve optimal care.

 

By combining Prestalia, DyrectAxess, and a specialty pharma network, we have created proprietary platform for drug adherence and the effective treatment of hypertension, improving the distribution of FDC hypertensive drugs, such as our FDA-approved product Prestalia, devices for therapeutic drug monitoring (e.g., blood pressure and other cardiac monitors), as well as patient counseling and prescription reminder services.

 

On November 15, 2016, Adhera entered into, and consummated the transactions contemplated by, an Agreement and Plan of Merger between and among IthenaPharma, Inc., a Delaware corporation (“IThena”), IThena Acquisition Corporation, a Delaware corporation and wholly-owned subsidiary of Adhera (“Merger Sub”), and a representative of the stockholders of IThena (the “Merger Agreement”), pursuant to which IThena merged into Merger Sub (the “Merger”).

 

As reported in our Annual Report on Form 10-K, in April 2018, we raised in excess of $10 million, net of fees and expenses, from a private placement of our newly created Series E Convertible Preferred Stock (See Recent Developments: Series E Convertible Preferred Stock Private Placement Offering below). Further, in May 2018, we raised an additional $2 million, net of fees and expenses, from the private placement. In July 2018, we raised $1.3 million net of fees and expenses, from a private placement of our newly created Series F Convertible Preferred Stock. The use of funds from the raise will be on the commercialization of Prestalia, funding working capital, capital expenditure needs, payment of certain liabilities and other general corporate requirements. We plan to license or divest our other pharmaceutical assets and halt any other FDC development programs, since they no longer align with our focus on the treatment of hypertension.

 

Change of Company Name and OTC Markets Symbol

 

On October 4, 2018, we filed a Certificate of Amendment to the Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware to change the name of our company from “Marina Biotech, Inc.” to “Adhera Therapeutics, Inc.” The change of name was effective October 9, 2018.

 

Following the name change from Marina Biotech, Inc. to Adhera Therapeutics, Inc., the common stock, par value $0.006 per share, of the Company began trading on the OTCQB tier of the OTC Markets under the symbol “ATRX”.

 

Reverse Stock Split

 

In August 2017, we filed a Certificate of Amendment of our Amended and Restated Certificate of Incorporation to effect a one-for-ten reverse split of our issued and outstanding shares of common stock. Our common stock commenced trading on the OTCQB tier of the OTC Markets on a split-adjusted basis on Thursday, August 3, 2017. Unless indicated otherwise, all share and per share information included in these financial statements and Notes to the Consolidated Financial Statements give effect to the reverse split.

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete audited financial statements. The accompanying unaudited financial information should be read in conjunction with the audited consolidated financial statements, including the notes thereto, as of and for the year ended December 31, 2017, included in our 2017 Annual Report on Form 10-K filed with the SEC. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the nine months ended September 30, 2018 are not necessarily indicative of the results for the year ending December 31, 2018 or for any future period.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of IThena and Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions.

 

Going Concern and Management’s Liquidity Plans 

 

The accompanying condensed consolidated financial statements have been prepared on the basis that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. At September 30, 2018, we had a significant accumulated deficit of approximately $22 million and working capital of approximately $5 million. Our operating activities consume the majority of our cash resources. We anticipate that we will continue to incur operating losses as we execute our commercialization plans for Prestalia, as well as strategic and business development initiatives. In addition, we have had and will continue to have negative cash flows from operations, at least into the near future. We have previously funded, and plan to continue funding, our losses primarily through the sale of common and preferred stock, combined with or without warrants, the sale of notes, cash generated from the outlicensing or sale of our licensed assets and, to a lesser extent, equipment financing facilities and secured loans. However, we cannot be certain that we will be able to obtain such funds required for our operations at terms acceptable to us or at all.

 

In April and May 2018, we raised approximately $12.2 million net proceeds from a private placement of shares of our Series E Convertible Preferred Stock, and warrants to purchase shares of our common stock. Further, in July 2018, we raised an additional $1.4 million net proceeds from the private placement of our Series F Convertible Preferred Stock. For our assessment as of September 30, 2018, we have considered the amount raised and we believe that the $13.6 million will provide us the ability to continue as a going concern for one year from the issuance date of this Form 10-Q. We may continue to attempt to obtain future financing or engage in strategic transactions which may require us to curtail our operations. We cannot predict, with certainty, the outcome of our actions to generate liquidity, including the availability of additional equity or debt financing, or whether such actions would generate the expected liquidity as currently planned.

 

Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include valuation allowance for deferred income tax assets, legal contingencies and fair value of financial instruments. Actual results could differ materially from such estimates under different assumptions or circumstances.

 

Fair Value of Financial Instruments

 

We consider the fair value of cash, accounts payable, due to related parties, notes payable, notes payable to related parties, accounts receivable and accrued liabilities not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
   
Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
   
Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

 

Our cash is subject to fair value measurement and is determined by Level 1 inputs. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. There were no liabilities measured at fair value as of September 30, 2018 or December 31, 2017.

 

Goodwill and Intangible Assets

 

The Company periodically reviews the carrying value of intangible assets, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit.

 

As of September 30, 2018, the Company determined that goodwill was impaired and, as a result, a loss on impairment of $3,502,830 was recognized for the three and nine-month periods ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company’s strategic objectives . There was no such loss on impairment for the year ended December 31, 2017.

 

Impairment of Long-Lived Assets

 

We review all of our long-lived assets for impairment indicators throughout the year and perform detailed testing whenever impairment indicators are present. In addition, we perform detailed impairment testing for indefinite-lived intangible assets, at least annually, at December 31. When necessary, we record charges for impairments. Specifically:

 

● For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, we compare the undiscounted amount of the projected cash flows associated with the asset, or asset group, to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate; and

 

● For indefinite-lived intangible assets, such as acquired in-process R&D assets, each year and whenever impairment indicators are present, we determine the fair value of the asset and record an impairment loss for the excess of book value over fair value, if any.

 

As of September 30, 2018, the Company determined that the intangible asset from the merger was impaired and, as a result, a loss on impairment of $1,291,200 was recognized for the three and nine-month periods ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company’s strategic objectives . There was no such loss on impairment for the year ended December 31, 2017.

 

Revenue Recognition

 

The Company has adopted the new revenue recognition guidelines in accordance with ASC 606, Revenue from Contracts with Customers (ASC 606), effective with the quarter ended March 31, 2018.

 

The Company sells its medicines primarily to wholesale distributors and specialty pharmacy providers. These customers subsequently resell the Company’s medicines to health care patients. In addition, the Company enters into arrangements with health care providers and payers that provide for government-mandated or privately-negotiated discounts and allowances related to the Company’s medicines. Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company’s contracts have a single performance obligation to transfer medicines. Accordingly, revenues from medicine sales are recognized when the customer obtains control of the Company’s medicines, which occurs at a point in time, typically upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring medicines and is generally based upon a list or fixed price less allowances for medicine returns, rebates and discounts. The Company sells its medicines to wholesale pharmaceutical distributors and pharmacies under agreements with payment terms typically less than 90 days.

 

Medicine Sales Discounts and Allowances

 

The nature of the Company’s contracts gives rise to variable consideration because of allowances for medicine returns, rebates and discounts. Allowances for medicine returns, rebates and discounts are recorded at the time of sale to wholesale pharmaceutical distributors and pharmacies. The Company applies significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, the Company will be required to make adjustments to these allowances in the future. The Company’s adjustments to gross sales are discussed further below.

 

Distribution Service Fees

 

The Company includes distribution service fees paid to its wholesalers for distribution and inventory management services as a reduction to revenue. The Company calculates accrued distribution service fee estimates using the most likely amount method. The Company accrues estimated distribution fees based on contractually determined amounts, typically as a percentage of revenue. Accrued distribution service fees are included in “accrued expenses”  on the condensed consolidated balance sheet.

 

Patient Access Programs

 

The Company offers discounts to patients under which the patient receives a discount on his or her prescription. In circumstances when a patient’s prescription is rejected by a third party payer, the Company will pay for the full cost of the prescription.  The Company reimburses pharmacies for this discount directly or through third-party vendors. The Company reduces gross sales by the amount of actual co-pay and other patient assistance in the period based on the invoices received. The Company also records an accrual to reduce gross sales for estimated co-pay and other patient assistance on units sold to distributors or pharmacies that have not yet been prescribed/dispensed to a patient. The Company calculates accrued co-pay and other patient assistance fee estimates using the expected value method. The estimate is based on contract prices, estimated percentages of medicine that will be prescribed to qualified patients, average assistance paid based on reporting from the third-party vendors and estimated levels of inventory in the distribution channel. Accrued co-pay and other patient assistance fees are included in “accrued expenses”  on the condensed consolidated balance sheet. Patient assistance programs include both co-pay assistance and fully bought down prescriptions.

 

Sales Returns

 

Consistent with industry practice, the Company maintains a return policy that allows customers to return medicines within a specified period prior to and subsequent to the medicine expiration date. Generally, medicines may be returned for a period beginning six months prior to its expiration date and up to one year after its expiration date. The right of return expires on the earlier of one year after the medicine expiration date or the time that the medicine is dispensed to the patient. The majority of medicine returns result from medicine dating, which falls within the range set by the Company’s policy, and are settled through the issuance of a credit to the customer. The Company calculates sales returns using the expected value method. The estimate of the provision for returns is based upon industry experience. This period is known to the Company based on the shelf life of medicines at the time of shipment.  The Company records sales returns in “accrued expenses” and as a reduction of revenue.  

 

Shipping Fees

 

The Company includes fees incurred by pharmacies for shipping medicines to patients as a reduction to revenue. The Company calculates accrued shipping fee estimates using the expected value method. The Company records accrued shipping fees in “accrued expenses” on the condensed consolidated balance sheet.

 

Licensing Agreements

 

In terms of licensing agreements entered into by the Company, they typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.

 

During the nine months ended September 30, 2018 , Adhera entered into a Licensing Agreement, whereby Adhera granted exclusive rights to the company’s DiLA2 delivery system in exchange for an upfront payment of approximately $200,000 and further potential future consideration dependent upon event and sales-based milestones. Under the terms of the agreement, Adhera has agreed to assign ownership of the intellectual property associated with the DiLA2 delivery system to the purchaser. The Company has yet to complete certain performance obligations under the agreement and accordingly has deferred the recognition of revenue from the sale of the asset until such obligations are fulfilled.

 

Recently Issued Accounting Pronouncements

 

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). Under the provisions of ASU 2014-09, entities should recognize revenue in an amount that reflects the consideration to which they expect to be entitled to in exchange for goods and services provided. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017. The Company adopted the provisions of this standard effective January 1, 2018.

 

In February 2016, the FASB issued ASU 2016 02, Leases (Topic 842) (“ASU 2016 02”). The provisions of ASU 2016 02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right of use asset and a lease liability for all leases with a term of greater than 12 months, regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases. ASU 2016 02 supersedes the previous lease standard, Topic 840, Leases. This guidance is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.

 

Net Income (Loss) per Common Share

 

Basic net income (loss) per common share (after giving effect of the one for ten reverse stock split) is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period, excluding any unvested restricted stock awards. Diluted net income (loss) per share includes the effect of common stock equivalents (stock options, unvested restricted stock, and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. Net income (loss) is adjusted for the dilutive effect of the change in fair value liability for price adjustable warrants, if applicable. The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive:

 

    Nine Months Ended September 30,  
    2018     2017  
             
Stock options outstanding     5,380,957       233,400  
Warrants     35,646,829       2,492,945  
Shares to be issued upon conversion of notes payable     -       315,746  
Restricted common stock     -       70,000  
Series E Preferred Stock     34,900,000       -  
Series F Preferred Stock     3,080,000       -  
Total     79,007,786       3,112,091  

 

Reclassification of Prior Period Presentation

 

Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Assets
 9 Months Ended
Sep. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Other Assets

NOTE 2 - OTHER ASSETS 

 

The Company has deposit of approximately $200,000 with a customer which is included in prepaid expenses and other assets on the accompanying balance sheet. The deposit is for use by the customer to fund co-pay assistance for a specified period of time, with any unused amounts to then be refunded to the Company.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets
 9 Months Ended
Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

Note 3 – Intangible Assets

 

Acquisition of Prestalia & DyrctAxess

 

In June 2017, we entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Symplmed Pharmaceuticals LLC (“Symplmed”) pursuant to which we purchased from Symplmed, for aggregate consideration of approximately $620,000 (consisting of $300,000 in cash plus the assumption of certain liabilities of Symplmed in the amount of approximately $320,000), Symplmed’s assets relating to a single-pill FDC of perindopril arginine and amlodipine besylate known as Prestalia® (“Prestalia”), that has been approved by the FDA for the treatment of hypertension. In addition, as part of the transactions contemplated by the Purchase Agreement: (i) Symplmed agreed to transfer to us, not later than 150 days following the closing date, the New Drug Applications for the approval of Prestalia as a new drug by the FDA; and (ii) Symplmed assigned to us all of its rights and obligations under that certain Amended and Restated License and Commercialization Agreement by and between Symplmed and Les Laboratoires Servier (“Servier”) dated January 2012, pursuant to which Symplmed has an exclusive license from Servier to manufacture, have manufactured, develop, promote, market, distribute and sell Prestalia in the U.S. (and its territories and possessions) in consideration of regulatory and sales-based milestone payments and royalty payments based on net sales. Management has determined that this acquisition was deemed an asset purchase under FASB ASC 805.

 

The purchase price of $620,000 was allocated based on a preliminary estimate of the fair value of the assets acquired and was included in intangible assets as of December 31, 2017. During the three months ended September 30, 2018, the allocation of the purchase price was finalized which resulted in $160,800 of the price being allocated to raw materials received from Symplmed, and the remaining $459,200 being allocated to intangible assets.

 

Further, we hired our current Chief Commercial Officer, who was the President and Chief Executive Officer of Symplmed, which appointment became effective in June 2017. We also agreed in such offer letter to issue 60,000 restricted shares of our common stock under our 2014 Long-Term Incentive Plan to our Chief Commercial Officer, with all of such shares vesting on the six (6) month anniversary of the date of grant. These shares were fully vested on December 31, 2017.

 

In furtherance of the acquisition and commercialization of Prestalia, in July 2017 we acquired from Symplmed and its wholly-owned subsidiary, Symplmed Technologies, LLC, certain of the intellectual property assets related to the patented technology platform known as DyrctAxess, also known as Total Care, that offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to help achieve optimal care for $75,000 in cash.

 

Intangible Asset Summary

 

The following table summarizes the estimated fair values as of September 30, 2018 of the identifiable intangible assets acquired, their useful life, and method of amortization:

 

    Estimated
Fair Value		    

Remaining

Estimated
Useful Life
(Years)

     Annual
Amortization
Expense		  
Intangible asset from the Merger   $ 590,267       4.17     $ 97,450  
Intangible asset - Prestalia     459,200       5.25       94,177  
Intangible asset – DyrctAxess     75,000       12.84       5,357  
Total   $ 1,124,467             $ 196,984  

 

As of September 30, 2018, the Company determined that the intangible asset from the Merger was impaired and, as a result, a loss on impairment of approximately $1,291,200 was recognized for the three and nine months ended September 30, 2018 (see Note 1).

 

The net intangible asset was $815,514, net of accumulated amortization of $308,953, as of September 30, 2018. Amortization expense was $288,460 and $327,642 for the nine months ended September 30, 2018 and 2017, respectively, and $41,937 and $123,038 for the three months ended September 30, 2018 and 2017, respectively.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions
 9 Months Ended
Sep. 30, 2018
Related Party Transactions [Abstract]  
Related Party Transactions

Note 4 - Related Party Transactions

 

Due to Related Party

 

The Company and other related entities have  had a commonality of ownership and/or management control, and as a result, the reported operating results and /or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous.

 

The Company had a Master Services Agreement (“MSA”) with Autotelic Inc ., a related party that is partly-owned by one of the Company’s Board members, namely Vuong Trieu, Ph.D., effective November 15, 2016. Autotelic Inc. currently owns less than 5% of the Company. The MSA states that Autotelic Inc. will provide business functions and services to the Company and allows Autotelic Inc. to charge the Company for these expenses paid on its behalf. The MSA includes personnel costs allocated based on amount of time incurred and other services such as consultant fees, clinical studies, conferences and other operating expenses incurred on behalf of the Company. The MSA requires a 90-day written termination notice in the event either party requires to terminate such services. We and Autotelic Inc. have agreed to terminate the MSA effective October 31, 2018. Dr. Trieu resigned as a director of our company effective October 1, 2018.

 

During the period commencing November 15, 2016 (the “Effective Date”) and ending on the date that the Company had completed an equity offering of either common or preferred stock in which the gross proceeds therefrom is no less than $10 million (the “Equity Financing Date”), the Company shall pay Autotelic the following compensation: cash in an amount equal to the actual labor cost (paid on a monthly basis), plus 100% markup in warrants for shares of the Company’s common stock with a strike price equal to the fair market value of the Company’s common stock at the time said warrants are issued. The Company shall also pay Autotelic for the services provided by third party contractors plus 20% mark up. The warrant price per share will be calculated based on the Black-Scholes model.

 

After the Equity Financing Date, the Company shall pay Autotelic Inc. a cash amount equal to the actual labor cost plus 100% mark up of provided services and 20% mark up of provided services by third party contractors or material used in connection with the performance of the contracts, including but not limited to clinical trial, non-clinical trial, Contract Manufacturing Organizations (“CMO”), FDA regulatory process, Contract Research Organizations (“CRO”) and Chemistry and Manufacturing Controls (“CMC”).

 

In accordance with the MSA, Autotelic Inc. billed the Company for personnel and service expenses Autotelic Inc. incurred on behalf of the Company. For the nine months ended September 30, 2018 and 2017, Autotelic Inc. billed a total of $777,928 and $492,406, including personnel costs of $370,520 and $386,954, respectively. An unpaid balance of $99,896 and $730,629 is included in due to related party in the accompanying balance sheet as of September 30, 2018 and December 31, 2017, respectively.

 

In April 2018, and in connection with the closing of our private placement on that date, we entered into a Compromise and Settlement Agreement with Autotelic Inc. pursuant to which we agreed to issue to Autotelic Inc. an aggregate of 162.59 shares of Series E Preferred Stock and Warrants to purchase up to 1,345,040 shares of common stock to satisfy accrued and unpaid fees in the aggregate amount of approximately $739,772, and other liabilities, owed to Autotelic Inc. as of March 31, 2018 pursuant to the MSA. The securities that were issued to Autotelic Inc., which were issued upon the closing described above, have the same terms and conditions as the securities that were issued to investors in the offering (See Note 5). The warrants have a five-year term, an exercise price of $0.55, and have a fair value of $1,494,469 resulting in a loss on settlement of debt of $754,697.

 

Resignation and Appointment of Officer and Directors 

 

On April 27, 2018, our Board of Directors (the “Board”) increased the size of the entire Board from five (5) directors to seven (7) directors, and it appointed each of Erik Emerson and Tim Boris to fill the vacancies created thereby.

 

In May 2018, each of Philip C. Ranker and Philippe P. Calais, Ph.D. resigned as members of the Board, and all committees thereof, effective immediately. In connection with their resignations: (i) each of Mr. Ranker and Dr. Calais released us from all claims arising prior to the date of his resignation; (ii) we granted to Mr. Ranker fully-vested options to purchase up to 200,000 shares of our common stock at an exercise price equal to $0.98 per share of common stock; and (iii) we granted to Dr. Calais fully-vested options to purchase up to 80,000 shares of our common stock at an exercise price equal to $0.98 per share of common stock. The foregoing options are exercisable for a period of five years from the grant date.

 

In May 2018, the Board accepted the resignation of Joseph W. Ramelli, our Chief Executive Officer, whereby Mr. Ramelli resigned as an officer of our company, and as a director and/or officer of any and all subsidiaries of our company, effective immediately, to pursue other opportunities. In connection with his resignation, Mr. Ramelli released us from all claims arising prior to the date of his resignation and affirmed his obligations to be bound by the restrictive covenants contained in the employment agreement between Mr. Ramelli and our company dated February 2, 2017, and we: (i) agreed to make severance payments to Mr. Ramelli in the amount of $60,000 to be paid over a six (6) month period; and (ii) granted to Mr. Ramelli fully-vested options, exercisable for a period of five years from the grant date, to purchase up to 100,000 shares of our common stock at an exercise price equal to $0.98 per share of common stock. In May 2018, the Board appointed Vuong Trieu, a director of the Company and former Executive Chairman, to serve as our Interim Chief Executive Officer, to replace Mr. Ramelli, effective with Mr. Ramelli’s departure. In his capacity as Interim Chief Executive Officer, Dr. Trieu received a salary in the amount of $20,000 per month. Dr. Trieu resigned from the position of Interim Chief Executive Officer on June 18, 2018.

 

On June 18, 2018, the Board appointed Robert C. Moscato, Jr., to serve as our Chief Executive Officer effective immediately. In connection with the appointment of Mr. Moscato as Chief Executive Officer, Dr. Trieu resigned as Interim Chief Executive Officer, and also from his position as Executive Chairman of our company, effective immediately.

 

On June 18, 2018, the Board appointed Uli Hacksell, Ph.D.to serve as a member of the Board, and as Chairman of the Board, effective July 1, 2018. Dr. Hacksell agreed to devote half of his business time to Adhera.

 

On June 28, 2018, the Board appointed Mr. Moscato to serve as a member of the Board, effective July 1, 2018.

 

We entered into an employment agreement with R. Eric Teague pursuant to which Mr. Teague began serving as our Chief Financial Officer on September 24, 2018. In connection with the appointment of Mr. Teague as our Chief Financial Officer, Amit Shah, our prior Chief Financial Officer, resigned from such position, effective September 24, 2018.

 

Issuance of Preferred Stock and Warrants to Directors

 

In April 2018, and in connection with the closing of our private placement on that date, we entered into Compromise and Settlement Agreements with four of the then current members of our Board of Directors and one former member of our Board of Directors pursuant to which we agreed to issue to such directors an aggregate of 58.25 shares of Series E Preferred Stock and Warrants to purchase up to 436,875 shares of common stock to satisfy accrued and unpaid fees owed to such directors for service as members of the Board of Directors during the period ending on December 31, 2017 in the aggregate amount of approximately $291,250. The securities that were issued to the directors, which were issued upon the closing of our private placement described above, have the same terms and conditions as the securities that were issued to investors in the offering.

 

Omnibus Settlement Agreement with Vuong Trieu, Ph.D. and Affiliated Entities

 

On October 1, 2018, we entered into an Omnibus Settlement Agreement (the “Settlement Agreement”) with Vuong Trieu, Ph.D., our former interim Chief Executive Officer, Executive Chairman and Chairman of our Board of Directors (the “Board”), Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. At the same time, and in connection therewith, we also entered into an Agreement and Release with each of Dr. Trieu and Falguni Trieu (the “Individual Releases”), and entered into an Agreement and Release with each of Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. (collectively, the “Entity Releases”). We also delivered a release (the “Company Release”) to Dr. Trieu, Ms. Trieu, Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. Pursuant to the Settlement Agreement, we agreed to make a payment to Dr. Trieu in the amount of $10,000 in consideration for Dr. Trieu entering into the Individual Releases between Dr. Trieu and our company. Dr. Trieu also agreed to sell, and we agreed to purchase, from Dr. Trieu for cancellation an aggregate of 500,000 shares of our common stock in consideration of an aggregate purchase price of $250,000. Additionally, each of Dr. Trieu, Autotelic Inc., Autotelic LLC, Oncotelic, Inc. and LipoMedics, Inc. agreed to certain restrictions on sale, transfer or assignment of our common stock.

 

Furthermore: (i) we and Autotelic Inc. agreed that the Master Services Agreement, dated as of November 15, 2016, by and between our company and Autotelic Inc., shall be terminated as of October 31, 2018; (ii) we and Autotelic BIO agreed that the Term Sheet, entered into as of January 11, 2018, by and between our company and Autotelic BIO, shall be terminated immediately; (iii) we and Oncotelic, Inc. confirmed that the License Agreement, dated July 17, 2017, by and between our company and Oncotelic Inc. was terminated effective May 15, 2018; and (iv) we and Lipomedics, Inc. agreed that the License Agreement, dated as of February 6, 2016, by and between our company and Lipomedics, Inc. would remain in effect.

 

Under the Settlement Agreement, we and Autotelic LLC agreed with respect to the License Agreement, dated as of November 15, 2016, by and between our company and Autotelic LLC, that such License Agreement shall continue, provided that Autotelic LLC shall be licensee and have a license to, without representation or warranty, nasal apomorphine and nasal scopolamine and related intellectual property in addition to nasal insulin, and Autotelic LLC shall not be a licensee or have a license to Familial Adenomatous Polyposis or CEQ508 and related intellectual property.

 

Pursuant to the Individual Releases, each of Dr. Trieu and Ms. Trieu, our former Director of Business Development and the spouse of Dr. Trieu, agreed to release us from all claims arising prior to the date of the Release Agreements. Pursuant to the Entity Releases, each of Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. agreed to release us from all claims arising prior to the date of the applicable Entity Release. Pursuant to the Company Release, we agreed to release each of Dr. Trieu, Ms. Trieu, Autotelic Inc., Autotelic LLC, Autotelic BIO, Oncotelic, Inc. and LipoMedics, Inc. from all claims arising prior to the date of the Company Release.

 

Transactions with BioMauris, LLC

 

During the nine months ended September 30, 2018, the company paid a total of $473,397 for services provided by BioMauris, LLC, of which Erik Emerson, our Chief Commercial Officer and a director of Adhera, is Executive Chairman. A total of $45,546 was due BioMauris, LLC as of September 30, 2018.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Notes Payable
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Notes Payable

Note 5 – Notes Payable

 

Following is a breakdown of notes payable as of September 30, 2018 and December 31, 2017:

 

    September 30, 2018     December 31, 2017  
             
Notes payable   $ -     $ 97,523  
Convertible notes payable     -       346,700  
Total notes payable   $ -     $ 444,223  
                 
Notes payable – related parties     -     $ 93,662  
Convertible notes payable – related parties (net of debt discount of $0 and $113,170 as of September 30, 2018 and December 31, 2017, respectively)     -       1,368,378  
Total notes payable – related parties   $ -     $ 1,462,040  

 

Note Payable – Service Provider

 

In December 2016, we entered into an Agreement and Promissory Note with a law firm for past services performed totaling $121,523. The note called for monthly payments of $6,000 per month, beginning with an initial payment on March 31, 2017. The note was unsecured and non-interest bearing. The note was paid in full in May 2018. The balance due on the note was $0 and $97,523 as of September 30, 2018 and December 31, 2017, respectively.

 

Note Purchase Agreement and Amendment

 

In July 2017, we entered into an amendment agreement (the “Amendment Agreement”) with the holders (such holders, the “June 2016 Noteholders”) of the promissory notes that we issued in June 2016 to the June 2016 Noteholders (the “2016 Notes”) with respect to the 2016 Notes and the warrants to purchase shares of our common stock that are held by the June 2016 Noteholders and that were originally issued pursuant to a certain Note and Warrant Purchase Agreement dated as of February 10, 2012 by and among Adhera, MDRNA, Cequent and the purchasers identified on the signature pages thereto (as amended from time to time), to, among other things, extend the maturity date of the 2016 Notes to December 31, 2017, to provide for the issuance of consideration securities at a cost of $375,000 (“Consideration Securities”) and to extend the price protection applicable to certain of the warrants held by the June 2016 Noteholders with respect to dilutive offerings afforded thereunder to February 10, 2020. Refer to our Form 10-Q for the six months ended June 30, 2017 for a more detailed discussion and additional terms for the 2016 Notes.

 

In April 2018, and in connection with the closing of our private placement on that date, we issued to the June 2016 Noteholders an aggregate of 71.46 shares of Series E Preferred Stock and Warrants to purchase up to 535,950 shares of common stock as a result of the conversion of the 2016 Notes. As a result of the conversion of the 2016 Notes and the issuance of the securities to the June 2016 Noteholders, the entire unpaid principal balance of the 2016 Notes, and the accrued and unpaid interest thereon, has been satisfied in full, and such notes are no longer outstanding.

 

In addition, in April 2018, and in connection with the closing of our private placement on that date, we issued to the June 2016 Noteholders an aggregate of 75 shares of Series E Preferred Stock and Warrants to purchase up to 562,500 shares of common stock in full and complete satisfaction of our obligations to issue $375,000 worth of Consideration Securities to the June 2016 Noteholders pursuant to the Amendment Agreement.

 

As of September 30, 2018 and December 31, 2017, the accrued interest expense on the 2016 Notes amounted to $0 and $46,700, respectively, with a total balance of principal and interest of $0 and $346,700, respectively.

 

2017 Bridge Note Financing

 

In June 2017, we issued convertible promissory notes (the “2017 Notes”) in the aggregate principal amount of $400,000 to 10 investors pursuant to a Note Purchase Agreement (the “Note Purchase Agreement”) that we entered into with such investors (the “June 2017 Noteholders”). The 2017 Notes bear interest at a rate of five percent (5%) per annum and are due and payable at any time on or after the earlier of (i) June 1, 2018 and (ii) the occurrence of an event of default (as defined in the Note Purchase Agreement). Our then Executive Chairman and our Chief Science Officer were each investors in the 2017 Notes.

 

As of September 30, 2018 and December 31, 2017, the accrued interest expense on the 2017 Notes amounted to $0 and $11,365, with a total balance of principal and interest of $0 and $411,365, respectively, and is included in notes payable – related parties on the accompanying balance sheet.

 

In April 2018, and in connection with the closing of our private placement on that date, we issued to the June 2017 Noteholders an aggregate of 74.17 shares of Series E Preferred Stock and Warrants to purchase up to 505,705 shares of common stock (and also paid to such holders an aggregate of $56 thousand in cash) as full and complete satisfaction of the unpaid principal balance (and accrued but unpaid interest thereon) owed by us to the June 2017 Noteholders under the 2017 Notes. As a result of the conversion of the 2017 Notes and the issuance of the securities to the June 2016 Noteholders (and payment of cash), the entire unpaid principal balance of the 2017 Notes, and the accrued and unpaid interest thereon, has been satisfied in full, and such notes are no longer outstanding. The securities that were issued to the June 2017 Noteholders have the same terms and conditions as the securities that were issued to investors in the offering.

 

Convertible Notes Payable

 

In July 2016, IThena issued convertible promissory notes with an aggregate principal balance of $50,000 to certain related-party investors. Borrowings under each of these convertible notes bore interest at 3% per annum and these notes mature on September 30, 2018. Upon the completion of certain funding events, IThena had the right to convert the outstanding principal amount of these notes into shares of IThena’s common stock. The notes were assumed by Autotelic Inc. on November 15, 2016 as part of its acquisition of the technology asset (IT-101).

  

In November 2017, the Company issued a convertible promissory note with a related party (a trust affiliated with Isaac Blech, a member of our Board of Directors) for $500,000 (the “Blech Note”), with annual interest at 8%, maturing on March 31, 2018, and convertible at the price equal to any financing transaction involving the sale by the Company of its equity securities yielding aggregate gross proceeds to the Company of not less than $5 million. The note included warrants to purchase 66,667 shares of the Company’s common stock, with a 5-year term and an exercise price of $0.75.

 

In April 2018, and in connection with the closing of our private placement on that date, we issued to the trust an aggregate of 103.18 shares of Series E Preferred Stock and Warrants to purchase up to 777,750 shares of common stock as a result of the conversion of the Blech Note in the original principal amount of $500,000. As a result of the conversion of the Blech Note and the issuance of the securities to the holder thereof, the entire unpaid principal balance of the Blech Note, and the accrued and unpaid interest thereon, has been satisfied in full, and the Blech Note is no longer outstanding. The securities that were issued to the holder of the Blech Note have the same terms and conditions as the securities that were issued to investors in the offering.

 

The Blech Note included a debt discount of $162,210 consisting of loan costs of $50,000 and the fair value of the warrants of $112,210. Total amortization of this debt discount was $113,171 for the nine months ended September 30, 2018, with a remaining unamortized value of $0. Total principal and interest was $0 and $504,274 as of September 30, 2018 and December 31, 2017, respectively, and is included in notes payable – related parties on the accompanying balance sheet.

 

Convertible Notes Payable, Dr. Trieu

 

In connection with the Merger, Adhera entered into a Line Letter dated November 15, 2016 with Dr. Trieu for an unsecured line of credit in an amount not to exceed $540,000, to be used for current operating expenses. Dr. Trieu has advanced the full $540,000 under the Line Letter as of December 31, 2017. The line of credit was convertible at any time into shares of the Company’s common stock at a price of $1.77 per share.

 

In April 2018, and in connection with the closing of our private placement on that date, we issued to Dr. Trieu 114.63 shares of Series E Preferred Stock and Warrants to purchase up to 859,725 shares of common stock as full and complete satisfaction of the unpaid principal balance (and accrued but unpaid interest thereon) owed by us to Dr. Trieu under the Line of Credit. As such, the Line of Credit was terminated in April 2018. The securities that were issued to Dr. Trieu have the same terms and conditions as the securities that were issued to investors in the offering.

 

Accrued interest on the Line Letter was $0 and $25,836 as of September 30, 2018 and December 31, 2017, respectively, and is included in notes payable - related parties on the accompanying consolidated balance sheets.

 

Line Letter with Autotelic, Inc.

 

In April 2017, the Company entered into a Line Letter with Autotelic Inc. for an unsecured line of credit in an amount not to exceed $500,000, to be used for current operating expenses. Autotelic Inc. is a stockholder of IThenaPharma that became the holder of 525,535 shares of Adhera common stock as a result of the Merger, and an entity of which Dr. Trieu serves as Chairman of the Board. Autotelic Inc. was to consider requests for advances under the Line Letter until September 1, 2017. Autotelic Inc. had the right at any time for any reason in its sole and absolute discretion to terminate the line of credit available under the Line Letter or to reduce the maximum amount available thereunder without notice. Advances made under the Line Letter bear interest at the rate of five percent (5%) per annum, are evidenced by the Demand Promissory Note issued to Autotelic Inc., and are due and payable upon demand by Autotelic, Inc. Autotelic Inc. advanced funds after September 1, 2017 but is no longer considering additional requests for advances as of December 31, 2017.

 

In April 2018, and in connection with the closing of our private placement on that date, we issued to Autotelic Inc. 19 shares of Series E Preferred Stock and Warrants to purchase up to 142,500 shares of common stock as full and complete satisfaction of the unpaid principal balance (and accrued but unpaid interest thereon) owed by us to Autotelic Inc. under the Line of Credit, of which $90,816 had been drawn down as of the date of the closing described above. As such, in April 2018, the line of credit with Autotelic Inc was terminated. The securities that were issued to Autotelic Inc. have the same terms and conditions as the securities that were issued to investors in the offering.

  

The balance under the line was $0 and $93,662, including accrued interest of $0 and $2,847 as of September 30, 2018 and December 31, 2017, respectively, and is included in notes payable - related parties on the accompanying consolidated balance sheet.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity
 9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Stockholders' Equity

Note 6 – Stockholders’ Equity

 

Preferred Stock

 

Adhera has authorized 100,000 shares of preferred stock for issuance and has designated 1,000 shares as Series B Preferred Stock (“Series B Preferred”) and 90,000 shares as Series A Junior Participating Preferred Stock (“Series A Preferred”). No shares of Series B Preferred or Series A Preferred are outstanding. In March 2014, Adhera designated 1,200 shares as Series C Convertible Preferred Stock (“Series C Preferred”). In August 2015, Adhera designated 220 shares as Series D Convertible Preferred Stock (“Series D Preferred”). In April 2018, Adhera designated 3,500 shares of Series E Convertible Preferred Stock. In July 2018, Adhera designated 2,200 shares of Series F Convertible Preferred Stock.

 

Series C Preferred

 

Each share of Series C Preferred has a stated value of $5,000 per share, has a $5,100 liquidation preference per share, has voting rights of 666.67 votes per share, and is convertible into shares of common stock at a conversion price of $7.50 per share. In September 2017, an investor converted 270 shares of Series C Preferred stock into 180,000 shares of our common stock.

 

In June 2018, an investor converted 650 shares of Series C Preferred stock into 433,334 shares of our common stock.

 

As of September 30, 2018 and December 31, 2017, 100 and 750 shares, respectively, of Series C Preferred remained outstanding.

 

Series D Preferred

 

In August 2015, Adhera entered into a Securities Purchase Agreement with certain investors pursuant to which Adhera sold 220 shares of Series D Preferred and warrants to purchase up to 344,000 shares of Adhera’s common stock at an initial exercise price of $4.00 per share before August 2021, for an aggregate purchase price of $1.1 million. Each share of Series D Preferred has a stated value of $5,000 per share, has a liquidation preference of $300 per share, has voting rights of 1,250 votes per share and is convertible into shares of common stock at a conversion price of $4.00 per share. The Series D Preferred is initially convertible into an aggregate of 275,000 shares of Adhera’s common stock, subject to certain limitations and adjustments, has a 5% stated dividend rate, is not redeemable and has voting rights on an as-converted basis.

 

In May 2018, an investor converted 20 shares of Series D Preferred into 25,000 shares of common stock.

 

As of September 30, 2018 and December 31, 2017, 40 and 60 shares, respectively, of Series D Preferred remained outstanding.

 

Series E Convertible Preferred Stock Private Placement

 

In April and May 2018, we entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 2,812 shares of our Series E convertible preferred stock (the “Preferred Stock”), at a purchase price of $5,000 per share of Preferred Stock. Each share of Preferred Stock is initially convertible into shares of our common stock at a conversion price of $0.50 per share of common stock. In addition, each investor received a 5-year warrant (the “Warrants”, and collectively with the Preferred Stock, the “Securities”) to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Preferred Stock purchased by such investor at an exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. The Preferred Stock accrues 8% dividends per annum and are payable in cash or stock at the Company’s discretion. The Preferred Stock has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights as described in the Certificate of Designation of Preferences, Rights and Limitations of the Preferred Stock, which we filed with the Secretary of State of Delaware in April 2018. The Warrants have full-ratchet anti-dilution protection, are exercisable for a period of five years and contain customary exercise limitations.

  

We received net proceeds of approximately $12.2 million from the sale of the Preferred Stock, after deducting placement agent fees and estimated expenses payable by us of approximately $2.0 million associated with such closing. We intend to use the proceeds of the offering for funding our commercial operations to the sale and promotion of our Prestalia product, working capital needs, capital expenditures, the repayment of certain liabilities and other general corporate purposes. In connection with the private placement described above, we also issued to the placement agent for such private placement a Warrant to purchase 2,958,460 shares of our common stock.

 

We accrued dividends on the Series E Preferred Stock of $351,897 for the three months ended September 30, 2018 and $622,530 for the nine months ended September 30, 2018. No similar dividends were accrued for the same periods of 2017.  

 

Series F Convertible Preferred Share Private Placement

 

In July 2018, we entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 308 shares of our Series F convertible preferred stock (the “Preferred Stock”), at a purchase price of $5,000 per share of Preferred Stock. Each share of Preferred Stock is initially convertible into shares of our common stock at a conversion price of $0.50 per share of common stock. In addition, each investor received a 5-year warrant (the “Warrants”, and collectively with the Preferred Stock, the “Securities”) to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Preferred Stock purchased by such investor at an exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. The Preferred Stock accrues 8% dividends per annum and are payable in cash or stock at the Company’s discretion. The Preferred Stock has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights as described in the Certificate of Designation of Preferences, Rights and Limitations of the Preferred Stock, which we filed with the Secretary of State of Delaware in July 2018. The Warrants have full-ratchet anti-dilution protection, are exercisable for a period of five years and contain customary exercise limitations. 

 

We received proceeds of approximately $1.3 million from the sale of the Securities, after deducting placement agent fees and estimated expenses payable by us of approximately $180,000 associated with such closing. We intend to use the proceeds of the offering for funding our commercial operations to the sale and promotion of our Prestalia product, working capital needs, capital expenditures, the repayment of certain liabilities and other general corporate purposes. In connection with the private placement described above, we also issued to the placement agent for such private placement a Warrant to purchase 308,000 shares of our common stock. The Warrant has a five-year term and an exercise price of $0.55 per share.

 

We accrued dividends on the Series F Preferred Stock of $27,327 for the 3 months and nine months ended September 30, 2018. No similar dividends were accrued for the same periods of 2017.  

 

Stock Option Grants

 

In July 2018, we granted our Chief Executive Officer, Robert Moscato, Jr., 1,500,000 stock options; Uli Hacksell, Ph. D., the Chairman of our Board, 1,000,000 stock options, Erik Emerson, our Chief Commercial Officer, 1,125,000 stock options, and Jay Schwartz, our VP of Operations, 250,000 stock options.

 

In September 2018, we granted our Chief Financial Officer, Eric Teague, 450,000 stock options.

 

Common Stock

 

Our common stock currently trades on the OTCQB tier of the OTC Markets under the symbol “ATRX”. We currently have 10,761,684 shares of our common stock outstanding.

 

Stock Issuances

 

In addition to the common stock and preferred stock issuances described above, we issued the following shares of the Company’s common stock during the nine months ended September 30, 2018.

  

As discussed in Note 8, in May 2018, we issued to Novosom 51,988 shares of our common stock as additional consideration pursuant to the Asset Purchase Agreement, dated as of July 27, 2010, between our company and Novosom. Such shares were due to Novosom as a result of the receipt by our company of a license fee under the License Agreement that we entered into with Lipomedics Inc. in February 2017.

 

As discussed in Note 9, in April 2018, we entered into a Stipulation of Settlement with Vaya Pharma and issued a total of 210,084 shares of our common stock with a fair value of $250,000.

 

In May 2018, an investor converted 20 shares of Series D Preferred into 25,000 shares of common stock.

 

In June 2018, an investor converted 650 shares of Series C Preferred stock into 433,334 shares of our common stock.

 

Warrants

 

As of September 30, 2018, there were 35,646,829 warrants outstanding, with a weighted average exercise price of $0.79 per share, and annual expirations as follows:

 

Expiring in 2018     -  
Expiring in 2019     600,000  
Expiring in 2020     1,189,079  
Expiring in 2021     343,750  
Expiring in 2022     29,202,227  
Expiring thereafter     4,311,773  
      35,646,829  

 

The above includes 29,135,560 warrants issued in April and May 2018 in connection with our Series E Preferred Stock offering with a fair value of $31,106,896 and 2,618,000  warrants issued with our Series F Preferred Stock offering with a fair value of $1,313,684 which are reflected in additional paid-in capital and additional paid in capital-warrants on the accompanying condensed consolidated statement of stockholders’ equity. The warrants have a five-year term and an exercise price of $0.55. There was no expense related to these warrants.

 

Additionally, the above includes 1,345,040 warrants issued to Autotelic, Inc. in April 2018 to satisfy accrued and unpaid fees in the aggregate amount of approximately $739,772, and other liabilities, owed to Autotelic Inc. as of March 31, 2018. The warrants have a five-year term, an exercise price of $0.55, and have a fair value of $1,494,469 resulting in a loss on settlement of liability of $754,697.

 

The above includes price adjustable warrants totaling 1,895,013 which are described more fully in our 2017 Annual Report on Form 10-K.

 

A total of 339,702 warrants expired during the nine months ended September 30, 2018.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Incentive Plans

Note 7 — Stock Incentive Plans

 

Stock Options

 

Stock option activity was as follows:

 

    Options Outstanding  
    Shares     Weighted
Average
Exercise Price		  
Outstanding, December 31, 2017     745,707     $ 8.84  
Options granted     4,724,000       0.67  
Options expired / forfeited     (88,750 )     67.40  
Outstanding, September 30, 2018     5,380,957       0.86  
Exercisable, September 30, 2018     1,638,991     $ 0.93  

 

The following table summarizes additional information on Adhera’s stock options outstanding at September 30, 2018:

 

      Options Outstanding     Options Exercisable  
Range of
Exercise
Prices		     Number Outstanding     Weighted- Average Remaining Contractual Life (Years)     Weighted Average Exercise Price     Number Exercisable     Weighted Average Exercise Price  
  $0.98       4,705,000       9.39     $ 0.67       1,467,500     $ 0.73  
  $1.00       7,000       3.13     $ 1.00       7,000     $ 1.06  
  $1.50 – $1.80       521,107       8.64     $ 1.79       136,641     $ 1.78  
  $2.60 – $8.20       135,200       3.78     $ 2.77       15,200     $ 4.48  
  $10.70 – $22.00       12,650       1.00     $ 10.92       12,650     $ 10.92  
                                             
  Totals       5,380,957       9.15     $ 0.86       1,638,991     $ 0.93  

 

Weighted-Average Exercisable Remaining Contractual Life (Years) 8.22

 

In January 2018, the Company granted a total of 19,000 stock options to directors and officers for services. The options have an exercise price of $1.56 and a five-year term.

 

In May 2018, the Company granted a total of 380,000 stock options to directors and officers for services. The options have an exercise price of $0.98 and a five-year term.

 

In July 2018, we granted our Chief Executive Officer, 1,500,000 stock options; Uli Hacksell, Ph.D., the Chairman of our Board, 1,000,000 stock options; and Erik Emerson, our Chief Commercial Officer, 1,125,000 stock options at an exercise prices of $0.66 per share with a 10-year term.

 

In July 2018 we granted our SVP of Commercial Operations 250,000 stock options at an exercise price of $0.575 per share with a 10-year term.

 

In September 2018 we granted our Chief Financial Officer 450,000 stock options at an exercise price of $0.55 per share with a 10-year term.

 

As of September 30, 2018, we had $523,943 of total unrecognized compensation expense related to unvested stock options. Total expense related to stock options was $1,307,046 and $218,295 for the nine months ended September 30, 2018 and 2017, respectively, and $814,008 and $5,109 for the three months ended September 30, 2018 and 2017, respectively.

 

As of September 30, 2018, the intrinsic value of options outstanding or exercisable was $0 as there were no options outstanding with an exercise price less than $0.54, the per share closing market price of our common stock at that date.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intellectual Property and Collaborative Agreements
 9 Months Ended
Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Intellectual Property and Collaborative Agreements

Note 8 — Intellectual Property and Collaborative Agreements

 

Novosom Agreements

 

In July 2010, Adhera entered into an asset purchase agreement with Novosom Verwaltungs GmbH (“Novosom”), pursuant to which Adhera acquired intellectual property for Novosom’s SMARTICLES-based liposomal delivery system.  In May 2018, we issued to Novosom 51,988 shares of our common stock, with a fair value of $75,000, as additional consideration pursuant to the Asset Purchase Agreement. Such shares were due to Novosom as a result of the receipt by our company of a license fee under the License Agreement that we entered into with Lipomedics Inc. in February 2017.

  

Arrangements with LipoMedics

 

In February 2017, we entered into a License Agreement (the “License Agreement”) with LipoMedics, pursuant to which, among other things, we provided to LipoMedics a license to our SMARTICLES platform for further development of Lipomedics’s proprietary phospholipid nanoparticles that can deliver protein, small molecule drugs, and peptides. These are not currently being developed at Adhera and Adhera has no IP around these products. On the same date, we also entered into a Stock Purchase Agreement with LipoMedics pursuant to which we issued to LipoMedics an aggregate of 86,207 shares of our common stock for a total purchase price of $250,000.

 

Under the terms of the License Agreement, we could receive success-based milestones based on commercial sales of licensed products. In addition, if LipoMedics determines to pursue further development and commercialization of products under the License Agreement, LipoMedics agreed, in connection therewith, to purchase shares of our common stock for an aggregate purchase price of $500,000, with the purchase price for each share of common stock being the greater of $2.90 or the volume weighted average price of our common stock for the thirty (30) trading days immediately preceding the date on which LipoMedics notifies us that it intends to pursue further development or commercialization of a licensed product.

 

If LipoMedics breaches the License Agreement, we shall have the right to terminate the License Agreement effective sixty (60) days following delivery of written notice to LipoMedics specifying the breach, if LipoMedics fails to cure such material breach within such sixty (60) day period.

 

Vuong Trieu, Ph.D. is the Chairman of the Board and Chief Operating Officer of LipoMedics.

 

In consideration Lipomedics agreed to the following fee schedule: 1) Evaluations License Fee. Simultaneous with the execution and delivery of the License Agreement, Lipomedics shall enter into a Stock Purchase Agreement in form and substance reasonably acceptable to Adhera and Lipomedics, pursuant to which Adhera will sell to Lipomedics shares of the common stock of Adhera for an aggregate purchase price of $0.25 million, with the purchase price for each share of Adhera common stock being $2.90. 2) Commercial License Fee. Unless the License Agreement is earlier terminated, within thirty (30) days following Lipomedics’s delivery of an Evaluation Notice advising that it intends to pursue, or cause to be pursued, further development and commercialization of Licensed Products. 3) For up to and including three Licensed Products, Lipomedics shall pay to Adhera a milestone (collectively the “Sales Milestones”) of $10 million upon reaching Commercial Sales in the Territory in any given twelve month period equal to or greater than $500 million for a given Licensed Product and of $20 million upon reaching Commercial Sales in any given twelve month period equal to or greater than $1 million for such Licensed Product, such payments to be made within thirty (30) days following the month in which such Commercial Sale targets are met.

 

Arrangements with Oncotelic Inc.

 

In July 2017, we entered into a License Agreement (the “License Agreement”) with Oncotelic, Inc. (“Oncotelic”) pursuant to which, among other things, we provided to Oncotelic a license to our SMARTICLES platform for the delivery of antisense DNA therapeutics, as well as a license to our conformationally restricted nucleotide (“CRN”) technology with respect to TGF-Beta. Under the terms of the License Agreement, Oncotelic also agreed to purchase 49,019 shares of our common stock for an aggregate purchase price of $0.25 million ($5.10 per share), with such purchase and sale to be made pursuant to a Stock Purchase Agreement to be entered into between us and Oncotelic within thirty (30) days following the date of the License Agreement. Oncotelic has not completed the purchase of the stock and we have not been able to reach to a definitive agreement, as such we have terminated the agreement.

  

Agreement with Autotelic BIO

 

On January 11, 2018, we entered into a binding agreement with Autotelic BIO (“ATB”) pursuant to which, among other things, and subject to the satisfaction of certain conditions on or prior to January 15, 2019, we shall grant to ATB a perpetual exclusive right of development and marketing of our IT-103 product candidate, which is a fixed dose combination of celecoxib and olmesartan medoxomil, at the currently approved dose/approved indications only for celecoxib (100 mg, 200mg and 400mg) for combined hypertension and arthritis only, with such right extending throughout the entire world (excluding the United States and Canada, and the territories of such countries). The grant of the license would be memorialized in a definitive license agreement to be entered into between the parties. On October 1, 2018, we and ATB agreed to terminate this arrangement.

 

Autotelic LLC, an entity that owns approximately 22% of the issued and outstanding shares of our common stock and of which Dr. Trieu serves as Chief Executive Officer, owns approximately 19% of the issued and outstanding shares of the common stock of ATB.

 

License of DiLA2 Assets

 

On March 16, 2018, Adhera entered into a Licensing Agreement, whereby Adhera granted exclusive rights to the company’s DiLA2 delivery system in exchange for an upfront payment of $200,000 and further potential future consideration dependent upon event and sales-based milestones. Under the terms of the agreement, Adhera has agreed to assign ownership of the intellectual property associated with the DiLA2 delivery system to the purchaser. The Company has yet to complete certain performance obligations under the agreement and accordingly has deferred the recognition of revenue from the sale of the asset until such obligations are fulfilled.

 

Asset Purchase Agreement

 

In July 2017, Adhera entered into an Asset Purchase Agreement with Symplmed Pharmaceuticals LLC and its wholly-owned subsidiary Symplmed Technologies, LLC pursuant to which the Company purchased from the Sellers, for an aggregate purchase price of $75,000 in cash, certain specified assets of the Sellers relating to the Sellers’ patented technology platform known as DyrctAxess that offers enhanced efficiency, control and information to empower patients, physicians and manufacturers to help achieve optimal care (see Note 3).
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 9 – Commitments and Contingencies

 

Amendment to Agreement with Windlas Healthcare Private Limited

 

On August 17, 2017, we entered into an amendment (the “Amendment”) of that certain Pharmaceutical Development Agreement dated as of March 30, 2017 by and between Windlas Healthcare Private Limited (“Windlas”) and our company (the “Development Agreement”), relating to the development by Windlas of certain pharmaceutical products to be used for conducting clinical trials or for regulatory submissions, as more fully described therein. Pursuant to the Amendment, we and Windlas agreed to amend the Development Agreement to reflect our agreement to issue to Windlas, and Windlas’ agreement to accept from us, in lieu of cash payments with respect to forty percent (40%) of the total amount reflected on invoices sent from time to time by Windlas to us, shares of our common stock having an aggregate value equal to forty percent (40%) of such invoiced amount (with the remaining portion of the invoiced amount being paid in cash). The maximum value of common stock that may be issued to Windlas pursuant to the Development Agreement (as modified by the Amendment) is $2 million. The parties also agreed that the foregoing payment arrangement would apply to any Contract Manufacturing and Supply Agreement (or similar agreement) relating to the manufacturing of commercial batches of the products covered by the Development Agreement that may be entered into between the parties.

 

Litigation 

 

Because of the nature of our activities, we are subject to claims and/or threatened legal actions, which arise out of the normal course of business. Other than the disclosure below, as of the date of this filing, we are not aware of any pending lawsuits against us, our officers or our directors.

 

We had been named on a complaint filed in New York State as a defendant in the matter entitled Vaya Pharma, Inc. v. Symplmed Technologies, Inc., Symplmed Pharmaceuticals, Inc., Erik Emerson and Marina Biotech, Inc. While this complaint had been filed in the Supreme Court of the State of New York, we had not been legally served. The complaint alleged, in relevant part, that: (i) the sale by Symplmed Pharmaceuticals, Inc. of its assets related to its Prestalia product, and the sale by Symplmed Technologies, Inc. of its assets related to its DyrctAxess platform, should be set aside pursuant to New York law as they were consummated without fair consideration to the sellers (the “Symplmed Defendants”), and thereby had the effect of fraudulently depriving the creditors of the Symplmed Defendants, including Vaya Pharma, Inc., of funds that could have been used to pay their debts; and (ii) we were liable, as successor, for any and all claims by Vaya Pharma, Inc. against the Symplmed Defendants, though pursuant to the agreement we are only contractually responsible for liabilities that accrue after the parties entered into the agreement for Prestalia and any liabilities that existed prior to the agreement are contractually held by Symplmed. In April 2018, we entered into a Stipulation of Settlement requiring us to issue to Vaya Pharma 210,084 shares of our common stock with a fair value of $250,000, which shares were issued in April of 2018. We accrued $0 and $250,000, as of September 30, 2018 and December 31, 2017, respectively, and such amount was included in accrued expenses on the accompanying consolidated balance sheets. 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
 9 Months Ended
Sep. 30, 2018
Subsequent Events [Abstract]  
Subsequent Events

Note 10 - Subsequent Events

 

Except for the event(s) discussed below, there were no subsequent events that required recognition or disclosure. The Company evaluated subsequent events through the date the financial statements were issued and filed with the Securities and Exchange Commission.

 

On November 9, 2018, we entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 73 shares of our Series F convertible preferred stock, par value of $0.01 per share (the “Preferred Stock”), at a purchase price of $5,000 per share of Preferred Stock. Each share of Preferred stock is initially convertible into shares of our common stock at a conversion price of $0.50 per share of common Stock. In addition, each investor received a 5-year warrant to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Preferred Stock purchased by such investor at an exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. We received total net proceeds of approximately $0.31 million from the issuance of the securities described above, after deducting placement agent fees and estimated expenses payable by us associated with such closing.

 

As discussed in Note 4, on October 1, 2018, we entered into a Settlement Agreement with Vuong Trieu, Ph.D., our former interim Chief Executive Officer, Executive Chairman and Chairman of our Board of Directors, which incuded the Company repurchasing 500,000 shares of our common stock from Dr. Trieu.

 

In October 2018, an investor converted 2 shares of Series E convertible preferred stock into 20,000 shares of our common stock.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Nature of Operations, Basis of Presentation and Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Use of Estimates

Use of Estimates

 

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include valuation allowance for deferred income tax assets, legal contingencies and fair value of financial instruments. Actual results could differ materially from such estimates under different assumptions or circumstances.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

We consider the fair value of cash, accounts payable, due to related parties, notes payable, notes payable to related parties, accounts receivable and accrued liabilities not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
   
Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
   
Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

 

Our cash is subject to fair value measurement and is determined by Level 1 inputs. We measure the liability for committed stock issuances with a fixed share number using Level 1 inputs. There were no liabilities measured at fair value as of September 30, 2018 or December 31, 2017.
Goodwill and Intangible Assets

Goodwill and Intangible Assets

 

The Company periodically reviews the carrying value of intangible assets, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit.

 

As of September 30, 2018, the Company determined that goodwill was impaired and, as a result, a loss on impairment of $3,502,830 was recognized for the three and nine-month periods ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company’s strategic objectives . There was no such loss on impairment for the year ended December 31, 2017.
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

We review all of our long-lived assets for impairment indicators throughout the year and perform detailed testing whenever impairment indicators are present. In addition, we perform detailed impairment testing for indefinite-lived intangible assets, at least annually, at December 31. When necessary, we record charges for impairments. Specifically:

 

● For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, we compare the undiscounted amount of the projected cash flows associated with the asset, or asset group, to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate; and

 

● For indefinite-lived intangible assets, such as acquired in-process R&D assets, each year and whenever impairment indicators are present, we determine the fair value of the asset and record an impairment loss for the excess of book value over fair value, if any.

 

As of September 30, 2018, the Company determined that the intangible asset from the merger was impaired and, as a result, a loss on impairment of $1,291,200 was recognized for the three and nine-month periods ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company’s strategic objectives . There was no such loss on impairment for the year ended December 31, 2017.
Revenue Recognition

Revenue Recognition

 

The Company has adopted the new revenue recognition guidelines in accordance with ASC 606, Revenue from Contracts with Customers (ASC 606), effective with the quarter ended March 31, 2018.

 

The Company sells its medicines primarily to wholesale distributors and specialty pharmacy providers. These customers subsequently resell the Company’s medicines to health care patients. In addition, the Company enters into arrangements with health care providers and payers that provide for government-mandated or privately-negotiated discounts and allowances related to the Company’s medicines. Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company’s contracts have a single performance obligation to transfer medicines. Accordingly, revenues from medicine sales are recognized when the customer obtains control of the Company’s medicines, which occurs at a point in time, typically upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring medicines and is generally based upon a list or fixed price less allowances for medicine returns, rebates and discounts. The Company sells its medicines to wholesale pharmaceutical distributors and pharmacies under agreements with payment terms typically less than 90 days.

 

Medicine Sales Discounts and Allowances

 

The nature of the Company’s contracts gives rise to variable consideration because of allowances for medicine returns, rebates and discounts. Allowances for medicine returns, rebates and discounts are recorded at the time of sale to wholesale pharmaceutical distributors and pharmacies. The Company applies significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, the Company will be required to make adjustments to these allowances in the future. The Company’s adjustments to gross sales are discussed further below.

 

Distribution Service Fees

 

The Company includes distribution service fees paid to its wholesalers for distribution and inventory management services as a reduction to revenue. The Company calculates accrued distribution service fee estimates using the most likely amount method. The Company accrues estimated distribution fees based on contractually determined amounts, typically as a percentage of revenue. Accrued distribution service fees are included in “accrued expenses”  on the condensed consolidated balance sheet.

 

Patient Access Programs

 

The Company offers discounts to patients under which the patient receives a discount on his or her prescription. In circumstances when a patient’s prescription is rejected by a managed care vendor, the Company will pay for the full cost of the prescription.  The Company reimburses pharmacies for this discount directly or through third-party vendors. The Company reduces gross sales by the amount of actual co-pay and other patient assistance in the period based on the invoices received. The Company also records an accrual to reduce gross sales for estimated co-pay and other patient assistance on units sold to distributors or pharmacies that have not yet been prescribed/dispensed to a patient. The Company calculates accrued co-pay and other patient assistance fee estimates using the expected value method. The estimate is based on contract prices, estimated percentages of medicine that will be prescribed to qualified patients, average assistance paid based on reporting from the third-party vendors and estimated levels of inventory in the distribution channel. Accrued co-pay and other patient assistance fees are included in “accrued expenses”  on the condensed consolidated balance sheet. Patient assistance programs include both co-pay assistance and fully bought down prescriptions.

 

Sales Returns

 

Consistent with industry practice, the Company maintains a return policy that allows customers to return medicines within a specified period prior to and subsequent to the medicine expiration date. Generally, medicines may be returned for a period beginning six months prior to its expiration date and up to one year after its expiration date. The right of return expires on the earlier of one year after the medicine expiration date or the time that the medicine is dispensed to the patient. The majority of medicine returns result from medicine dating, which falls within the range set by the Company’s policy, and are settled through the issuance of a credit to the customer. The Company calculates sales returns using the expected value method. The estimate of the provision for returns is based upon industry experience. This period is known to the Company based on the shelf life of medicines at the time of shipment.  The Company records sales returns in “accrued expenses” and as a reduction of revenue.  

 

Shipping Fees

 

The Company includes fees incurred by pharmacies for shipping medicines to patients as a reduction to revenue. The Company calculates accrued shipping fee estimates using the expected value method. The Company records accrued shipping fees in “accrued expenses” on the condensed consolidated balance sheet.

 

Licensing Agreements

 

In terms of licensing agreements entered into by the Company, they typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.

 

During the nine months ended September 30, 2018 , Adhera entered into a Licensing Agreement, whereby Adhera granted exclusive rights to the company’s DiLA2 delivery system in exchange for an upfront payment of approximately $200,000 and further potential future consideration dependent upon event and sales-based milestones. Under the terms of the agreement, Adhera has agreed to assign ownership of the intellectual property associated with the DiLA2 delivery system to the purchaser. The Company has yet to complete certain performance obligations under the agreement and accordingly has deferred the recognition of revenue from the sale of the asset until such obligations are fulfilled.
Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). Under the provisions of ASU 2014-09, entities should recognize revenue in an amount that reflects the consideration to which they expect to be entitled to in exchange for goods and services provided. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017. The Company adopted the provisions of this standard effective January 1, 2018.

 

In February 2016, the FASB issued ASU 2016 02, Leases (Topic 842) (“ASU 2016 02”). The provisions of ASU 2016 02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right of use asset and a lease liability for all leases with a term of greater than 12 months, regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases. ASU 2016 02 supersedes the previous lease standard, Topic 840, Leases. This guidance is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.
Net Income (Loss) Per Common Share

Net Income (Loss) per Common Share

 

Basic net income (loss) per common share (after giving effect of the one for ten reverse stock split) is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period, excluding any unvested restricted stock awards. Diluted net income (loss) per share includes the effect of common stock equivalents (stock options, unvested restricted stock, and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. Net income (loss) is adjusted for the dilutive effect of the change in fair value liability for price adjustable warrants, if applicable. The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive:

 

    Nine Months Ended September 30,  
    2018     2017  
             
Stock options outstanding     5,380,957       233,400  
Warrants     35,646,829       2,492,945  
Shares to be issued upon conversion of notes payable     -       315,746  
Restricted common stock     -       70,000  
Series E Preferred Stock     34,900,000       -  
Series F Preferred Stock     3,080,000       -  
Total     79,007,786       3,112,091  
Reclassification of Prior Period Presentation

Reclassification of Prior Period Presentation

 

Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Nature of Operations, Basis of Presentation and Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Schedule of Anti-dilutive Securities

The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive:

 

    Nine Months Ended September 30,  
    2018     2017  
             
Stock options outstanding     5,380,957       233,400  
Warrants     35,646,829       2,492,945  
Shares to be issued upon conversion of notes payable     -       315,746  
Restricted common stock     -       70,000  
Series E Preferred Stock     34,900,000       -  
Series F Preferred Stock     3,080,000       -  
Total     79,007,786       3,112,091  
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets

The following table summarizes the estimated fair values as of September 30, 2018 of the identifiable intangible assets acquired, their useful life, and method of amortization:

 

    Estimated
Fair Value		    

Remaining

Estimated
Useful Life
(Years)

     Annual
Amortization
Expense		  
Intangible asset from the Merger   $ 590,267       4.17     $ 97,450  
Intangible asset - Prestalia     459,200       5.25       94,177  
Intangible asset – DyrctAxess     75,000       12.84       5,357  
Total   $ 1,124,467             $ 196,984  
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Notes Payable (Tables)
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Summary of Notes Payable

Following is a breakdown of notes payable as of September 30, 2018 and December 31, 2017:

 

    September 30, 2018     December 31, 2017  
             
Notes payable   $ -     $ 97,523  
Convertible notes payable     -       346,700  
Total notes payable   $ -     $ 444,223  
                 
Notes payable – related parties     -     $ 93,662  
Convertible notes payable – related parties (net of debt discount of $0 and $113,170 as of September 30, 2018 and December 31, 2017, respectively)     -       1,368,378  
Total notes payable – related parties   $ -     $ 1,462,040  
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Schedule of Warrant Activity

Expiring in 2018     -  
Expiring in 2019     600,000  
Expiring in 2020     1,189,079  
Expiring in 2021     343,750  
Expiring in 2022     29,202,227  
Expiring thereafter     4,311,773  
      35,646,829  
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans (Tables)
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Stock Option Activity

Stock option activity was as follows:

 

    Options Outstanding  
    Shares     Weighted
Average
Exercise Price		  
Outstanding, December 31, 2017     745,707     $ 8.84  
Options granted     4,724,000       0.67  
Options expired / forfeited     (88,750 )     67.40  
Outstanding, September 30, 2018     5,380,957       0.86  
Exercisable, September 30, 2018     1,638,991     $ 0.93  
Summary of Additional Information on Stock Options Outstanding

The following table summarizes additional information on Adhera’s stock options outstanding at September 30, 2018:

 

      Options Outstanding     Options Exercisable  
Range of
Exercise
Prices		     Number Outstanding     Weighted- Average Remaining Contractual Life (Years)     Weighted Average Exercise Price     Number Exercisable     Weighted Average Exercise Price  
  $0.98       4,705,000       9.39     $ 0.67       1,467,500     $ 0.73  
  $1.00       7,000       3.13     $ 1.00       7,000     $ 1.06  
  $1.50 – $1.80       521,107       8.64     $ 1.79       136,641     $ 1.78  
  $2.60 – $8.20       135,200       3.78     $ 2.77       15,200     $ 4.48  
  $10.70 – $22.00       12,650       1.00     $ 10.92       12,650     $ 10.92  
                                             
  Totals       5,380,957       9.15     $ 0.86       1,638,991     $ 0.93  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Nature of Operations, Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)
 1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 16, 2018
Jul. 31, 2018
May 31, 2018
Apr. 30, 2018
May 31, 2018
Sep. 30, 2018
Sep. 30, 2018
Dec. 31, 2017
Proceeds from private placement             $ 13,600,000  
Common stock, par value           $ 0.006 $ 0.006 $ 0.006
Accumulated deficit           $ (22,467,340) $ (22,467,340) $ (8,028,707)
Working capital           5,000,000 5,000,000  
Loss on impairment of goodwill           3,502,830 3,502,830
Loss on impairment of intangible assets           $ 1,291,200 1,291,200
Licensing Agreement [Member]                
Upfront payment $ 200,000           $ 200,000  
Series E Convertible Preferred Stock [Member]                
Proceeds from private placement     $ 2,000,000 $ 10,000,000        
Series F Convertible Preferred Stock [Member]                
Proceeds from private placement   $ 1,400,000            
Proceeds from private placement, net of fees and expenses   $ 1,300,000            
Series E Convertible Preferred Stock And Warrants [Member]                
Proceeds from private placement         $ 12,200,000      
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Nature of Operations, Basis of Presentation and Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) - shares
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Anti-dilutive securities 79,007,786 3,112,091
Stock Options Outstanding [Member]    
Anti-dilutive securities 5,380,957 233,400
Warrants [Member]    
Anti-dilutive securities 35,646,829 2,492,945
Shares to be Issued Upon Conversion of Notes Payable [Member]    
Anti-dilutive securities 315,746
Restricted Common Stock [Member]    
Anti-dilutive securities 70,000
Series E Preferred Stock [Member]    
Anti-dilutive securities 34,900,000
Series F Preferred Stock [Member]    
Anti-dilutive securities 3,080,000
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Assets (Details Narrative)
Sep. 30, 2018
USD ($)
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Deposits with a customer $ 200,000
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Jul. 31, 2017
Fair value of the assets acquired       $ 620,000   $ 620,000  
Intangible asset   $ 815,514   815,514      
Loss on impairment       1,291,200      
Accumulated amortization of intangible assets   308,953   308,953      
Amortization   41,937 $ 123,038 $ 288,460 $ 327,642    
2014 Long-Term Incentive Plan [Member] | Chief Commercial Officer [Member]              
Number of restricted shares of common stock       60,000      
Symplmed Pharmaceuticals LLC [Member] | Purchase Agreement [Member]              
Purchase consideration $ 620,000            
Payment to acquire business $ 300,000            
Liabilities assumed     $ 320,000   $ 320,000    
Fair value of the assets acquired   160,800          
Intangible asset   $ 459,200   $ 459,200      
Symplmed Technologies, LLC [Member]              
Intangible asset             $ 75,000
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets - Schedule of Intangible Assets (Details)
 9 Months Ended
Sep. 30, 2018
USD ($)
Estimated Fair Value, Intangible assets $ 1,124,467
Annual Amortization Expense, Intangible assets 196,984
Merger [Member]  
Estimated Fair Value, Intangible assets $ 590,267
Estimated Useful Life, Intangible assets 4 years 2 months 1 day
Annual Amortization Expense, Intangible assets $ 97,450
Prestalia [Member]  
Estimated Fair Value, Intangible assets $ 459,200
Estimated Useful Life, Intangible assets 5 years 2 months 30 days
Annual Amortization Expense, Intangible assets $ 94,177
DyrctAxess [Member]  
Estimated Fair Value, Intangible assets $ 75,000
Estimated Useful Life, Intangible assets 12 years 10 months 3 days
Annual Amortization Expense, Intangible assets $ 5,357
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 01, 2018
Dec. 31, 2017
May 31, 2018
Apr. 30, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Due to related party   $ 730,629     $ 99,896   $ 99,896  
Number of stock issued during the period, shares     51,988          
Fair value of warrant         $ (7,442) $ 106,345
Loss on settlement of debt         (874,697)
Aggregate of cancellation shares, value             46,311  
BioMauris, LLC [Member]                
Due to related party         $ 45,546   45,546  
Paid to related party for services             473,397  
Philip C. Ranker [Member]                
Options to purchase share     200,000          
Exercise price of common shares     $ 0.98          
Philippe P. Calais [Member]                
Options to purchase share     80,000          
Exercise price of common shares     $ 0.98          
Joseph W. Ramelli [Member]                
Severance payments     $ 60,000          
Exercisable period     5 years          
Number of exercisable options grants     100,000          
Exercise price of common stock     $ 0.98          
Dr. Trieu [Member]                
Salary received amount per month             $ 20,000  
Warrants [Member]                
Warrant term             5 years  
Exercise price of warrants         $ 0.55   $ 0.55  
Fair value of warrant             $ 1,494,469  
Loss on settlement of debt             $ 754,697  
Series E Preferred Stock [Member]                
Aggregate of cancellation shares             9  
Aggregate of cancellation shares, value              
Autotelic [Member]                
Billed expenses             777,928 492,406
Personnel cost             370,520 $ 386,954
Master Services Agreement [Member]                
Proceeds from common or preferred stock, gross             $ 10,000,000  
Compensation description             After the Equity Financing Date, the Company shall pay Autotelic Inc. a cash amount equal to the actual labor cost plus 100% mark up of provided services and 20% mark up of provided services by third party contractors or material used in connection with the performance of the contracts, including but not limited to clinical trial, non-clinical trial, Contract Manufacturing Organizations ("CMO"), FDA regulatory process, Contract Research Organizations ("CRO") and Chemistry and Manufacturing Controls ("CMC").  
Master Services Agreement [Member] | Related Party [Member]                
Service provider percentage             20.00%  
Settlement Agreement with Autotelic Inc [Member] | Maximum [Member]                
Warrants to purchase common shares       1,345,040        
Settlement Agreement with Autotelic Inc [Member] | Series E Preferred Stock [Member]                
Number of stock issued during the period, shares       162.59        
Accrued and unpaid fees       $ 739,772        
Compromise and Settlement Agreements [Member] | Board of Directors [Member]                
Number of stock issued during the period, shares       58.25        
Warrants to purchase common shares       436,875        
Accrued and unpaid fees   $ 291,250            
Omnibus Settlement Agreement [Member] | Dr. Trieu [Member]                
Due to related party $ 10,000              
Aggregate of cancellation shares 500,000              
Aggregate of cancellation shares, value $ 250,000              
Master Services Agreement [Member]                
Ownership interest         5.00%   5.00%  
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Notes Payable (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2017
May 31, 2018
Apr. 30, 2018
Nov. 30, 2017
Jul. 31, 2017
Apr. 30, 2017
Jul. 31, 2016
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Nov. 15, 2016
Number of stock issued during the period, shares   51,988                          
Gross proceeds from debt                   $ 400,000        
Unamortization of debt discount               $ 0   0     $ 113,170    
Fair value of warrants               $ (7,442) 106,345        
Amortization of debt discount                   113,171        
Line Letter [Member]                              
Accrued interest expenses               0   0     25,836    
Line Letter [Member] | Autotelic Inc [Member]                              
Number of stock issued during the period, shares     19                        
Purchase of warrants     142,500                        
Line of credit maximum borrowing capacity           $ 500,000                  
Line of credit               0   0     93,662    
Line of credit interest                   0   $ 2,847      
Number of common stock issued for merger           525,535                  
Line of credit bears interest rate           5.00%                  
Line of credit drawn down amount     $ 90,816                        
Executive Chairman [Member] | Line Letter [Member]                              
Line of credit maximum borrowing capacity                             $ 540,000
Dr. Trieu [Member] | Line Letter [Member]                              
Number of stock issued during the period, shares     114.63                        
Purchase of warrants     859,725                        
Debt conversion price per share                             $ 1.77
Line of credit                         540,000    
Private Placement [Member ]                              
Number of stock issued during the period, shares     71.46                        
Purchase of warrants     535,950                        
Amendment Agreement [Member] | February 10, 2012 [Member]                              
Debt instrument maturity date         Dec. 31, 2017                    
Issuance of consideration securities         $ 375,000                    
Note Purchase Agreement [Member]                              
Notes payable     $ 56,000                        
Purchase of warrants     505,705                        
Note Purchase Agreement [Member] | 10 Investors [Member]                              
Debt instrument face amount                 $ 400,000   $ 400,000        
Debt instrument interest rate                 5.00%   5.00%        
Original principal amount                 $ 400,000   $ 400,000        
Note Purchase Agreement [Member] | Private Placement [Member ]                              
Number of stock issued during the period, shares     74.17                        
Promissory Note [Member]                              
Debt instrument face amount                           $ 121,523  
Debt periodic payment $ 6,000                            
Original principal amount                           $ 121,523  
Notes Payable [Member]                              
Notes payable               0   0     97,523    
June 2016 Noteholders [Member] | Private Placement [Member ]                              
Number of stock issued during the period, shares     75                        
Purchase of warrants     562,500                        
Obligation issued amount     $ 375,000                        
Notes One [Member]                              
Accrued interest expenses               0   0     46,700    
Interest                   0     346,700    
Notes Two [Member]                              
Accrued interest expenses               0   0     11,365    
Interest                   0     411,365    
Convertible Promissory Notes [Member]                              
Debt instrument face amount             $ 50,000                
Debt instrument interest rate       8.00%     3.00%                
Debt instrument maturity date       Mar. 31, 2018     Sep. 30, 2018                
Purchase of warrants       66,667                      
Notes payable to related party       $ 500,000                      
Gross proceeds from debt       $ 5,000,000                      
Convertible note payable               0   0     $ 504,274    
Warrants terms       5 years                      
Exercise price of warrants       $ 0.75                      
Original principal amount             $ 50,000                
Unamortization of debt discount       $ 162,210       $ 0   0          
Fair value of warrants       $ 112,210                      
Amortization of debt discount                   $ 113,171          
Convertible Notes Payable [Member]                              
Debt instrument face amount     $ 500,000                        
Number of stock issued during the period, shares     103.18                        
Purchase of warrants     777,750                        
Original principal amount     $ 500,000                        
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Notes Payable - Summary of Notes Payable (Details) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Total notes payable $ 444,223
Total notes payable - related parties 1,462,040
Notes Payable [Member]    
Total notes payable 97,523
Convertible Notes Payable [Member]    
Total notes payable 346,700
Notes Payable Related Parties [Member]    
Total notes payable - related parties 93,662
Convertible Notes Payable Related Parties [Member]    
Total notes payable - related parties $ 1,368,378
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Notes Payable - Summary of Notes Payable (Details) (Parenthetical) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Debt Disclosure [Abstract]    
Convertible notes payable - related parties net of debt discount $ 0 $ 113,170
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Details Narrative) - USD ($)
 1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Aug. 31, 2015
Jul. 31, 2018
May 31, 2018
Apr. 30, 2018
Sep. 30, 2017
May 31, 2018
Sep. 30, 2018
Sep. 30, 2017
Jun. 30, 2018
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Mar. 31, 2014
Preferred stock, shares authorized             100,000     100,000   100,000  
Preferred stock, par value             $ 0.01     $ 0.01   $ 0.01  
Number of stock issued during the period, shares     51,988                    
Sale of preferred stock                   $ 13,585,894    
Accrued dividends                   649,857    
Proceeds from private placement                   $ 13,600,000      
Stock option granted during the period                   4,724,000      
Common stock, shares outstanding             11,241,684     11,241,684   10,521,728  
Number shares issued, value     $ 75,000                    
Fair value of warrants             $ (7,442)   106,345    
Loss on settlement of debt               $ (874,697)    
Warrants [Member]                          
Weighted average exercise price                   $ 0.79      
Number of warrants expired                   339,702      
Vaya Pharma LLC [Member]                          
Number of stock issued during the period, shares       210,084                  
Number shares issued, value       $ 250,000                  
Robert Moscato Jr [Member]                          
Stock option granted during the period   1,500,000                      
Uli Hacksell [Member]                          
Stock option granted during the period   1,000,000                      
Erik Emerson [Member]                          
Stock option granted during the period   1,125,000                      
VP of Operations [Member]                          
Stock option granted during the period   250,000                      
Eric Teague [Member]                          
Stock option granted during the period                   450,000      
Private Placement [Member ]                          
Number of stock issued during the period, shares       71.46                  
Warrants to purchase of common stock shares       535,950                  
Warrants [Member]                          
Common stock exercise price, per share             $ 0.55     $ 0.55      
Warrants outstanding             35,646,829     35,646,829      
Fair value of warrants                   $ 1,494,469      
Loss on settlement of debt                   $ 754,697      
Adjustable warrants, shares             1,895,013     1,895,013      
Warrants [Member] | Autotelic Inc [Member]                          
Common stock exercise price, per share             $ 0.55     $ 0.55      
Warrant term             5 years     5 years      
Fair value of warrants                   $ 1,494,469      
Loss on settlement of debt                   $ 754,697      
Subscription Agreements [Member] | Private Placement [Member ]                          
Warrants to purchase of common stock shares     2,958,460     2,958,460              
Sale of preferred stock           $ 12,200,000              
Placement agent fees and estimated expenses           $ 2,000,000              
Subscription Agreements [Member] | Warrants [Member]                          
Preferred stock, par value   $ 0.75                      
Warrants to purchase of common stock shares   0.75                      
Common stock exercise price, per share   $ 0.55                      
Asset Purchase Agreement [Member] | Novosom Verwaltungs GmbH [Member]                          
Number of stock issued during the period, shares     51,988                    
Series B Preferred Stock [Member]                          
Preferred stock designated, shares             1,000     1,000      
Preferred stock shares outstanding                      
Series A Preferred Stock [Member]                          
Preferred stock designated, shares             90,000     90,000      
Preferred stock shares outstanding                      
Series C Preferred Stock [Member]                          
Preferred stock designated, shares                         1,200
Preferred stock, par value             $ 5,000     $ 5,000      
Preferred stock liquidation preference per share             5,100     $ 5,100      
Preferred stock voting rights                   voting rights of 666.67 votes per share      
Common stock at a conversion price, per share             $ 7.50     $ 7.50      
Number of stock issued during the period, shares                   100   750  
Series C Preferred Stock [Member] | Investor [Member]                          
Conversion of stock, shares converted         270       650        
Number of stock issued during the period, shares         180,000       433,334        
Series D Preferred Stock [Member]                          
Preferred stock designated, shares 220                        
Number of stock issued during the period, shares                   40   60  
Series D Preferred Stock [Member] | Securities Purchase Agreement [Member]                          
Preferred stock, par value $ 5,000                        
Preferred stock liquidation preference per share $ 300                        
Preferred stock voting rights voting rights of 1,250 votes per share                        
Common stock at a conversion price, per share $ 4.00                        
Number of stock issued during the period, shares 275,000                        
Sale of stock, shares 220                        
Warrants to purchase of common stock shares 344,000                        
Common stock exercise price, per share $ 4.00                        
Proceeds from exercise price of warrants to common stock $ 1,100,000                        
Preferred stock stated dividend rate 5.00%                        
Preferred stock, dividend rate 5.00%                        
Series D Preferred Stock [Member] | Investor [Member]                          
Conversion of stock, shares converted     20                    
Number of stock issued during the period, shares     25,000                    
Series E Convertible Preferred Stock [Member]                          
Preferred stock, shares authorized             3,500     3,500   3,500  
Preferred stock designated, shares       3,500                  
Preferred stock shares outstanding             3,490     3,490   0  
Preferred stock, par value             $ 0.01     $ 0.01   $ 0.01  
Accrued dividends             $ 351,897     $ 622,530      
Proceeds from private placement     $ 2,000,000 $ 10,000,000                  
Series E Convertible Preferred Stock [Member] | Subscription Agreements [Member]                          
Sale of stock, shares           2,812              
Preferred stock stated dividend rate           8.00%              
Preferred stock, dividend rate           8.00%              
Series E Convertible Preferred Stock [Member] | Subscription Agreements [Member] | Warrants [Member]                          
Preferred stock, par value     $ 5,000     $ 5,000              
Common stock at a conversion price, per share     $ 0.50     $ 0.50              
Warrants to purchase of common stock shares     0.75     0.75              
Common stock exercise price, per share     $ 0.55     $ 0.55              
Warrant term     5 years     5 years              
Series F Convertible Preferred Stock [Member]                          
Preferred stock, shares authorized             2,200     2,200   2,200  
Preferred stock designated, shares   2,200                      
Preferred stock shares outstanding             308     308   0  
Preferred stock, par value             $ 0.01     $ 0.01   $ 0.01  
Accrued dividends             $ 27,327   $ 27,340    
Proceeds from private placement   $ 1,400,000                      
Series F Convertible Preferred Stock [Member] | Subscription Agreements [Member]                          
Preferred stock, par value   $ 5,000                      
Common stock at a conversion price, per share   $ 0.50                      
Sale of stock, shares   308                      
Warrants to purchase of common stock shares   308,000                      
Common stock exercise price, per share   $ 0.55                      
Preferred stock stated dividend rate   8.00%                      
Warrant term   5 years                      
Placement agent fees and estimated expenses   $ 180,000                      
Preferred stock, dividend rate   8.00%                      
Proceeds from private placement   $ 1,300,000                      
Common Stock [Member]                          
Common stock, shares outstanding             10,761,684     10,761,684      
Series E Preferred Stock [Member] | Warrants [Member]                          
Warrant issued           29,135,560              
Fair value of warrants           $ 31,106,896              
Series F Preferred Stock [Member] | Warrants [Member]                          
Warrant issued           2,618,000              
Fair value of warrants           $ 1,313,684              
Warrants [Member]                          
Common stock exercise price, per share     $ 0.55     $ 0.55              
Warrant term     5 years     5 years              
Warrants [Member] | Autotelic Inc [Member]                          
Warrant issued           1,345,040              
Accrued and unpaid fees           $ 739,772              
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Schedule of Warrant Activity (Details)
 9 Months Ended
Sep. 30, 2018
shares
Equity [Abstract]  
Expiring in 2018
Expiring in 2019 600,000
Expiring in 2020 1,189,079
Expiring in 2021 343,750
Expiring in 2022 29,202,227
Expiring thereafter 4,311,773
Total 35,646,829
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2018
May 31, 2018
Jan. 31, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Jan. 31, 2017
Weighted-average exercisable remaining contractual life (years)           8 years 2 months 19 days    
Stock option granted during the period           4,724,000    
Stock option weighted average period term 10 years              
Stock option outstanding exercise price $ 0.66     $ 0.54   $ 0.54    
Stock option unrecognized compensation expense       $ 523,943   $ 523,943    
Stock option expenses       814,008 $ 5,109 1,307,046 $ 218,295  
Stock option outstanding, intrinsic value       $ 0   $ 0    
Option outstanding              
Director and Officers [Member]                
Stock option granted during the period   380,000 19,000          
Options to purchase exercise price, per share   $ 0.98           $ 1.56
Stock option weighted average period term   5 years 5 years          
Robert Moscato Jr [Member]                
Stock option granted during the period 1,500,000              
Uli Hacksell [Member]                
Stock option granted during the period 1,000,000              
Erik Emerson [Member]                
Stock option granted during the period 1,125,000              
SVP of Commercial Operations [Member]                
Stock option granted during the period 250,000              
Options to purchase exercise price, per share $ 0.575              
Stock option weighted average period term 10 years              
Chief Financial Officer [Member]                
Stock option granted during the period           450,000    
Options to purchase exercise price, per share       $ 0.55   $ 0.55    
Stock option weighted average period term           10 years    
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans - Schedule of Stock Option Activity (Details)
 9 Months Ended
Sep. 30, 2018
$ / shares
shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Options Outstanding Beginning, Shares | shares 745,707
Options Outstanding, granted | shares 4,724,000
Options Outstanding, expired/ forfeited | shares (88,750)
Options Outstanding Ending, Shares | shares 5,380,957
Options Outstanding Exercisable, Shares | shares 1,638,991
Options Outstanding Weighted Average Exercise Price, Beginning | $ / shares $ 8.84
Options Outstanding Weighted Average Exercise Price, granted | $ / shares 0.67
Options Outstanding Weighted Average Exercise Price, expired/ forfeited | $ / shares 67.40
Options Outstanding Weighted Average Exercise Price, Ending | $ / shares 0.86
Options Outstanding Exercisable Weighted Average Exercise Price | $ / shares $ 0.93
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Incentive Plans - Summary of Additional Information on Stock Options Outstanding (Details)
 9 Months Ended
Sep. 30, 2018
$ / shares
shares
Number of Options Outstanding, Shares | shares 5,380,957
Options Outstanding Weighted-average Remaining Contractual Life (years) 9 years 1 month 24 days
Options Outstanding Weighted Average Exercise Price $ 0.86
Number of Option Exercisable, Shares | shares 1,638,991
Options Exercisable Weighted Average Exercise Price $ 0.93
Range One [Member]  
Range of Exercise Prices, Upper $ 0.98
Number of Options Outstanding, Shares | shares 4,705,000
Options Outstanding Weighted-average Remaining Contractual Life (years) 9 years 4 months 20 days
Options Outstanding Weighted Average Exercise Price $ 0.67
Number of Option Exercisable, Shares | shares 1,467,500
Options Exercisable Weighted Average Exercise Price $ 0.73
Range Two [Member]  
Range of Exercise Prices, Upper $ 1.00
Number of Options Outstanding, Shares | shares 7,000
Options Outstanding Weighted-average Remaining Contractual Life (years) 3 years 1 month 16 days
Options Outstanding Weighted Average Exercise Price $ 1.00
Number of Option Exercisable, Shares | shares 7,000
Options Exercisable Weighted Average Exercise Price $ 1.06
Range Three [Member]  
Range of Exercise Prices, Lower 1.50
Range of Exercise Prices, Upper $ 1.80
Number of Options Outstanding, Shares | shares 521,107
Options Outstanding Weighted-average Remaining Contractual Life (years) 8 years 7 months 21 days
Options Outstanding Weighted Average Exercise Price $ 1.79
Number of Option Exercisable, Shares | shares 136,641
Options Exercisable Weighted Average Exercise Price $ 1.78
Range Four [Member]  
Range of Exercise Prices, Lower 2.60
Range of Exercise Prices, Upper $ 8.20
Number of Options Outstanding, Shares | shares 135,200
Options Outstanding Weighted-average Remaining Contractual Life (years) 3 years 9 months 11 days
Options Outstanding Weighted Average Exercise Price $ 2.77
Number of Option Exercisable, Shares | shares 15,200
Options Exercisable Weighted Average Exercise Price $ 4.48
Range Five [Member]  
Range of Exercise Prices, Lower 10.70
Range of Exercise Prices, Upper $ 22.00
Number of Options Outstanding, Shares | shares 12,650
Options Outstanding Weighted-average Remaining Contractual Life (years) 1 year
Options Outstanding Weighted Average Exercise Price $ 10.92
Number of Option Exercisable, Shares | shares 12,650
Options Exercisable Weighted Average Exercise Price $ 10.92
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intellectual Property and Collaborative Agreements (Details Narrative) - USD ($)
 1 Months Ended 9 Months Ended
Mar. 16, 2018
May 31, 2018
Jul. 31, 2017
Jun. 30, 2017
Feb. 28, 2017
Sep. 30, 2018
Sale of common stock to related party, shares   51,988        
Sale of common stock to related party   $ 75,000        
Executive Chairman [Member]            
Ownership percentage           22.00%
Chief Executive Officer [Member]            
Ownership percentage           19.00%
License Agreement [Member]            
Sale of stock price per share     $ 5.10      
License Agreement [Member] | Oncotelic, Inc. [Member]            
Purchase price, shares     49,019      
Purchase price     $ 250,000      
License Agreement [Member] | Lipo Medics [Member]            
Sale of common stock to related party         $ 500,000  
Number of shares issued for equity components         86,207  
Number of value issued for equity components         $ 250,000  
Weighted average price per share         $ 2.90  
Intellectual property collaboration description         In consideration Lipomedics agreed to the following fee schedule: 1) Evaluations License Fee. Simultaneous with the execution and delivery of the License Agreement, Lipomedics shall enter into a Stock Purchase Agreement in form and substance reasonably acceptable to Adhera and Lipomedics, pursuant to which Adhera will sell to Lipomedics shares of the common stock of Adhera for an aggregate purchase price of $0.25 million, with the purchase price for each share of Adhera common stock being $2.90. 2) Commercial License Fee. Unless the License Agreement is earlier terminated, within thirty (30) days following Lipomedics's delivery of an Evaluation Notice advising that it intends to pursue, or cause to be pursued, further development and commercialization of Licensed Products. 3) For up to and including three Licensed Products, Lipomedics shall pay to Adhera a milestone (collectively the "Sales Milestones") of $10 million upon reaching Commercial Sales in the Territory in any given twelve month period equal to or greater than $500 million for a given Licensed Product and of $20 million upon reaching Commercial Sales in any given twelve month period equal to or greater than $1 million for such Licensed Product, such payments to be made within thirty (30) days following the month in which such Commercial Sale targets are met.  
Licensing Agreement [Member]            
Upfront payment of future consideration $ 200,000         $ 200,000
Purchase Agreement [Member] | Symplmed Pharmaceuticals LLC [Member]            
Purchase price     $ 75,000      
Upfront payment of future consideration       $ 620,000    
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies (Details Narrative) - USD ($)
 1 Months Ended 9 Months Ended
May 31, 2018
Apr. 30, 2018
Sep. 30, 2018
Dec. 31, 2017
Issuance of common stock, value $ 75,000      
Issuance of common stock, shares 51,988      
Accrued expenses     $ 0 $ 250,000
Vaya Pharma, Inc. [Member]        
Issuance of common stock, value   $ 250,000    
Issuance of common stock, shares   210,084    
Pharmaceutical Development Agreement [Member]        
Commitments, description     The Amendment, we and Windlas agreed to amend the Development Agreement to reflect our agreement to issue to Windlas, and Windlas' agreement to accept from us, in lieu of cash payments with respect to forty percent (40%) of the total amount reflected on invoices sent from time to time by Windlas to us, shares of our common stock having an aggregate value equal to forty percent (40%) of such invoiced amount (with the remaining portion of the invoiced amount being paid in cash).  
Cash payments percentage     40.00%  
Pharmaceutical Development Agreement [Member] | Maximum [Member]        
Issuance of common stock, value     $ 2,000,000  
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events (Details Narrative) - USD ($)
 1 Months Ended 9 Months Ended
Nov. 09, 2018
Oct. 01, 2018
Oct. 31, 2018
May 31, 2018
Sep. 30, 2018
Jul. 31, 2018
Dec. 31, 2017
Number of stock issued during the period, shares       51,988      
Preferred stock, par value         $ 0.01   $ 0.01
Common Stock [Member]              
Stock repurchasing common stock            
Warrants [Member]              
Warrant term         5 years    
Series F Convertible Preferred Stock [Member]              
Preferred stock, par value         $ 0.01   $ 0.01
Subscription Agreements [Member] | Warrants [Member]              
Preferred stock, par value           $ 0.75  
Subscription Agreements [Member] | Series F Convertible Preferred Stock [Member]              
Preferred stock, par value           $ 5,000  
Subsequent Event [Member] | Series E Convertible Preferred Stock And Warrants [Member] | Investors [Member]              
Conversion of stock, share     2        
Subsequent Event [Member] | Common Stock [Member] | Investors [Member]              
Conversion of stock, share     20,000        
Subsequent Event [Member] | Subscription Agreements [Member]              
Number of stock issued during the period, shares 73            
Proceeds from issuance $ 310,000            
Subsequent Event [Member] | Subscription Agreements [Member] | Common Stock [Member]              
Debt conversion price $ 0.50            
Subsequent Event [Member] | Subscription Agreements [Member] | Warrants [Member]              
Warrant term 5 years            
Exercise price of common stock $ 0.75            
Debt description In addition, each investor received a 5-year warrant to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Preferred Stock purchased by such investor at an exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder.            
Subsequent Event [Member] | Subscription Agreements [Member] | Series F Convertible Preferred Stock [Member]              
Preferred stock, par value $ 0.01            
Purchase price of common stock $ 5,000            
Subsequent Event [Member] | Settlement Agreement [Member] | Dr. Trieu [Member]              
Stock repurchasing common stock   500,000          
EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 52 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 220 272 1 false 94 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://marinabio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://marinabio.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://marinabio.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://marinabio.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://marinabio.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Sheet http://marinabio.com/role/StatementsOfShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies Sheet http://marinabio.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPolicies Nature of Operations, Basis of Presentation and Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Other Assets Sheet http://marinabio.com/role/OtherAssets Other Assets Notes 8 false false R9.htm 00000009 - Disclosure - Intangible Assets Sheet http://marinabio.com/role/IntangibleAssets Intangible Assets Notes 9 false false R10.htm 00000010 - Disclosure - Related Party Transactions Sheet http://marinabio.com/role/RelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 00000011 - Disclosure - Notes Payable Notes http://marinabio.com/role/NotesPayable Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Stockholders' Equity Sheet http://marinabio.com/role/StockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 00000013 - Disclosure - Stock Incentive Plans Sheet http://marinabio.com/role/StockIncentivePlans Stock Incentive Plans Notes 13 false false R14.htm 00000014 - Disclosure - Intellectual Property and Collaborative Agreements Sheet http://marinabio.com/role/IntellectualPropertyAndCollaborativeAgreements Intellectual Property and Collaborative Agreements Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://marinabio.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Events Sheet http://marinabio.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 00000017 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://marinabio.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesPolicies Nature of Operations, Basis of Presentation and Significant Accounting Policies (Policies) Policies http://marinabio.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Tables) Sheet http://marinabio.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesTables Nature of Operations, Basis of Presentation and Significant Accounting Policies (Tables) Tables http://marinabio.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Intangible Assets (Tables) Sheet http://marinabio.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://marinabio.com/role/IntangibleAssets 19 false false R20.htm 00000020 - Disclosure - Notes Payable (Tables) Notes http://marinabio.com/role/NotesPayableTables Notes Payable (Tables) Tables http://marinabio.com/role/NotesPayable 20 false false R21.htm 00000021 - Disclosure - Stockholders' Equity (Tables) Sheet http://marinabio.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://marinabio.com/role/StockholdersEquity 21 false false R22.htm 00000022 - Disclosure - Stock Incentive Plans (Tables) Sheet http://marinabio.com/role/StockIncentivePlansTables Stock Incentive Plans (Tables) Tables http://marinabio.com/role/StockIncentivePlans 22 false false R23.htm 00000023 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Details Narrative) Sheet http://marinabio.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative Nature of Operations, Basis of Presentation and Significant Accounting Policies (Details Narrative) Details http://marinabio.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesTables 23 false false R24.htm 00000024 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) Sheet http://marinabio.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPolicies-ScheduleOfAnti-dilutiveSecuritiesDetails Nature of Operations, Basis of Presentation and Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) Details 24 false false R25.htm 00000025 - Disclosure - Other Assets (Details Narrative) Sheet http://marinabio.com/role/OtherAssetsDetailsNarrative Other Assets (Details Narrative) Details http://marinabio.com/role/OtherAssets 25 false false R26.htm 00000026 - Disclosure - Intangible Assets (Details Narrative) Sheet http://marinabio.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://marinabio.com/role/IntangibleAssetsTables 26 false false R27.htm 00000027 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://marinabio.com/role/IntangibleAssets-ScheduleOfIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 27 false false R28.htm 00000028 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://marinabio.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://marinabio.com/role/RelatedPartyTransactions 28 false false R29.htm 00000029 - Disclosure - Notes Payable (Details Narrative) Notes http://marinabio.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://marinabio.com/role/NotesPayableTables 29 false false R30.htm 00000030 - Disclosure - Notes Payable - Summary of Notes Payable (Details) Notes http://marinabio.com/role/NotesPayable-SummaryOfNotesPayableDetails Notes Payable - Summary of Notes Payable (Details) Details 30 false false R31.htm 00000031 - Disclosure - Notes Payable - Summary of Notes Payable (Details) (Parenthetical) Notes http://marinabio.com/role/NotesPayable-SummaryOfNotesPayableDetailsParenthetical Notes Payable - Summary of Notes Payable (Details) (Parenthetical) Details 31 false false R32.htm 00000032 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://marinabio.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://marinabio.com/role/StockholdersEquityTables 32 false false R33.htm 00000033 - Disclosure - Stockholders' Equity - Schedule of Warrant Activity (Details) Sheet http://marinabio.com/role/StockholdersEquity-ScheduleOfWarrantActivityDetails Stockholders' Equity - Schedule of Warrant Activity (Details) Details 33 false false R34.htm 00000034 - Disclosure - Stock Incentive Plans (Details Narrative) Sheet http://marinabio.com/role/StockIncentivePlansDetailsNarrative Stock Incentive Plans (Details Narrative) Details http://marinabio.com/role/StockIncentivePlansTables 34 false false R35.htm 00000035 - Disclosure - Stock Incentive Plans - Schedule of Stock Option Activity (Details) Sheet http://marinabio.com/role/StockIncentivePlans-ScheduleOfStockOptionActivityDetails Stock Incentive Plans - Schedule of Stock Option Activity (Details) Details 35 false false R36.htm 00000036 - Disclosure - Stock Incentive Plans - Summary of Additional Information on Stock Options Outstanding (Details) Sheet http://marinabio.com/role/StockIncentivePlans-SummaryOfAdditionalInformationOnStockOptionsOutstandingDetails Stock Incentive Plans - Summary of Additional Information on Stock Options Outstanding (Details) Details 36 false false R37.htm 00000037 - Disclosure - Intellectual Property and Collaborative Agreements (Details Narrative) Sheet http://marinabio.com/role/IntellectualPropertyAndCollaborativeAgreementsDetailsNarrative Intellectual Property and Collaborative Agreements (Details Narrative) Details http://marinabio.com/role/IntellectualPropertyAndCollaborativeAgreements 37 false false R38.htm 00000038 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://marinabio.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://marinabio.com/role/CommitmentsAndContingencies 38 false false R39.htm 00000039 - Disclosure - Subsequent Events (Details Narrative) Sheet http://marinabio.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://marinabio.com/role/SubsequentEvents 39 false false All Reports Book All Reports atrx-20180930.xml atrx-20180930.xsd atrx-20180930_cal.xml atrx-20180930_def.xml atrx-20180930_lab.xml atrx-20180930_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 57 0001493152-18-016490-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-016490-xbrl.zip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�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�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